BBIO


Line plots across dimensions of each concept
Line plots across concepts
Tables

Table of contents



us-gaap:CommonStockValue
us-gaap:Range, us-gaap:SubsequentEventType, us-gaap:SubsidiarySaleOfStock

us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted

us-gaap:EarningsPerShareBasicAndDiluted

us-gaap:AllocatedShareBasedCompensationExpense
us-gaap:AwardType, us-gaap:PlanName
us-gaap:ConsolidatedEntities
us-gaap:ConsolidatedEntities, us-gaap:IncomeStatementLocation
us-gaap:IncomeStatementLocation
us-gaap:PlanName, us-gaap:ShareRepurchaseProgram
us-gaap:SubsidiarySaleOfStock

us-gaap:ComprehensiveIncomeNetOfTax

us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest

us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest

us-gaap:CostOfGoodsAndServicesSold

us-gaap:CostsAndExpenses

us-gaap:GeneralAndAdministrativeExpense

us-gaap:InterestExpense

us-gaap:InterestExpenseDebt
us-gaap:DebtInstrument
us-gaap:LineOfCreditFacility

us-gaap:InterestPaidNet

us-gaap:NetIncomeLossAttributableToNoncontrollingInterest

us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic

us-gaap:NonoperatingIncomeExpense

us-gaap:OperatingExpenses

us-gaap:OperatingIncomeLoss

us-gaap:OtherNonoperatingIncomeExpense

us-gaap:ProfitLoss

us-gaap:ResearchAndDevelopmentExpense
us-gaap:AdjustmentsForNewAccountingPronouncements
us-gaap:ContingentConsiderationByType

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:CounterpartyName, us-gaap:ProductOrService, us-gaap:TypeOfArrangement
us-gaap:ProductOrService

us-gaap:SellingGeneralAndAdministrativeExpense
us-gaap:ContingentConsiderationByType

us-gaap:Assets

us-gaap:Liabilities

us-gaap:LiabilitiesAndStockholdersEquity

us-gaap:StockholdersEquity

us-gaap:AssetsCurrent

us-gaap:CashAndCashEquivalentsAtCarryingValue

us-gaap:MarketableSecuritiesCurrent

us-gaap:AccountsReceivableNetCurrent

us-gaap:PrepaidExpenseAndOtherAssetsCurrent

us-gaap:PropertyPlantAndEquipmentNet

us-gaap:IntangibleAssetsNetIncludingGoodwill

us-gaap:OperatingLeaseRightOfUseAsset

us-gaap:OtherAssetsNoncurrent

us-gaap:AccountsPayableCurrent

us-gaap:LiabilitiesCurrent

us-gaap:LongTermDebtCurrent

us-gaap:OperatingLeaseLiabilityCurrent

us-gaap:OtherAccruedLiabilitiesCurrent

us-gaap:LongTermDebtNoncurrent
us-gaap:DebtInstrument
us-gaap:DebtInstrument
us-gaap:DeferredFinanceCostsNoncurrentNet

us-gaap:MinorityInterest
dei:LegalEntity

us-gaap:OtherLiabilitiesNoncurrent
us-gaap:Restatement, us-gaap:AdjustmentsForNewAccountingPronouncements

us-gaap:OperatingLeaseLiabilityNoncurrent

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive

us-gaap:OperatingLeaseLiability

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue

us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount

us-gaap:StockholdersEquity

us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
us-gaap:CumulativeEffectPeriodOfAdoption, us-gaap:AdjustmentsForNewAccountingPronouncements
us-gaap:CumulativeEffectPeriodOfAdoption, us-gaap:AdjustmentsForNewAccountingPronouncements, us-gaap:StatementEquityComponents
us-gaap:StatementEquityComponents

us-gaap:CommonStockValue
us-gaap:Range, us-gaap:SubsequentEventType, us-gaap:SubsidiarySaleOfStock

us-gaap:AdditionalPaidInCapitalCommonStock
us-gaap:Restatement, us-gaap:AdjustmentsForNewAccountingPronouncements

us-gaap:RetainedEarningsAccumulatedDeficit
us-gaap:CumulativeEffectPeriodOfAdoption, us-gaap:AdjustmentsForNewAccountingPronouncements

us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax

us-gaap:TreasuryStockValue

us-gaap:MinorityInterest
dei:LegalEntity

us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
us-gaap:StatementEquityComponents

us-gaap:NetCashProvidedByUsedInOperatingActivities

us-gaap:NetCashProvidedByUsedInInvestingActivities

us-gaap:NetCashProvidedByUsedInFinancingActivities

us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

us-gaap:AmortizationOfFinancingCosts
us-gaap:DebtInstrument

us-gaap:IncreaseDecreaseInAccountsPayable

us-gaap:NetCashProvidedByUsedInOperatingActivities

us-gaap:ProfitLoss

us-gaap:ShareBasedCompensation

us-gaap:NetCashProvidedByUsedInInvestingActivities

us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

us-gaap:NetCashProvidedByUsedInFinancingActivities

us-gaap:PaymentsForRepurchaseOfCommonStock
us-gaap:DebtInstrument
us-gaap:DebtInstrument, us-gaap:ShareRepurchaseProgram
us-gaap:DebtInstrument, us-gaap:SubsequentEventType
us-gaap:DebtInstrument
us-gaap:DebtInstrumentInterestRateStatedPercentage
us-gaap:ConsolidatedEntities
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
us-gaap:ConsolidatedEntities, us-gaap:PlanName
us-gaap:PlanName
us-gaap:PlanName, us-gaap:ShareRepurchaseProgram

us-gaap:DeferredTaxLiabilities
us-gaap:BalanceSheetLocation

us-gaap:DeferredTaxAssetsNet

us-gaap:UnrecognizedTaxBenefits

us-gaap:DeferredTaxAssetsValuationAllowance

bbio:AdjustmentsOfCarryingValueOfNoncontrollingInterestAdditionalPaidInCapital

bbio:AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCalls
us-gaap:StatementEquityComponents
us-gaap:DebtInstrument
bbio:AdjustmentsToAdditionalPaidInCapitalRelatedToPremiumPayments

bbio:CallOptionExpenseIncome
us-gaap:DebtInstrument
bbio:DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock

bbio:DirectTransactionCostsInRepurchaseOfNoncontrollingInterestIncludedInAccountsPayableAndAccruedProfessionalServices

bbio:DirectTransactionCostsInRepurchaseOfNoncontrollingInterestRecordedInAdditionalPaidInCapitalPreviouslyClassifiedInPrepaidExpensesAndOtherCurrentAssets

bbio:FinanceLeaseStraightLineFinanceLeaseCosts

bbio:IncreaseDecreaseInAccruedProfessionalService

bbio:IncreaseDecreaseInAccruedResearchAndDevelopmentLiabilities

bbio:IncreaseDecreaseInOperatingLeaseLiabilities
us-gaap:ConsolidatedEntities, us-gaap:LineOfCreditFacility
bbio:InterestExpenseAndAmortizationOfDebtDiscount

bbio:IssuanceRepurchaseOfNoncontrollingInterest
us-gaap:StatementEquityComponents
us-gaap:Ownership, us-gaap:TypeOfArrangement
bbio:LicenseAgreementPercentageShareOfProfitsAndLosses
us-gaap:AdjustmentsForNewAccountingPronouncements
bbio:LicenseAgreementsShareOfCoCommercializationLossAsReductionToSellingGeneralAndAdministrativeExpenses

bbio:NetIncomeLossExcludingRedeemableNoncontrollingInterestsNetIncomeLoss
us-gaap:StatementEquityComponents

bbio:NetNonCashPortionOfRepurchaseOfNoncontrollingInterests
us-gaap:PropertyPlantAndEquipmentByType
bbio:NewAccountingPronouncementEffectOfAdoption

bbio:NoncashOrPartNoncashInvestingTransferFromToNoncontrollingInterest
us-gaap:CounterpartyName, us-gaap:TypeOfArrangement
bbio:NonrefundableUpfrontPaymentReceivable
us-gaap:ConsolidatedEntities, us-gaap:SubsequentEventType
bbio:NumberOfSharesIssuedInExchangeOfSubsidiaryEquity
us-gaap:CounterpartyName, us-gaap:TypeOfArrangement
bbio:PercentageShareOfGlobalDevelopmentCosts
us-gaap:Ownership, us-gaap:TypeOfArrangement
us-gaap:ConsolidatedEntities
bbio:PerformanceBasedMilestoneAwardsCompensationExpense
us-gaap:AwardType, us-gaap:PlanName
bbio:PerformanceBasedMilestoneAwardsCompensationExpenseSettledWithEquity
us-gaap:AwardType, us-gaap:ShareRepurchaseProgram
us-gaap:ShareRepurchaseProgram
bbio:PerformanceBasedMilestoneAwardsCompensationRecognized
us-gaap:AwardType, us-gaap:PlanName
bbio:PerformanceBasedMilestoneAwardsGrantsInPeriodWeightedAverageGrantDateFairValue
us-gaap:ConsolidatedEntities, us-gaap:TypeOfArrangement
bbio:PotentialTerminationFee
dei:LegalEntity
bbio:PreferredStockOwnershipPercentage
us-gaap:DebtInstrument
bbio:ProceedsFromIssuanceOfNotesAfterDeductingDiscountAndOfferingExpenses
us-gaap:DebtInstrument, us-gaap:SubsequentEventType

bbio:PurchaseOfCappedCalls
us-gaap:DebtInstrument
us-gaap:DebtInstrument, us-gaap:SubsequentEventType

bbio:RepurchaseOfNoncontrollingInterestIncludingDirectTransactionCosts

bbio:StockBasedCompensationExpenseToBeSettledInEitherCashOrEquity
us-gaap:StatementEquityComponents
bbio:StockBasedCompensationExpenseToBeSettledInEquity
us-gaap:StatementClassOfStock
bbio:TemporaryEquityFairValueOfNoncontrollingInterest
us-gaap:StatementClassOfStock
bbio:TemporaryEquityIssuanceRepurchaseOfNoncontrollingInterestValue
us-gaap:StatementClassOfStock
bbio:TemporaryEquityTransferToFromNoncontrollingInterest
us-gaap:TypeOfArrangement
bbio:TerminationFee

us-gaap:AccretionExpense
us-gaap:AwardType
us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
us-gaap:AwardType, us-gaap:StatementEquityComponents

us-gaap:AmortizationOfDebtDiscountPremium
us-gaap:DebtInstrument
us-gaap:LineOfCreditFacility
us-gaap:AmortizationOfFinancingCostsAndDiscounts
us-gaap:ConsolidatedEntities
us-gaap:BusinessCombinationConsiderationTransferred1

us-gaap:CapitalExpendituresIncurredButNotYetPaid
us-gaap:ConsolidatedEntities, us-gaap:DebtInstrument, us-gaap:LineOfCreditFacility, us-gaap:VariableRate
us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
us-gaap:LineOfCreditFacility, us-gaap:SubsequentEventType, us-gaap:VariableRate
us-gaap:LineOfCreditFacility, us-gaap:VariableRate
us-gaap:DebtInstrument
us-gaap:DebtInstrumentConvertibleConversionRatio1
us-gaap:DebtInstrument
us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal
us-gaap:DebtInstrument
us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
us-gaap:DebtInstrument
us-gaap:DebtInstrumentConvertibleThresholdTradingDays
us-gaap:FairValueByLiabilityClass
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements

us-gaap:FinanceLeaseInterestPaymentOnLiability
us-gaap:BalanceSheetLocation
us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
us-gaap:IncomeStatementLocation

us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities

us-gaap:IncreaseDecreaseInDueFromRelatedParties

us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities

us-gaap:IncreaseDecreaseInOtherOperatingAssets

us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

us-gaap:InterestExpenseDebtExcludingAmortization
us-gaap:DebtInstrument

us-gaap:InvestmentIncomeInterest

us-gaap:LeaseCost

us-gaap:MinorityInterestDecreaseFromRedemptions
us-gaap:ConsolidatedEntities, us-gaap:StatementEquityComponents
us-gaap:StatementEquityComponents

us-gaap:MinorityInterestPeriodIncreaseDecrease
us-gaap:StatementEquityComponents

us-gaap:OperatingLeaseCost

us-gaap:OperatingLeaseImpairmentLoss

us-gaap:OperatingLeasePayments

us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense

us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
us-gaap:StatementEquityComponents

us-gaap:OtherNoncashIncomeExpense
us-gaap:ConsolidatedEntities, us-gaap:DebtInstrument, us-gaap:LineOfCreditFacility, us-gaap:SubsequentEventType
us-gaap:PaymentsOfDebtExtinguishmentCosts

us-gaap:PaymentsOfDebtIssuanceCosts

us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
us-gaap:ConsolidatedEntities
us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
us-gaap:ConsolidatedEntities, us-gaap:SubsequentEventType

us-gaap:PaymentsToAcquireMarketableSecurities

us-gaap:ProceedsFromConvertibleDebt
us-gaap:LineOfCreditFacility, us-gaap:SubsequentEventType
us-gaap:ProceedsFromIssuanceOfDebt
us-gaap:DebtInstrument, us-gaap:SubsequentEventType
us-gaap:ProceedsFromNotesPayable

us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities

us-gaap:ProceedsFromStockOptionsExercised

us-gaap:ProceedsFromStockPlans

us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
us-gaap:AwardType, us-gaap:PlanName
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
us-gaap:AwardType, us-gaap:PlanName
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
us-gaap:AwardType, us-gaap:PlanName
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
us-gaap:AwardType
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
us-gaap:SubsidiarySaleOfStock
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
us-gaap:SubsidiarySaleOfStock
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
us-gaap:AwardType
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
us-gaap:SubsidiarySaleOfStock
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
us-gaap:SubsidiarySaleOfStock
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
us-gaap:AwardType
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
us-gaap:SubsidiarySaleOfStock
us-gaap:ConsolidatedEntities, us-gaap:PlanName
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
us-gaap:PlanName
us-gaap:PlanName, us-gaap:ShareRepurchaseProgram
us-gaap:PlanName
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
us-gaap:PlanName, us-gaap:ShareRepurchaseProgram
us-gaap:ConsolidatedEntities, us-gaap:PlanName
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
us-gaap:PlanName
us-gaap:AwardType
us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
us-gaap:AwardType, us-gaap:StatementEquityComponents
us-gaap:StatementClassOfStock
us-gaap:TemporaryEquityNetIncome

us-gaap:TreasuryStockValueAcquiredCostMethod
us-gaap:StatementEquityComponents
dei:LegalEntity, us-gaap:ConsolidatedEntities
us-gaap:VariableInterestEntityOwnershipPercentage

us-gaap:VariableLeaseCost

bbio:AccruedResearchAndDevelopmentLiabilitiesCurrent
us-gaap:ConsolidatedEntities, us-gaap:TypeOfArrangement
bbio:BusinessAcquisitionCashPerShare
us-gaap:ConsolidatedEntities, us-gaap:TypeOfArrangement
bbio:BusinessAcquisitionCommonShare
us-gaap:ConsolidatedEntities
bbio:BusinessAcquisitionEquityInterestsIssuedOrIssuableFairValue
us-gaap:ConsolidatedEntities, us-gaap:Range, us-gaap:TypeOfArrangement
bbio:BusinessCombinationPotentialCashConsideration
us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency
bbio:CallOptionLiabilityFairValueDisclosure
us-gaap:FairValueByMeasurementFrequency

bbio:ConvertibleSeniorNotes
us-gaap:CumulativeEffectPeriodOfAdoption, us-gaap:AdjustmentsForNewAccountingPronouncements, us-gaap:DebtInstrument
us-gaap:DebtInstrument
us-gaap:Restatement, us-gaap:AdjustmentsForNewAccountingPronouncements, us-gaap:DebtInstrument
us-gaap:LineOfCreditFacility
bbio:DebtInstrumentAdditionalIncreaseAvailableInLoanFacilities
us-gaap:LineOfCreditFacility
bbio:DebtInstrumentAdditionalIncreaseAvailableInLoanFacilitiesNoLaterThanFourteenMonths
us-gaap:LineOfCreditFacility, us-gaap:SubsequentEventType
us-gaap:LineOfCreditFacility
bbio:DebtInstrumentAdditionalIncreaseAvailableInLoanFacilitiesUponAchievementOfCertainPerformanceMilestones
us-gaap:LineOfCreditFacility, us-gaap:SubsequentEventType
us-gaap:LineOfCreditFacility
bbio:DebtInstrumentAdditionalIncreaseAvailableInLoanFacilitiesYearThree
us-gaap:LineOfCreditFacility, us-gaap:SubsequentEventType
us-gaap:DebtInstrument, us-gaap:LineOfCreditFacility
bbio:DebtInstrumentAdditionalPrincipalBorrowingAmount
us-gaap:DebtInstrument
bbio:DebtInstrumentCappedCallTransactionCapPricePerShare
us-gaap:DebtInstrument
bbio:DebtInstrumentOptionToPurchaseAdditionalNotes
us-gaap:DebtInstrument, us-gaap:SubsequentEventType
us-gaap:DebtInstrument
bbio:DebtInstrumentOptionToPurchaseAdditionalNotesExercised
us-gaap:DebtInstrument, us-gaap:SubsequentEventType
us-gaap:DebtInstrument
bbio:DebtInstrumentOptionToPurchaseAdditionalNotesRemainingPortionExercised
us-gaap:DebtInstrument
bbio:DebtIssuanceCostsAndDebtAccretion

bbio:DeferredTaxAssetsAmortizationOfAssets

bbio:DeferredTaxAssetsLeaseLiabilities

bbio:DeferredTaxLiabilitiesRightOfUseAssets
us-gaap:ConsolidatedEntities, us-gaap:SubsequentEventType
bbio:EstimatedTransactionCostsIncurredInMergerTransactions

bbio:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFour

bbio:InvestmentsInEquitySecurities
us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency
us-gaap:FairValueByMeasurementFrequency

bbio:LEOCallOptionLiabilityCurrent

bbio:LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedFuturePayments
us-gaap:PropertyPlantAndEquipmentByType

bbio:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
us-gaap:FairValueByAssetClass, us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency
bbio:LongTermMarketableSecuritiesFairValueDisclosure
us-gaap:FairValueByAssetClass, us-gaap:FairValueByMeasurementFrequency
us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency
us-gaap:FairValueByMeasurementFrequency
us-gaap:ShareRepurchaseProgram
bbio:MaximumPotentialPerformanceBasedMilestoneAwardsToBeSettledInShares

bbio:PayableRelatedToManufacturingSuite
us-gaap:Range, us-gaap:SubsequentEventType, us-gaap:SubsidiarySaleOfStock
bbio:PercentageOfCashCommissionOnGrossProceedsOfSalesOfCommonStock
us-gaap:ShareRepurchaseProgram
bbio:PerformanceBasedMilestoneAwards

bbio:PotentialMilestoneAccruedAmountSettlementInCash

bbio:PotentialMilestoneAccruedAmountSettlementInCashOrStockAtSoleDiscretion

bbio:PotentialMilestoneAccruedAmountSettlementInStock

bbio:PotentialMilestoneAccruedSettlementAmount

bbio:PotentialMilestoneAmount
us-gaap:Range

bbio:PotentialMilestoneFixedMonetaryAmountSettlementInCash

bbio:PotentialMilestoneFixedMonetaryAmountSettlementInCashOrStockAtSoleDiscretion

bbio:PotentialMilestoneFixedMonetaryAmountSettlementInStock

bbio:PotentialMilestoneFixedMonetarySettlementAmount
us-gaap:Ownership, us-gaap:Range, us-gaap:TypeOfArrangement
bbio:PotentialMilestonePayments

bbio:ReceivableCurrentFromLicensingAndCollaborationAgreements
us-gaap:AdjustmentsForNewAccountingPronouncements
us-gaap:ProductOrService, us-gaap:TypeOfArrangement
us-gaap:ConsolidatedEntities, us-gaap:TypeOfArrangement
bbio:RegulatoryMilestonePaymentReceivableSubjectToAchievementOfRegulatorMilestones
us-gaap:ContingentConsiderationByType
bbio:RegulatoryMilestonePayments

bbio:RepurchaseOfNoncontrollingInterestsTransactionCosts
us-gaap:FairValueByAssetClass, us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency
bbio:ShortTermMarketableSecuritiesFairValueDisclosure
us-gaap:FairValueByAssetClass, us-gaap:FairValueByMeasurementFrequency
us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency
us-gaap:FairValueByMeasurementFrequency
us-gaap:Range, us-gaap:StatementEquityComponents, us-gaap:SubsidiarySaleOfStock
bbio:StockIssuableInTransactionValueNewIssues
us-gaap:Collateral, us-gaap:LineOfCreditFacility
bbio:TermLoanMandatoryPrepaymentPercentageOnNetCashProceedsReceived
us-gaap:Ownership, us-gaap:TypeOfArrangement
bbio:UpfrontRegulatoryAndLaunchMilestonePaymentsYetToBeReceived
us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency
bbio:WarrantsFairValueDisclosure
us-gaap:FairValueByMeasurementFrequency

us-gaap:AccruedProfessionalFeesCurrent
us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency
us-gaap:AssetsFairValueDisclosure
us-gaap:FairValueByMeasurementFrequency

us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
us-gaap:FairValueByAssetClass, us-gaap:InvestmentType
us-gaap:InvestmentType

us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
us-gaap:FairValueByAssetClass, us-gaap:InvestmentType
us-gaap:InvestmentType

us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
us-gaap:FairValueByAssetClass, us-gaap:InvestmentType
us-gaap:InvestmentType

us-gaap:AvailableForSaleSecuritiesDebtSecurities
us-gaap:FairValueByAssetClass, us-gaap:InvestmentType
us-gaap:InvestmentType
us-gaap:FairValueByAssetClass, us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency
us-gaap:CashAndCashEquivalentsFairValueDisclosure
us-gaap:FairValueByAssetClass, us-gaap:FairValueByMeasurementFrequency
us-gaap:InvestmentType

us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
us-gaap:InvestmentType
us-gaap:CashEquivalentsAtCarryingValue
us-gaap:ConsolidatedEntities, us-gaap:DebtInstrument, us-gaap:FinancialInstrument
us-gaap:ContractualObligation
us-gaap:FinancialInstrument
us-gaap:FinancialInstrument
us-gaap:ContractualObligationDueAfterFifthYear
us-gaap:FinancialInstrument
us-gaap:ContractualObligationDueInFifthYear
us-gaap:ConsolidatedEntities, us-gaap:DebtInstrument, us-gaap:FinancialInstrument
us-gaap:ContractualObligationDueInNextTwelveMonths
us-gaap:FinancialInstrument
us-gaap:ConsolidatedEntities, us-gaap:DebtInstrument, us-gaap:FinancialInstrument
us-gaap:ContractualObligationDueInSecondYear
us-gaap:FinancialInstrument
us-gaap:ConsolidatedEntities, us-gaap:DebtInstrument, us-gaap:FinancialInstrument
us-gaap:ContractualObligationDueInThirdYear
us-gaap:FinancialInstrument
us-gaap:ConsolidatedEntities, us-gaap:DebtInstrument, us-gaap:LineOfCreditFacility
us-gaap:DebtInstrumentCarryingAmount
us-gaap:ConsolidatedEntities, us-gaap:LineOfCreditFacility
us-gaap:DebtInstrument
us-gaap:DebtInstrument
us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
us-gaap:DebtInstrument
us-gaap:DebtInstrumentConvertibleConversionPrice1
us-gaap:DebtInstrument
us-gaap:DebtInstrumentFaceAmount
us-gaap:DebtInstrument, us-gaap:SubsequentEventType
us-gaap:DebtInstrument
us-gaap:DebtInstrumentInterestRateEffectivePercentage
us-gaap:ConsolidatedEntities, us-gaap:DebtInstrument, us-gaap:LineOfCreditFacility
us-gaap:DebtInstrumentUnamortizedDiscount
us-gaap:ConsolidatedEntities, us-gaap:LineOfCreditFacility
us-gaap:DebtInstrument
us-gaap:DebtInstrument
us-gaap:DebtInstrumentUnamortizedDiscountNoncurrent
us-gaap:ConsolidatedEntities, us-gaap:Range, us-gaap:DebtInstrument, us-gaap:LineOfCreditFacility
us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount
us-gaap:ConsolidatedEntities, us-gaap:BalanceSheetLocation
us-gaap:DeferredCosts
us-gaap:DebtInstrument
us-gaap:DeferredFinanceCostsNet

us-gaap:DeferredIncomeTaxLiabilities

us-gaap:DeferredTaxAssetsEquityMethodInvestments

us-gaap:DeferredTaxAssetsGross

us-gaap:DeferredTaxAssetsOperatingLossCarryforwards

us-gaap:DeferredTaxAssetsOther

us-gaap:DeferredTaxAssetsTaxCreditCarryforwards

us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost

us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals

us-gaap:DeferredTaxLiabilitiesFinancingArrangements

us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
us-gaap:ConsolidatedEntities, us-gaap:DebtInstrument, us-gaap:LineOfCreditFacility
us-gaap:DerivativeFairValueOfDerivativeLiability

us-gaap:DueFromRelatedPartiesCurrent
us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency
us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
us-gaap:FairValueByMeasurementFrequency

us-gaap:EmployeeRelatedLiabilitiesCurrent
us-gaap:PlanName
us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
us-gaap:AwardType, us-gaap:PlanName
us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
us-gaap:AwardType, us-gaap:PlanName
us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
dei:LegalEntity, us-gaap:StatementEquityComponents
us-gaap:EquityMethodInvestmentOwnershipPercentage
dei:LegalEntity
us-gaap:EquityMethodInvestments
us-gaap:FairValueByLiabilityClass
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue

us-gaap:FinanceLeaseLiability

us-gaap:FinanceLeaseLiabilityCurrent

us-gaap:FinanceLeaseLiabilityNoncurrent

us-gaap:FinanceLeaseLiabilityPaymentsDue

us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive

us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths

us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive

us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour

us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree

us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo

us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear

us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency
us-gaap:FinancialLiabilitiesFairValueDisclosure
us-gaap:FairValueByMeasurementFrequency

us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths

us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear

us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour

us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree

us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths

us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear

us-gaap:MarketableSecuritiesNoncurrent
us-gaap:DebtInstrument
us-gaap:NotesPayableFairValueDisclosure

us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
us-gaap:IncomeTaxAuthority
us-gaap:OperatingLossCarryforwards
us-gaap:StatementGeographical, us-gaap:IncomeTaxAuthority

us-gaap:RestrictedCash
us-gaap:BalanceSheetLocation

us-gaap:RestrictedCashCurrent

us-gaap:RestrictedCashNoncurrent
us-gaap:ProductOrService, us-gaap:TypeOfArrangement
us-gaap:RevenueRemainingPerformanceObligation
us-gaap:AwardType
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
us-gaap:AwardType, us-gaap:PlanName
us-gaap:ConsolidatedEntities
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
us-gaap:ConsolidatedEntities, us-gaap:PlanName
us-gaap:PlanName
us-gaap:PlanName, us-gaap:ShareRepurchaseProgram
us-gaap:ConsolidatedEntities
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
us-gaap:ConsolidatedEntities, us-gaap:PlanName
us-gaap:PlanName
us-gaap:PlanName, us-gaap:ShareRepurchaseProgram
us-gaap:ConsolidatedEntities
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
us-gaap:ConsolidatedEntities
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
us-gaap:DebtInstrument, us-gaap:ShareRepurchaseProgram
us-gaap:SharePrice
us-gaap:ConsolidatedEntities
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
us-gaap:ConsolidatedEntities, us-gaap:PlanName
us-gaap:PlanName
us-gaap:PlanName, us-gaap:ShareRepurchaseProgram
us-gaap:Range, us-gaap:ShareRepurchaseProgram, us-gaap:StatementEquityComponents
us-gaap:StockRepurchaseProgramAuthorizedAmount1
us-gaap:IncomeTaxAuthority, us-gaap:TaxCreditCarryforward
us-gaap:TaxCreditCarryforwardAmount

us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
us-gaap:StatementClassOfStock
us-gaap:StatementEquityComponents

Plots across concepts


IncomeStatement
Profit Loss
Balance Sheet
Stockholders Equity
Assets
Operating Lease Right Of Use Asset
Current Assets
Accounts Receivable Net Current
NonCurrent Assets
Operating Lease Right Of Use Asset
Liabilities
Operating Lease Liability
Current Liabilities
Long Term Debt Current
Noncurrent Liabilities
Minority Interest
Stockholders Equity
Retained Earnings Accumulated Deficit
CashFlow
Profit Loss
NetCashProvidedByUsedInOperatingActivities
Profit Loss
NetCashProvidedByUsedInInvestingActivities
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInFinancingActivities
Net Cash Provided By Used In Financing Activities
OperatingLeaseLiability
Operating Lease Liability Current
NonoperatingIncomeExpense
Nonoperating Income Expense
LesseeOperatingLeaseLiabilityPaymentsDue
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year

Tables

  2021-06-302021-03-312019-12-312019-09-30
us-gaap:CommonStockValue ██▂▁0.1530.1520.1240.117
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted █▁146.754299138.627729NA117.071188
us-gaap:EarningsPerShareBasicAndDiluted ▆▁▇█-0.66-1.18-0.6199999999999999-0.51
  2021-06-302021-03-312019-12-312019-09-30
  2021-06-302021-03-312019-12-312019-09-30
  2021-06-302021-03-312019-12-312019-09-30
us-gaap:AllocatedShareBasedCompensationExpense ▇█▂▁32.03534.89610.0075.846
us-gaap:ComprehensiveIncomeNetOfTax ▅▁██-96.255-163.328-56.051-60.512
us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest █▁-5.726-8.003NANA
us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest █▁-101.981-171.331NANA
us-gaap:CostOfGoodsAndServicesSold 0.109NANANA
us-gaap:CostsAndExpenses 148.039NANANA
us-gaap:GeneralAndAdministrativeExpense NA45.40734.97223.495
us-gaap:InterestExpense █▇▂▁10.8399.7383.042.113
us-gaap:InterestExpenseDebt 8.509NANANA
us-gaap:InterestPaidNet ▁█▁▁1.9018.9131.7561.753
us-gaap:NetIncomeLossAttributableToNoncontrollingInterest ▄▃▁█-5.726-8.003-10.693-0.684
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic ▆▁▇█-96.348-163.079-73.458-59.98
us-gaap:NonoperatingIncomeExpense ▁█▅▄-8.059-3.578-5.513-6.132
us-gaap:OperatingExpenses NA167.96692.45781.273
us-gaap:OperatingIncomeLoss ▆▁▇█-94.015-167.504-78.638-54.532
us-gaap:OtherNonoperatingIncomeExpense ▅█▁▂2.4575.766-1.586-0.026
us-gaap:ProfitLoss ▅▁▇█-102.074-171.082-84.151-60.664
us-gaap:ResearchAndDevelopmentExpense ▆█▁▁101.96122.55957.48555.278
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax █▁▃▄54.0240.46213.81926.741
us-gaap:SellingGeneralAndAdministrativeExpense 45.97NANANA
  2021-06-302021-03-312019-12-312019-09-30
  2021-06-302021-03-312019-12-312019-09-30
us-gaap:Assets ██▁▁1081.4861093.308631.679640.53
us-gaap:Liabilities ██▁▁1537.1111481.402155.703116.263
us-gaap:LiabilitiesAndStockholdersEquity ██▁▁1081.4861093.308631.679640.53
us-gaap:StockholdersEquity ▁▂██-464.294-395.294408.454459.758
  2021-06-302021-03-312019-12-312019-09-30
us-gaap:AssetsCurrent ▇█▁▁909.871945.114568.622558.155
us-gaap:CashAndCashEquivalentsAtCarryingValue ▂█▁▄378.42471.176363.773413.973
us-gaap:MarketableSecuritiesCurrent ██▁459.243447.942182.22NA
us-gaap:AccountsReceivableNetCurrent 1.213NANANA
us-gaap:PrepaidExpenseAndOtherAssetsCurrent █▆▂▁26.6725.53422.62922.102
  2021-06-302021-03-312019-12-312019-09-30
us-gaap:PropertyPlantAndEquipmentNet █▇▂▁26.27222.8165.6252.984
us-gaap:IntangibleAssetsNetIncludingGoodwill 20.0NANANA
us-gaap:OperatingLeaseRightOfUseAsset █▁15.96412.997NANA
us-gaap:OtherAssetsNoncurrent █▅▅▁49.79730.17926.2882.598
  2021-06-302021-03-312019-12-312019-09-30
us-gaap:AccountsPayableCurrent █▂▁▂22.32910.348.85210.27
us-gaap:LiabilitiesCurrent █▅▃▁131.90994.72960.38539.858
us-gaap:LongTermDebtCurrent NA3.646NANA
us-gaap:OperatingLeaseLiabilityCurrent █▁4.543.807NANA
us-gaap:OtherAccruedLiabilitiesCurrent █▇▁▁21.17718.2543.023.219
  2021-06-302021-03-312019-12-312019-09-30
us-gaap:LongTermDebtNoncurrent █▅▅▁102.61190.76291.79175.017
 us-gaap:DeferredFinanceCostsNoncurrentNet us-gaap:DebtInstrument bbio:TwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySevenNANANANA
us-gaap:MinorityInterest ▁▁██6.8045.92965.27961.939
us-gaap:OtherLiabilitiesNoncurrent █▇▂▁13.26511.6123.5271.388
us-gaap:OperatingLeaseLiabilityNoncurrent █▁18.02213.862NANA
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo █▁4.2873.488NANA
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree █▁4.0113.282NANA
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour █▁3.983.487NANA
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive NANANANA
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive NANANANA
  2021-06-302021-03-312019-12-312019-09-30
us-gaap:StockholdersEquity ▁▂██-464.294-395.294408.454459.758
us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest ▁▁██-457.49-389.365473.733521.697
 us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest us-gaap:CumulativeEffectPeriodOfAdoption,us-gaap:AdjustmentsForNewAccountingPronouncements srt:CumulativeEffectPeriodOfAdoptionAdjustedBalance,bbio:AccountingStandardsUpdate202006NANANANA
 us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest us-gaap:CumulativeEffectPeriodOfAdoption,us-gaap:AdjustmentsForNewAccountingPronouncements,us-gaap:StatementEquityComponents srt:CumulativeEffectPeriodOfAdoptionAdjustedBalance,bbio:AccountingStandardsUpdate202006,us-gaap:AdditionalPaidInCapitalNANANANA
 us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest us-gaap:CumulativeEffectPeriodOfAdoption,us-gaap:AdjustmentsForNewAccountingPronouncements,us-gaap:StatementEquityComponents srt:CumulativeEffectPeriodOfAdoptionAdjustedBalance,bbio:AccountingStandardsUpdate202006,us-gaap:ParentNANANANA
 us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest us-gaap:CumulativeEffectPeriodOfAdoption,us-gaap:AdjustmentsForNewAccountingPronouncements,us-gaap:StatementEquityComponents srt:CumulativeEffectPeriodOfAdoptionAdjustedBalance,bbio:AccountingStandardsUpdate202006,us-gaap:RetainedEarningsNANANANA
 us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest us-gaap:StatementEquityComponents us-gaap:AccumulatedOtherComprehensiveIncome▃▁█▆0.036-0.0570.2540.152
 us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest us-gaap:StatementEquityComponents us-gaap:AdditionalPaidInCapital▄▁█▆799.679767.117848.107826.062
 us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest us-gaap:StatementEquityComponents us-gaap:CommonStock0.153NA0.1240.117
 us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest us-gaap:StatementEquityComponents us-gaap:NoncontrollingInterest▁▁██6.8045.92965.27961.939
 us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest us-gaap:StatementEquityComponents us-gaap:Parent▁▂██-464.294-395.294408.454459.758
 us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest us-gaap:StatementEquityComponents us-gaap:RetainedEarnings▁▂▇█-1133.854-1037.506-440.031-366.573
 us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest us-gaap:StatementEquityComponents us-gaap:TreasuryStock▁█-130.308-125.0NANA
us-gaap:CommonStockValue ██▂▁0.1530.1520.1240.117
us-gaap:AdditionalPaidInCapitalCommonStock ▄▁█▆799.679767.117848.107826.062
us-gaap:RetainedEarningsAccumulatedDeficit ▁▂▇█-1133.854-1037.506-440.031-366.573
 us-gaap:RetainedEarningsAccumulatedDeficit us-gaap:CumulativeEffectPeriodOfAdoption,us-gaap:AdjustmentsForNewAccountingPronouncements srt:CumulativeEffectPeriodOfAdoptionAdjustment,bbio:AccountingStandardsUpdate202006NANANANA
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax ▃▁█0.036-0.0570.254NA
us-gaap:TreasuryStockValue █▁130.308125.0NANA
us-gaap:MinorityInterest ▁▁██6.8045.92965.27961.939
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue █▁32.50919.841NANA
  2021-06-302021-03-312019-12-312019-09-30
us-gaap:NetCashProvidedByUsedInOperatingActivities ▅▁▆█-91.713-150.765-76.203-49.996
us-gaap:NetCashProvidedByUsedInInvestingActivities █▁█▃0.458-282.052-16.901-197.342
us-gaap:NetCashProvidedByUsedInFinancingActivities ▁█▂▆-1.391547.91242.904367.508
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect ▁█▂█-92.646115.095-50.2120.17
  2021-06-302021-03-312019-12-312019-09-30
us-gaap:AmortizationOfFinancingCosts 0.024NANANA
us-gaap:IncreaseDecreaseInAccountsPayable █▃▂▁11.2331.792-1.418-3.385
us-gaap:NetCashProvidedByUsedInOperatingActivities ▅▁▆█-91.713-150.765-76.203-49.996
us-gaap:ProfitLoss ▅▁▇█-102.074-171.082-84.151-60.664
us-gaap:ShareBasedCompensation ▇█▂▁30.11233.57710.0075.777
  2021-06-302021-03-312019-12-312019-09-30
us-gaap:NetCashProvidedByUsedInInvestingActivities █▁█▃0.458-282.052-16.901-197.342
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment █▇▆▁2.2871.9611.7470.381
  2021-06-302021-03-312019-12-312019-09-30
us-gaap:NetCashProvidedByUsedInFinancingActivities ▁█▂▆-1.391547.91242.904367.508
us-gaap:PaymentsForRepurchaseOfCommonStock ▁█5.30850.0NANA
  2021-06-302021-03-312019-12-312019-09-30
 us-gaap:DebtInstrumentInterestRateStatedPercentage us-gaap:DebtInstrument bbio:TwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySevenNANANANA

Common Stock Value

us-gaap:CommonStockValue

us-gaap:CommonStockValue


Common
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-312019-09-302019-06-302019-05-172019-03-312018-12-312017-12-312016-12-31
Value0.1530.1520.1250.1250.1240.1240.1170.00.00.0920.0920.0510.021
Percentage of CommonStockValue100.0100.0100.0100.0100.0100.0100.00.00.0100.0100.0100.0100.0
Percentage of Assets0.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:CommonStockValue us-gaap:Range, us-gaap:SubsequentEventType, us-gaap:SubsidiarySaleOfStock

srt:Maximum, us-gaap:SubsequentEvent, bbio:AtTheMarketSalesAgreement


Common
Period End2020-07-07
Value350
Percentage of CommonStockValue0.0
Percentage of Assets0.0
Percentage of Assets srt:Maximum us-gaap:SubsequentEvent bbio:AtTheMarketSalesAgreement0.0

Weighted Average Number Of Share Outstanding Basic And Diluted

us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted

us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted


Weighted
Period End2021-06-302021-03-312020-06-302020-03-312019-09-302019-06-302019-03-312018-09-30
Value146138117117117929260
Percentage of WeightedAverageNumberOfShareOutstandingBasicAndDiluted100.0100.0100.0100.0100.0100.0100.0100.0

Earnings Per Share Basic And Diluted

us-gaap:EarningsPerShareBasicAndDiluted

us-gaap:EarningsPerShareBasicAndDiluted


Earnings
Period End2021-06-302021-03-312020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-30
Value-0.66-1.18-1.03-0.78-0.62-0.51-0.71-0.66-0.52-0.52
Percentage of EarningsPerShareBasicAndDiluted100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Allocated Share Based Compensation Expense

us-gaap:AllocatedShareBasedCompensationExpense

us-gaap:AllocatedShareBasedCompensationExpense


Allocated
Period End2021-06-302021-03-312020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-30
Value32341810105.8463.3582.2323.1131.186
Percentage of AllocatedShareBasedCompensationExpense100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax59.37553.20.00.072.421.90.00.00.00.0

us-gaap:AllocatedShareBasedCompensationExpense us-gaap:AwardType, us-gaap:PlanName

bbio:OtherRSAs, bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlan


Allocated
Period End2021-06-30
Value1.489
Percentage of AllocatedShareBasedCompensationExpense4.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax bbio:OtherRSAs bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlan0.0

us-gaap:EmployeeStockOption, bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlan


Allocated
Period End2021-06-302021-03-312020-06-302020-03-31
Value7.85.93.12.9
Percentage of AllocatedShareBasedCompensationExpense24.316.916.928.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax14.41277.10.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:EmployeeStockOption bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlan0.00.00.00.0

us-gaap:RestrictedStock, bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlan


Allocated
Period End2021-06-302021-03-312020-06-302020-03-31
Value188.51.83.0
Percentage of AllocatedShareBasedCompensationExpense56.824.49.829.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax33.71839.80.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:RestrictedStock bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlan0.00.00.00.0

us-gaap:RestrictedStockUnitsRSU, bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlan


Allocated
Period End2021-06-302021-03-312020-06-302020-03-31
Value5.84.62.00.7
Percentage of AllocatedShareBasedCompensationExpense18.113.210.96.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax10.7995.70.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:RestrictedStockUnitsRSU bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlan0.00.00.00.0

us-gaap:AllocatedShareBasedCompensationExpense us-gaap:ConsolidatedEntities

bbio:BridgeBioServicesInc


Allocated
Period End2021-06-302021-03-312020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-31
Value3131158.0637.8143.9522.1881.2362.209
Percentage of AllocatedShareBasedCompensationExpense98.988.984.478.978.167.665.255.471.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax58.76716.70.00.056.514.80.00.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax bbio:BridgeBioServicesInc0.00.00.00.00.00.00.00.00.0

bbio:OtherConsolidatedEntities


Allocated
Period End2021-06-302021-03-312020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-30
Value0.343.8650.1520.2320.5450.230.0040.0320.0760.166
Percentage of AllocatedShareBasedCompensationExpense1.111.10.82.35.43.90.11.42.414.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.6836.60.00.03.90.90.00.00.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax bbio:OtherConsolidatedEntities0.00.00.00.00.00.00.00.00.00.0

us-gaap:AllocatedShareBasedCompensationExpense us-gaap:ConsolidatedEntities, us-gaap:IncomeStatementLocation

bbio:BridgeBioServicesInc, us-gaap:GeneralAndAdministrativeExpense


Allocated
Period End2021-03-312020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-31
Value9.7317.9057.467.4373.3432.1881.2362.209
Percentage of AllocatedShareBasedCompensationExpense27.943.073.074.357.265.255.471.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2106.30.00.053.812.50.00.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax bbio:BridgeBioServicesInc us-gaap:GeneralAndAdministrativeExpense0.00.00.00.00.00.00.00.0

bbio:BridgeBioServicesInc, us-gaap:ResearchAndDevelopmentExpense


Allocated
Period End2021-06-302021-03-312020-06-302020-03-312019-12-31
Value19217.6170.6030.377
Percentage of AllocatedShareBasedCompensationExpense59.861.041.45.93.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax35.54610.40.00.02.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax bbio:BridgeBioServicesInc us-gaap:ResearchAndDevelopmentExpense0.00.00.00.00.0

bbio:BridgeBioServicesInc, us-gaap:SellingGeneralAndAdministrativeExpenses


Allocated
Period End2021-06-30
Value12
Percentage of AllocatedShareBasedCompensationExpense39.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax23.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax bbio:BridgeBioServicesInc us-gaap:SellingGeneralAndAdministrativeExpenses0.0

bbio:OtherConsolidatedEntities, us-gaap:GeneralAndAdministrativeExpense


Allocated
Period End2021-03-312020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-30
Value2.7160.0460.110.30.1280.0020.0150.0320.086
Percentage of AllocatedShareBasedCompensationExpense7.80.31.13.02.20.10.71.07.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax587.90.00.02.20.50.00.00.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax bbio:OtherConsolidatedEntities us-gaap:GeneralAndAdministrativeExpense0.00.00.00.00.00.00.00.00.0

bbio:OtherConsolidatedEntities, us-gaap:ResearchAndDevelopmentExpense


Allocated
Period End2021-06-302021-03-312020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-30
Value0.1211.1490.1060.1220.2450.1020.0020.0170.0440.08
Percentage of AllocatedShareBasedCompensationExpense0.43.30.61.22.41.70.10.81.46.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.2248.70.00.01.80.40.00.00.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax bbio:OtherConsolidatedEntities us-gaap:ResearchAndDevelopmentExpense0.00.00.00.00.00.00.00.00.00.0

bbio:OtherConsolidatedEntities, us-gaap:SellingGeneralAndAdministrativeExpenses


Allocated
Period End2021-06-30
Value0.219
Percentage of AllocatedShareBasedCompensationExpense0.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.4
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax bbio:OtherConsolidatedEntities us-gaap:SellingGeneralAndAdministrativeExpenses0.0

us-gaap:AllocatedShareBasedCompensationExpense us-gaap:IncomeStatementLocation

us-gaap:GeneralAndAdministrativeExpense


Allocated
Period End2021-03-312020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-30
Value129.2218.5828.7024.5092.8041.7632.6130.857
Percentage of AllocatedShareBasedCompensationExpense35.750.184.087.077.183.579.083.972.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax2694.20.00.063.016.90.00.00.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:GeneralAndAdministrativeExpense0.00.00.00.00.00.00.00.00.0

us-gaap:ResearchAndDevelopmentExpense


Allocated
Period End2021-06-302021-03-312020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-30
Value19229.1711.641.3051.3370.5540.4690.50.329
Percentage of AllocatedShareBasedCompensationExpense60.264.349.916.013.022.916.521.016.127.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax35.74859.10.00.09.45.00.00.00.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:ResearchAndDevelopmentExpense0.00.00.00.00.00.00.00.00.00.0

us-gaap:SellingGeneralAndAdministrativeExpenses


Allocated
Period End2021-06-30
Value12
Percentage of AllocatedShareBasedCompensationExpense39.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax23.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:SellingGeneralAndAdministrativeExpenses0.0

us-gaap:AllocatedShareBasedCompensationExpense us-gaap:PlanName, us-gaap:ShareRepurchaseProgram

bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlan, bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgram


Allocated
Period End2021-06-30
Value16
Percentage of AllocatedShareBasedCompensationExpense52.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax30.9
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlan bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgram0.0

us-gaap:AllocatedShareBasedCompensationExpense us-gaap:SubsidiarySaleOfStock

us-gaap:EmployeeStock


Allocated
Period End2021-03-312020-06-302020-03-312019-12-312019-09-30
Value0.40.40.10.10.3
Percentage of AllocatedShareBasedCompensationExpense1.12.21.01.05.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax86.60.00.00.71.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:EmployeeStock0.00.00.00.00.0

Comprehensive Income Net Of Tax

us-gaap:ComprehensiveIncomeNetOfTax

us-gaap:ComprehensiveIncomeNetOfTax


Comprehensive
Period End2021-06-302021-03-312020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-30
Value-96255000.0-163330000.0-120900000.0-91378000.0-56051000.0-60512000.0-65964000.0-61185000.0-10539000.0-42078000.0
Percentage of ComprehensiveIncomeNetOfTax100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax-178.2-35352.40.00.0-405.6-226.30.00.00.00.0

Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest

us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest

us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest


Comprehensive
Period End2021-06-302021-03-312020-06-302020-03-312019-06-302019-03-31
Value-5726000.0-8003000.0-15180000.0-12232000.0-8370000.0-8251000.0
Percentage of ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax-10.6-1732.30.00.00.00.0

Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest

us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest

us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest


Comprehensive
Period End2021-06-302021-03-312020-06-302020-03-312019-06-302019-03-31
Value-101980000.0-171330000.0-136080000.0-103610000.0-74334000.0-69436000.0
Percentage of ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax-188.8-37084.60.00.00.00.0

Cost Of Goods And Services Sold

us-gaap:CostOfGoodsAndServicesSold

us-gaap:CostOfGoodsAndServicesSold


Cost
Period End2021-06-30
Value109000.0
Percentage of CostOfGoodsAndServicesSold100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.2

Costs And Expenses

us-gaap:CostsAndExpenses

us-gaap:CostsAndExpenses


Costs
Period End2021-06-302020-06-30
Value148124
Percentage of CostsAndExpenses100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax274.00.0

General And Administrative Expense

us-gaap:GeneralAndAdministrativeExpense

us-gaap:GeneralAndAdministrativeExpense


General
Period End2021-03-312020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-30
Value453734342316181410
Percentage of GeneralAndAdministrativeExpense100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax9828.40.00.0253.187.90.00.00.00.0

Interest Expense

us-gaap:InterestExpense

us-gaap:InterestExpense


Interest
Period End2021-06-302021-03-312020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-30
Value109.738104.013.042.1131.9411.6711.1791.156
Percentage of InterestExpense100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax20.12107.80.00.022.07.90.00.00.00.0

Interest Expense Debt

us-gaap:InterestExpenseDebt

us-gaap:InterestExpenseDebt


Interest
Period End2021-06-302020-06-30
Value8.50910
Percentage of InterestExpenseDebt100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax15.80.0

us-gaap:InterestExpenseDebt us-gaap:DebtInstrument

bbio:TwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySeven


Interest
Period End2021-06-302021-03-312020-06-302020-03-31
Value3.853.8478.2032.014
Percentage of InterestExpenseDebt45.20.080.30.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax7.1832.70.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax bbio:TwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySeven0.00.00.00.0

bbio:TwoPointTwoFivePercentageConvertibleSeniorNotesDueTwoThousandAndTwentyNine


Interest
Period End2021-06-302021-03-31
Value4.6593.254
Percentage of InterestExpenseDebt54.80.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax8.6704.3
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax bbio:TwoPointTwoFivePercentageConvertibleSeniorNotesDueTwoThousandAndTwentyNine0.00.0

us-gaap:InterestExpenseDebt us-gaap:LineOfCreditFacility

bbio:HerculesCapitalInc


Interest
Period End2021-06-302021-03-312020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-30
Value2.42.03.91.52.62.11.91.71.40.9
Percentage of InterestExpenseDebt28.20.038.20.00.00.00.00.00.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax4.4432.90.00.018.87.90.00.00.00.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax bbio:HerculesCapitalInc0.00.00.00.00.00.00.00.00.00.0

Interest Paid Net

us-gaap:InterestPaidNet

us-gaap:InterestPaidNet


Interest
Period End2021-06-302021-03-312020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-31
Value1.9018.9132.0682.0541.7561.7531.4071.1760.856
Percentage of InterestPaidNet100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax3.51929.20.00.012.76.60.00.00.0

Net Income Loss Attributable To Noncontrolling Interest

us-gaap:NetIncomeLossAttributableToNoncontrollingInterest

us-gaap:NetIncomeLossAttributableToNoncontrollingInterest


Net
Period End2021-06-302021-03-312020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-30
Value-5726000.0-8003000.0-15180000.0-12232000.0-10693000.0-684000.0-8370000.0-8251000.0-10600000.0-10677000.0
Percentage of NetIncomeLossAttributableToNoncontrollingInterest100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax-10.6-1732.30.00.0-77.4-2.60.00.00.00.0

Net Income Loss Available To Common Stockholders Basic

us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic

us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic


Net
Period End2021-06-302021-03-312020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-30
Value-96348000.0-163080000.0-121030000.0-91850000.0-73458000.0-59980000.0-65964000.0-61185000.0-38641000.0-31401000.0
Percentage of NetIncomeLossAvailableToCommonStockholdersBasic100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax-178.3-35298.50.00.0-531.6-224.30.00.00.00.0

Nonoperating Income Expense

us-gaap:NonoperatingIncomeExpense

us-gaap:NonoperatingIncomeExpense


Nonoperating
Period End2021-06-302021-03-312020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-30
Value-8.059-3.578-11.647-1.595-5.513-6.132-5.016-5.68416-0.622
Percentage of NonoperatingIncomeExpense100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax-14.9-774.50.00.0-39.9-22.90.00.00.00.0

Operating Expenses

us-gaap:OperatingExpenses

us-gaap:OperatingExpenses


Operating
Period End2021-03-312020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-30
Value167124102928169636541
Percentage of OperatingExpenses100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax36356.30.00.0669.1303.90.00.00.00.0

Operating Income Loss

us-gaap:OperatingIncomeLoss

us-gaap:OperatingIncomeLoss


Operating
Period End2021-06-302021-03-312020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-30
Value-94015000.0-167500000.0-124570000.0-102490000.0-78638000.0-54532000.0-69318000.0-63752000.0-65583000.0-41456000.0
Percentage of OperatingIncomeLoss100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax-174.0-36256.30.00.0-569.1-203.90.00.00.00.0

Other Nonoperating Income Expense

us-gaap:OtherNonoperatingIncomeExpense

us-gaap:OtherNonoperatingIncomeExpense


Other
Period End2021-06-302021-03-312020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-30
Value2457000.05766000.0-1827000.0474000.0-1586000.0-26000.0219000.0-1521000.0-3004000.06000.0
Percentage of OtherNonoperatingIncomeExpense100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax4.51248.10.00.0-11.5-0.10.00.00.00.0

Profit Loss

us-gaap:ProfitLoss

us-gaap:ProfitLoss


Profit
Period End2021-06-302021-03-312020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-30
Value-102070000.0-171080000.0-136210000.0-104080000.0-84151000.0-60664000.0-74334000.0-69436000.0-49241000.0-42078000.0
Percentage of ProfitLoss100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax-188.9-37030.70.00.0-609.0-226.90.00.00.00.0

Research And Development Expense

us-gaap:ResearchAndDevelopmentExpense

us-gaap:ResearchAndDevelopmentExpense


Research
Period End2021-06-302021-03-312020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-30
Value1011228668575552445131
Percentage of ResearchAndDevelopmentExpense100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax188.726527.90.00.0416.0206.70.00.00.00.0

us-gaap:ResearchAndDevelopmentExpense us-gaap:AdjustmentsForNewAccountingPronouncements

us-gaap:AccountingStandardsUpdate201818


Research
Period End2021-06-30
Value19
Percentage of ResearchAndDevelopmentExpense19.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax36.1
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:AccountingStandardsUpdate2018180.0

us-gaap:ResearchAndDevelopmentExpense us-gaap:ContingentConsiderationByType

bbio:RegulatoryMilestonePaymentUponFDAApprovalOfNulibry


Research
Period End2021-03-31
Value2.0
Percentage of ResearchAndDevelopmentExpense1.6
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax432.9
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax bbio:RegulatoryMilestonePaymentUponFDAApprovalOfNulibry0.0

Revenue From Contract With Customer Excluding Assessed Tax

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax


Revenue
Period End2021-06-302021-03-312019-12-312019-09-30
Value540.4621326
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax100.0100.0100.0100.0

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:CounterpartyName, us-gaap:ProductOrService, us-gaap:TypeOfArrangement

bbio:LianBio, us-gaap:License, bbio:LicenseAgreement


Revenue
Period End2021-06-30
Value8.5
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax15.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax15.7
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax bbio:LianBio us-gaap:License bbio:LicenseAgreement100.0

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:ProductOrService

us-gaap:License


Revenue
Period End2021-06-30
Value53
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax98.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax98.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:License100.0

us-gaap:Product


Revenue
Period End2021-06-30
Value0.987
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.8
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax us-gaap:Product100.0

Selling General And Administrative Expense

us-gaap:SellingGeneralAndAdministrativeExpense

us-gaap:SellingGeneralAndAdministrativeExpense


Selling
Period End2021-06-302020-06-30
Value4537
Percentage of SellingGeneralAndAdministrativeExpense100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax85.10.0

us-gaap:SellingGeneralAndAdministrativeExpense us-gaap:ContingentConsiderationByType

bbio:SalesBasedMilestonePayment


Selling
Period End2021-06-30
Value1.0
Percentage of SellingGeneralAndAdministrativeExpense2.2
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax1.9
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax bbio:SalesBasedMilestonePayment0.0

Assets

us-gaap:Assets

us-gaap:Assets


Assets
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-312019-09-302018-12-31
Value10811093703905989631640464
Percentage of Assets100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets100.0100.0100.0100.0100.0100.0100.0100.0

Liabilities

us-gaap:Liabilities

us-gaap:Liabilities


Liabilities
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-312019-09-302018-12-31
Value1537148159557753715511687
Percentage of Liabilities100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets142.1135.584.763.854.324.618.218.8

Liabilities And Stockholders Equity

us-gaap:LiabilitiesAndStockholdersEquity

us-gaap:LiabilitiesAndStockholdersEquity


Liabilities
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-312019-09-302018-12-31
Value10811093703905989631640464
Percentage of LiabilitiesAndStockholdersEquity100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets100.0100.0100.0100.0100.0100.0100.0100.0

Stockholders Equity

us-gaap:StockholdersEquity

us-gaap:StockholdersEquity


Stockholders
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-312019-09-302019-06-302019-05-172019-03-312018-12-312017-12-312016-12-31
Value-464.294-395.294572653804084590.00.02523148514
Percentage of StockholdersEquity100.0100.0100.0100.0100.0100.0100.00.00.0100.0100.0100.0100.0
Percentage of Assets-42.9-36.28.229.438.564.771.80.00.00.067.70.00.0

Assets Current

us-gaap:AssetsCurrent

us-gaap:AssetsCurrent


Assets
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-312019-09-302018-12-31
Value909945642861924568558445
Percentage of AssetsCurrent100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets84.186.491.495.293.490.087.195.8

Cash And Cash Equivalents At Carrying Value

us-gaap:CashAndCashEquivalentsAtCarryingValue

us-gaap:CashAndCashEquivalentsAtCarryingValue


Cash
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302017-12-31
Value37847135654075736341311237323821191
Percentage of CashAndCashEquivalentsAtCarryingValue100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets35.043.150.659.876.557.664.60.00.051.30.00.0

Marketable Securities Current

us-gaap:MarketableSecuritiesCurrent

us-gaap:MarketableSecuritiesCurrent


Marketable
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-31
Value459447251300148182
Percentage of MarketableSecuritiesCurrent100.0100.0100.0100.0100.0100.0
Percentage of Assets42.541.035.733.115.028.8

Accounts Receivable Net Current

us-gaap:AccountsReceivableNetCurrent

us-gaap:AccountsReceivableNetCurrent


Accounts
Period End2021-06-30
Value1213000.0
Percentage of AccountsReceivableNetCurrent100.0
Percentage of Assets0.1

Prepaid Expense And Other Assets Current

us-gaap:PrepaidExpenseAndOtherAssetsCurrent

us-gaap:PrepaidExpenseAndOtherAssetsCurrent


Prepaid
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-312019-09-302018-12-31
Value262535201922229.137
Percentage of PrepaidExpenseAndOtherAssetsCurrent100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets2.52.35.12.32.03.63.52.0

Property Plant And Equipment Net

us-gaap:PropertyPlantAndEquipmentNet

us-gaap:PropertyPlantAndEquipmentNet


Property
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-312019-09-302018-12-31
Value26222015155.6252.9841.575
Percentage of PropertyPlantAndEquipmentNet100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets2.42.12.91.71.60.90.50.3

Intangible Assets Net Including Goodwill

us-gaap:IntangibleAssetsNetIncludingGoodwill

us-gaap:IntangibleAssetsNetIncludingGoodwill


Intangible
Period End2021-06-30
Value20
Percentage of IntangibleAssetsNetIncludingGoodwill100.0
Percentage of Assets1.8

Operating Lease Right Of Use Asset

us-gaap:OperatingLeaseRightOfUseAsset

us-gaap:OperatingLeaseRightOfUseAsset


Operating
Period End2021-06-302021-03-312020-12-312020-06-302020-03-31
Value151216108.855
Percentage of OperatingLeaseRightOfUseAsset100.0100.0100.0100.0100.0
Percentage of Assets1.51.22.31.20.9

Other Assets Noncurrent

us-gaap:OtherAssetsNoncurrent

us-gaap:OtherAssetsNoncurrent


Other
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-312019-09-302018-12-31
Value4930231717262.5981.093
Percentage of OtherAssetsNoncurrent100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets4.62.83.41.91.74.20.40.2

Accounts Payable Current

us-gaap:AccountsPayableCurrent

us-gaap:AccountsPayableCurrent


Accounts
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-312019-09-302018-12-31
Value22108.94512138.8521013
Percentage of AccountsPayableCurrent100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets2.10.91.31.41.31.41.62.9

Liabilities Current

us-gaap:LiabilitiesCurrent

us-gaap:LiabilitiesCurrent


Liabilities
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-312019-09-302018-12-31
Value13194959264603932
Percentage of LiabilitiesCurrent100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets12.28.713.610.26.69.66.27.0

Long Term Debt Current

us-gaap:LongTermDebtCurrent

us-gaap:LongTermDebtCurrent


Long
Period End2021-03-312020-12-31
Value3646000.01458000.0
Percentage of LongTermDebtCurrent100.0100.0
Percentage of Assets0.30.2

Operating Lease Liability Current

us-gaap:OperatingLeaseLiabilityCurrent

us-gaap:OperatingLeaseLiabilityCurrent


Operating
Period End2021-06-302021-03-312020-12-312020-06-302020-03-31
Value4540000.03807000.03795000.03627000.02510000.0
Percentage of OperatingLeaseLiabilityCurrent100.0100.0100.0100.0100.0
Percentage of Assets0.40.30.50.40.3

Other Accrued Liabilities Current

us-gaap:OtherAccruedLiabilitiesCurrent

us-gaap:OtherAccruedLiabilitiesCurrent


Other
Period End2021-06-302021-03-312020-12-312019-12-312019-09-302018-12-31
Value2118133.023.2191.328
Percentage of OtherAccruedLiabilitiesCurrent100.0100.0100.0100.0100.0100.0
Percentage of Assets2.01.71.90.50.50.3

Long Term Debt Noncurrent

us-gaap:LongTermDebtNoncurrent

us-gaap:LongTermDebtNoncurrent


Long
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-312019-09-302018-12-31
Value10290929292917554
Percentage of LongTermDebtNoncurrent100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets9.58.313.110.39.314.511.711.7

us-gaap:LongTermDebtNoncurrent us-gaap:DebtInstrument

bbio:HerculesTermLoan


Long
Period End2020-12-312019-12-312018-12-31
Value767554
Percentage of LongTermDebtNoncurrent83.282.4100.0
Percentage of Assets10.912.011.7
Percentage of Assets bbio:HerculesTermLoan0.00.00.0

bbio:TwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySeven


Long
Period End2021-06-302021-03-312020-12-312020-06-302020-03-31
Value539538383373368
Percentage of LongTermDebtNoncurrent525.4593.5414.9402.2399.2
Percentage of Assets49.849.354.541.337.3
Percentage of Assets bbio:TwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySeven0.00.00.00.00.0

bbio:TwoPointTwoFivePercentageConvertibleSeniorNotesDueTwoThousandAndTwentyNine


Long
Period End2021-06-302021-03-31
Value732731
Percentage of LongTermDebtNoncurrent713.6806.2
Percentage of Assets67.766.9
Percentage of Assets bbio:TwoPointTwoFivePercentageConvertibleSeniorNotesDueTwoThousandAndTwentyNine0.00.0

Deferred Finance Costs Noncurrent Net

us-gaap:DeferredFinanceCostsNoncurrentNet us-gaap:DebtInstrument

us-gaap:DeferredFinanceCostsNoncurrentNet

bbio:TwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySeven


Deferred
Period End2020-12-312020-06-302020-03-312020-03-09
Value8160000.08642000.08875000.08900000.0
Percentage of DeferredFinanceCostsNoncurrentNet100.0100.0100.0100.0
Percentage of Assets1.21.00.90.0
Percentage of Assets bbio:TwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySeven0.00.00.00.0

Minority Interest

us-gaap:MinorityInterest

us-gaap:MinorityInterest


Minority
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312017-12-312016-12-31
Value6.8045.92948596865614858622.4982.595
Percentage of MinorityInterest100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets0.60.56.96.66.910.39.70.00.013.40.00.0

us-gaap:MinorityInterest dei:LegalEntity

bbio:EidosTherapeuticsInc


Minority
Period End2020-12-312020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312017-12-312016-12-31
Value40536259554654580.7660.605
Percentage of MinorityInterest83.189.791.691.589.495.193.593.330.723.3
Percentage of Assets5.75.96.39.58.60.00.012.50.00.0
Percentage of Assets bbio:EidosTherapeuticsInc0.00.00.00.00.00.00.00.00.00.0

Other Liabilities Noncurrent

us-gaap:OtherLiabilitiesNoncurrent

us-gaap:OtherLiabilitiesNoncurrent


Other
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-312019-09-302018-12-31
Value13119.529.3992.7973.5271.3880.495
Percentage of OtherLiabilitiesNoncurrent100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets1.21.11.41.00.30.60.20.1

us-gaap:OtherLiabilitiesNoncurrent us-gaap:Restatement, us-gaap:AdjustmentsForNewAccountingPronouncements

srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustment, bbio:AccountingStandardsUpdate202006


Other
Period End2021-01-01
Value-1.095
Percentage of OtherLiabilitiesNoncurrent0.0
Percentage of Assets0.0
Percentage of Assets srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustment bbio:AccountingStandardsUpdate2020060.0

Operating Lease Liability Noncurrent

us-gaap:OperatingLeaseLiabilityNoncurrent

us-gaap:OperatingLeaseLiabilityNoncurrent


Operating
Period End2021-06-302021-03-312020-12-312020-06-302020-03-31
Value1813149.1178.678
Percentage of OperatingLeaseLiabilityNoncurrent100.0100.0100.0100.0100.0
Percentage of Assets1.71.32.11.00.9

Lessee Operating Lease Liability Payments Due Year Two

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo


Lessee
Period End2021-06-302021-03-312020-12-31
Value4287000.03488000.04291000.0
Percentage of LesseeOperatingLeaseLiabilityPaymentsDueYearTwo100.0100.0100.0
Percentage of Assets0.40.30.6

Lessee Operating Lease Liability Payments Due Year Three

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree


Lessee
Period End2021-06-302021-03-312020-12-31
Value4011000.03282000.03434000.0
Percentage of LesseeOperatingLeaseLiabilityPaymentsDueYearThree100.0100.0100.0
Percentage of Assets0.40.30.5

Lessee Operating Lease Liability Payments Due Year Four

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour


Lessee
Period End2021-06-302021-03-312020-12-31
Value3980000.03487000.03231000.0
Percentage of LesseeOperatingLeaseLiabilityPaymentsDueYearFour100.0100.0100.0
Percentage of Assets0.40.30.5

Lessee Operating Lease Liability Payments Due Year Five

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive


Lessee
Period End2020-12-31
Value3430000.0
Percentage of LesseeOperatingLeaseLiabilityPaymentsDueYearFive100.0
Percentage of Assets0.5

Lessee Operating Lease Liability Payments Due After Year Five

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive


Lessee
Period End2020-12-31
Value2608000.0
Percentage of LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive100.0
Percentage of Assets0.4

Operating Lease Liability

us-gaap:OperatingLeaseLiability

us-gaap:OperatingLeaseLiability


Operating
Period End2021-06-302021-03-312020-12-312020-06-302020-03-31
Value2217181211
Percentage of OperatingLeaseLiability100.0100.0100.0100.0100.0
Percentage of Assets2.11.62.61.41.1

Lessee Operating Lease Liability Payments Due

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue


Lessee
Period End2021-06-302021-03-312020-12-31
Value262021
Percentage of LesseeOperatingLeaseLiabilityPaymentsDue100.0100.0100.0
Percentage of Assets2.51.93.1

Lessee Operating Lease Liability Undiscounted Excess Amount

us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount

us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount


Lessee
Period End2021-06-302021-03-312020-12-31
Value4278000.03090000.03347000.0
Percentage of LesseeOperatingLeaseLiabilityUndiscountedExcessAmount100.0100.0100.0
Percentage of Assets0.40.30.5

Stockholders Equity

us-gaap:StockholdersEquity

us-gaap:StockholdersEquity


Stockholders
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-312019-09-302019-06-302019-05-172019-03-312018-12-312017-12-312016-12-31
Value-464.294-395.294572653804084590.00.02523148514
Percentage of StockholdersEquity100.0100.0100.0100.0100.0100.0100.00.00.0100.0100.0100.0100.0
Percentage of Assets-42.9-36.28.229.438.564.771.80.00.00.067.70.00.0

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest


Stockholders
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312016-12-31
Value-457.49-389.365106325449473521211310377165204618817
Percentage of StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets-42.3-35.615.136.045.475.081.40.00.081.10.00.00.00.00.0

us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest us-gaap:CumulativeEffectPeriodOfAdoption, us-gaap:AdjustmentsForNewAccountingPronouncements

srt:CumulativeEffectPeriodOfAdoptionAdjustedBalance, bbio:AccountingStandardsUpdate202006


Stockholders
Period End2020-12-31
Value-153.75
Percentage of StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-144.7
Percentage of Assets-21.9
Percentage of Assets srt:CumulativeEffectPeriodOfAdoptionAdjustedBalance bbio:AccountingStandardsUpdate2020060.0

us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest us-gaap:CumulativeEffectPeriodOfAdoption, us-gaap:AdjustmentsForNewAccountingPronouncements, us-gaap:StatementEquityComponents

srt:CumulativeEffectPeriodOfAdoptionAdjustedBalance, bbio:AccountingStandardsUpdate202006, us-gaap:AdditionalPaidInCapital


Stockholders
Period End2020-12-31
Value-168.078
Percentage of StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-158.2
Percentage of Assets-23.9
Percentage of Assets srt:CumulativeEffectPeriodOfAdoptionAdjustedBalance bbio:AccountingStandardsUpdate202006 us-gaap:AdditionalPaidInCapital0.0

srt:CumulativeEffectPeriodOfAdoptionAdjustedBalance, bbio:AccountingStandardsUpdate202006, us-gaap:Parent


Stockholders
Period End2020-12-31
Value-153.75
Percentage of StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-144.7
Percentage of Assets-21.9
Percentage of Assets srt:CumulativeEffectPeriodOfAdoptionAdjustedBalance bbio:AccountingStandardsUpdate202006 us-gaap:Parent0.0

srt:CumulativeEffectPeriodOfAdoptionAdjustedBalance, bbio:AccountingStandardsUpdate202006, us-gaap:RetainedEarnings


Stockholders
Period End2020-12-31
Value14
Percentage of StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest13.5
Percentage of Assets2.0
Percentage of Assets srt:CumulativeEffectPeriodOfAdoptionAdjustedBalance bbio:AccountingStandardsUpdate202006 us-gaap:RetainedEarnings0.0

us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest us-gaap:StatementEquityComponents

us-gaap:AccumulatedOtherComprehensiveIncome


Stockholders
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-312019-09-302019-03-312018-12-31
Value0.036-0.0570.1920.8580.7260.2540.152492494
Percentage of StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-0.00.00.20.30.20.10.0158.7131.0
Percentage of Assets0.0-0.00.00.10.10.00.00.0106.3
Percentage of Assets us-gaap:AccumulatedOtherComprehensiveIncome0.00.00.00.00.00.00.00.00.0

us-gaap:AdditionalPaidInCapital


Stockholders
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312016-12-31
Value799767102199298684882646949249422923113813432
Percentage of StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-174.8-197.0961.2304.9219.8179.0158.3222.1158.7131.0138.4113.3224.8152.2188.7
Percentage of Assets73.970.2145.2109.799.7134.3129.00.00.0106.30.00.00.00.00.0
Percentage of Assets us-gaap:AdditionalPaidInCapital0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:CommonStock


Stockholders
Period End2021-06-302020-12-312020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312016-12-31
Value0.1530.1250.1250.1240.1240.1170.0930.0930.0920.0610.060.0520.0510.021
Percentage of StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-0.00.10.00.00.00.00.00.00.00.00.00.10.10.1
Percentage of Assets0.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Percentage of Assets us-gaap:CommonStock0.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:NoncontrollingInterest


Stockholders
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312016-12-31
Value6.8045.929485968656148586277825.8012.4982.595
Percentage of StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-1.5-1.545.518.415.213.811.922.918.816.546.540.29.42.814.8
Percentage of Assets0.60.56.96.66.910.39.70.00.013.40.00.00.00.00.0
Percentage of Assets us-gaap:NoncontrollingInterest0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:Parent


Stockholders
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312016-12-31
Value-464.294-395.2945726538040845916225231488122558514
Percentage of StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest101.5101.554.581.684.886.288.177.181.283.553.559.890.697.285.2
Percentage of Assets-42.9-36.28.229.438.564.771.80.00.067.70.00.00.00.00.0
Percentage of Assets us-gaap:Parent0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:RetainedEarnings


Stockholders
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312016-12-31
Value-1133.854-1037.506-888.755-652.915-531.881-440.031-366.573-306.593-240.629-179.444-140.803-109.402-82.851-48.695-18.13
Percentage of StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest247.8266.5-836.4-200.5-118.5-92.9-70.3-145.1-77.5-47.6-84.9-53.5-134.3-55.1-103.7
Percentage of Assets-104.8-94.9-126.3-72.1-53.7-69.7-57.20.00.0-38.60.00.00.00.00.0
Percentage of Assets us-gaap:RetainedEarnings0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:TreasuryStock


Stockholders
Period End2021-06-302021-03-312020-12-312020-06-302020-03-31
Value-130.308-125.0-75.0-75.0-75.0
Percentage of StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest28.532.1-70.6-23.0-16.7
Percentage of Assets-12.0-11.4-10.7-8.3-7.6
Percentage of Assets us-gaap:TreasuryStock0.00.00.00.00.0

Common Stock Value

us-gaap:CommonStockValue

us-gaap:CommonStockValue


Common
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-312019-09-302019-06-302019-05-172019-03-312018-12-312017-12-312016-12-31
Value0.1530.1520.1250.1250.1240.1240.1170.00.00.0920.0920.0510.021
Percentage of CommonStockValue100.0100.0100.0100.0100.0100.0100.00.00.0100.0100.0100.0100.0
Percentage of Assets0.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:CommonStockValue us-gaap:Range, us-gaap:SubsequentEventType, us-gaap:SubsidiarySaleOfStock

srt:Maximum, us-gaap:SubsequentEvent, bbio:AtTheMarketSalesAgreement


Common
Period End2020-07-07
Value350
Percentage of CommonStockValue0.0
Percentage of Assets0.0
Percentage of Assets srt:Maximum us-gaap:SubsequentEvent bbio:AtTheMarketSalesAgreement0.0

Additional Paid In Capital Common Stock

us-gaap:AdditionalPaidInCapitalCommonStock

us-gaap:AdditionalPaidInCapitalCommonStock


Additional
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312017-12-312016-12-31
Value799767102199298684882646949249413432
Percentage of AdditionalPaidInCapitalCommonStock100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets73.970.2145.2109.799.7134.3129.00.00.0106.30.00.0

us-gaap:AdditionalPaidInCapitalCommonStock us-gaap:Restatement, us-gaap:AdjustmentsForNewAccountingPronouncements

srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustment, bbio:AccountingStandardsUpdate202006


Additional
Period End2021-01-01
Value-168.078
Percentage of AdditionalPaidInCapitalCommonStock0.0
Percentage of Assets0.0
Percentage of Assets srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustment bbio:AccountingStandardsUpdate2020060.0

Retained Earnings Accumulated Deficit

us-gaap:RetainedEarningsAccumulatedDeficit

us-gaap:RetainedEarningsAccumulatedDeficit


Retained
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312017-12-312016-12-31
Value-1133.854-1037.506-888.755-652.915-531.881-440.031-366.573-0.069-240.629-179.444-48.695-18.13
Percentage of RetainedEarningsAccumulatedDeficit100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets-104.8-94.9-126.3-72.1-53.7-69.7-57.20.00.0-38.60.00.0

us-gaap:RetainedEarningsAccumulatedDeficit us-gaap:CumulativeEffectPeriodOfAdoption, us-gaap:AdjustmentsForNewAccountingPronouncements

srt:CumulativeEffectPeriodOfAdoptionAdjustment, bbio:AccountingStandardsUpdate202006


Retained
Period End2021-01-01
Value14
Percentage of RetainedEarningsAccumulatedDeficit0.0
Percentage of Assets0.0
Percentage of Assets srt:CumulativeEffectPeriodOfAdoptionAdjustment bbio:AccountingStandardsUpdate2020060.0

Accumulated Other Comprehensive Income Loss Net Of Tax

us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax

us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax


Accumulated
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-31
Value36000.0-57000.0192000.0858000.0726000.0254000.0
Percentage of AccumulatedOtherComprehensiveIncomeLossNetOfTax100.0100.0100.0100.0100.0100.0
Percentage of Assets0.0-0.00.00.10.10.0

Treasury Stock Value

us-gaap:TreasuryStockValue

us-gaap:TreasuryStockValue


Treasury
Period End2021-06-302021-03-312020-12-31
Value13012575
Percentage of TreasuryStockValue100.0100.0100.0
Percentage of Assets12.011.410.7

Minority Interest

us-gaap:MinorityInterest

us-gaap:MinorityInterest


Minority
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312017-12-312016-12-31
Value6.8045.92948596865614858622.4982.595
Percentage of MinorityInterest100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets0.60.56.96.66.910.39.70.00.013.40.00.0

us-gaap:MinorityInterest dei:LegalEntity

bbio:EidosTherapeuticsInc


Minority
Period End2020-12-312020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312017-12-312016-12-31
Value40536259554654580.7660.605
Percentage of MinorityInterest83.189.791.691.589.495.193.593.330.723.3
Percentage of Assets5.75.96.39.58.60.00.012.50.00.0
Percentage of Assets bbio:EidosTherapeuticsInc0.00.00.00.00.00.00.00.00.00.0

Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value

us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue


Adjustments
Period End2021-06-302021-03-312020-06-302020-03-312019-06-30
Value32197.2958.0630.069
Percentage of AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue100.0100.0100.0100.0100.0
Percentage of Assets0.00.00.00.00.0

us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue us-gaap:StatementEquityComponents

us-gaap:AdditionalPaidInCapital


Adjustments
Period End2021-06-302021-03-312020-06-302020-03-312019-06-30
Value32197.2958.0630.069
Percentage of AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue100.0100.0100.0100.0100.0
Percentage of Assets0.00.00.00.00.0
Percentage of Assets us-gaap:AdditionalPaidInCapital0.00.00.00.00.0

us-gaap:Parent


Adjustments
Period End2021-06-302021-03-312020-06-302020-03-31
Value32197.2958.063
Percentage of AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue100.0100.0100.0100.0
Percentage of Assets0.00.00.00.0
Percentage of Assets us-gaap:Parent0.00.00.00.0

Net Cash Provided By Used In Operating Activities

us-gaap:NetCashProvidedByUsedInOperatingActivities

us-gaap:NetCashProvidedByUsedInOperatingActivities


Net
Period End2021-06-302021-03-312020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-31
Value-91713000.0-150760000.0-87849000.0-83920000.0-76203000.0-49996000.0-68248000.0-59140000.0-46414000.0
Percentage of NetCashProvidedByUsedInOperatingActivities100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax-169.8-32633.10.00.0-551.4-187.00.00.00.0

Net Cash Provided By Used In Investing Activities

us-gaap:NetCashProvidedByUsedInInvestingActivities

us-gaap:NetCashProvidedByUsedInInvestingActivities


Net
Period End2021-06-302021-03-312020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-31
Value0.458-282.052-128.98438-16.901-197.342-0.583-2.427-3.599
Percentage of NetCashProvidedByUsedInInvestingActivities100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.8-61050.20.00.0-122.3-738.00.00.00.0

Net Cash Provided By Used In Financing Activities

us-gaap:NetCashProvidedByUsedInFinancingActivities

us-gaap:NetCashProvidedByUsedInFinancingActivities


Net
Period End2021-06-302021-03-312020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-31
Value-1.3915470.70343942367-9.969-1.651274
Percentage of NetCashProvidedByUsedInFinancingActivities100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax-2.6118595.70.00.0310.51374.30.00.00.0

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect

us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect


Cash
Period End2021-06-302021-03-312020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-31
Value-92.646115-216.13393-50.2120-78.8-63.218224
Percentage of CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax-171.524912.30.00.0-363.3449.40.00.00.0

Amortization Of Financing Costs

us-gaap:AmortizationOfFinancingCosts

us-gaap:AmortizationOfFinancingCosts


Amortization
Period End2021-06-302020-06-30
Value24000.0289000.0
Percentage of AmortizationOfFinancingCosts100.0100.0

us-gaap:AmortizationOfFinancingCosts us-gaap:DebtInstrument

bbio:TwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySeven


Amortization
Period End2021-06-302021-03-312020-06-302020-03-31
Value24000.023000.0233000.056000.0
Percentage of AmortizationOfFinancingCosts100.00.080.60.0

Increase Decrease In Accounts Payable

us-gaap:IncreaseDecreaseInAccountsPayable

us-gaap:IncreaseDecreaseInAccountsPayable


Increase
Period End2021-06-302021-03-312020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-31
Value111.792-0.2514.234-1.418-3.3852.098-1.9527.747
Percentage of IncreaseDecreaseInAccountsPayable100.0100.0100.0100.0100.0100.0100.0100.0100.0

Net Cash Provided By Used In Operating Activities

us-gaap:NetCashProvidedByUsedInOperatingActivities

us-gaap:NetCashProvidedByUsedInOperatingActivities


Net
Period End2021-06-302021-03-312020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-31
Value-91713000.0-150760000.0-87849000.0-83920000.0-76203000.0-49996000.0-68248000.0-59140000.0-46414000.0
Percentage of NetCashProvidedByUsedInOperatingActivities100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax-169.8-32633.10.00.0-551.4-187.00.00.00.0

Profit Loss

us-gaap:ProfitLoss

us-gaap:ProfitLoss


Profit
Period End2021-06-302021-03-312020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-30
Value-102070000.0-171080000.0-136210000.0-104080000.0-84151000.0-60664000.0-74334000.0-69436000.0-49241000.0-42078000.0
Percentage of ProfitLoss100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax-188.9-37030.70.00.0-609.0-226.90.00.00.00.0

Share Based Compensation

us-gaap:ShareBasedCompensation

us-gaap:ShareBasedCompensation


Share
Period End2021-06-302021-03-312020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-31
Value30331810105.7773.3582.2323.113
Percentage of ShareBasedCompensation100.0100.0100.0100.0100.0100.0100.0100.0100.0

Net Cash Provided By Used In Investing Activities

us-gaap:NetCashProvidedByUsedInInvestingActivities

us-gaap:NetCashProvidedByUsedInInvestingActivities


Net
Period End2021-06-302021-03-312020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-31
Value0.458-282.052-128.98438-16.901-197.342-0.583-2.427-3.599
Percentage of NetCashProvidedByUsedInInvestingActivities100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax0.8-61050.20.00.0-122.3-738.00.00.00.0

Payments To Acquire Property Plant And Equipment

us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

us-gaap:PaymentsToAcquirePropertyPlantAndEquipment


Payments
Period End2021-06-302021-03-312020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-31
Value2287000.01961000.0346000.04477000.01747000.0381000.083000.0427000.0741000.0
Percentage of PaymentsToAcquirePropertyPlantAndEquipment100.0100.0100.0100.0100.0100.0100.0100.0100.0

Net Cash Provided By Used In Financing Activities

us-gaap:NetCashProvidedByUsedInFinancingActivities

us-gaap:NetCashProvidedByUsedInFinancingActivities


Net
Period End2021-06-302021-03-312020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-31
Value-1.3915470.70343942367-9.969-1.651274
Percentage of NetCashProvidedByUsedInFinancingActivities100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of RevenueFromContractWithCustomerExcludingAssessedTax-2.6118595.70.00.0310.51374.30.00.00.0

Payments For Repurchase Of Common Stock

us-gaap:PaymentsForRepurchaseOfCommonStock

us-gaap:PaymentsForRepurchaseOfCommonStock


Payments
Period End2021-06-302021-03-312020-06-302020-03-31
Value5.308500.075
Percentage of PaymentsForRepurchaseOfCommonStock100.0100.00.0100.0

us-gaap:PaymentsForRepurchaseOfCommonStock us-gaap:DebtInstrument

bbio:TwoPointTwoFivePercentageConvertibleSeniorNotesDueTwoThousandAndTwentyNine


Payments
Period End2021-01-28
Value50
Percentage of PaymentsForRepurchaseOfCommonStock0.0

us-gaap:PaymentsForRepurchaseOfCommonStock us-gaap:DebtInstrument, us-gaap:ShareRepurchaseProgram

bbio:TwoThousandTwentyOneCappedCallTransactions, bbio:ShareRepurchaseTransactions


Payments
Period End2021-01-25
Value50
Percentage of PaymentsForRepurchaseOfCommonStock0.0

us-gaap:PaymentsForRepurchaseOfCommonStock us-gaap:DebtInstrument, us-gaap:SubsequentEventType

bbio:TwoPointTwoFivePercentageConvertibleSeniorNotesDueTwoThousandAndTwentyNine, us-gaap:SubsequentEvent


Payments
Period End2021-01-28
Value50
Percentage of PaymentsForRepurchaseOfCommonStock0.0

Debt Instrument Interest Rate Stated Percentage

us-gaap:DebtInstrumentInterestRateStatedPercentage us-gaap:DebtInstrument

us-gaap:DebtInstrumentInterestRateStatedPercentage

bbio:TwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySeven


Debt
Period End2020-12-312020-06-302020-03-312020-03-09
Value2.50.0250.0250.025
Percentage of DebtInstrumentInterestRateStatedPercentage100.0100.0100.0100.0
Percentage of LongTermDebtAndCapitalLeaseObligations0.00.00.00.0
Percentage of LongTermDebtAndCapitalLeaseObligations bbio:TwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySeven0.00.00.00.0

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice us-gaap:ConsolidatedEntities

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

bbio:EidosTherapeuticsInc


Share
Period End2020-12-312020-06-302020-03-312019-12-312019-09-302019-06-302018-12-31
Value29.7126.5219.616.9114.0211.668.55
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice100.0100.0100.0100.0100.0100.0100.0

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice us-gaap:ConsolidatedEntities, us-gaap:PlanName

bbio:EidosTherapeuticsInc, bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlan


Share
Period End2021-06-302021-03-31
Value16.1516.54
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice0.00.0

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice us-gaap:PlanName

bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlan


Share
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-31
Value29.1327.1623.8323.4320.7920.1
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice0.00.080.288.3106.1118.9

bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlans


Share
Period End2020-12-312018-12-31
Value23.8320.1
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice80.2235.1

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice us-gaap:PlanName, us-gaap:ShareRepurchaseProgram

bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlan, bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgram


Share
Period End2021-06-302021-03-312020-12-312020-06-30
Value2.492.52.221.59
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice0.00.07.56.0

bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlans, bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgram


Share
Period End2020-12-31
Value2.22
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice7.5

Deferred Tax Liabilities

us-gaap:DeferredTaxLiabilities

us-gaap:DeferredTaxLiabilities


Deferred
Period End2020-12-31
Value1095000.0
Percentage of DeferredTaxLiabilities100.0

us-gaap:DeferredTaxLiabilities us-gaap:BalanceSheetLocation

us-gaap:OtherLiabilities


Deferred
Period End2020-12-31
Value1100000.0
Percentage of DeferredTaxLiabilities100.5

Deferred Tax Assets Net

us-gaap:DeferredTaxAssetsNet

us-gaap:DeferredTaxAssetsNet


Deferred
Period End2020-12-312019-12-312018-12-31
Value350.290.018
Percentage of DeferredTaxAssetsNet100.0100.0100.0

Unrecognized Tax Benefits

us-gaap:UnrecognizedTaxBenefits

us-gaap:UnrecognizedTaxBenefits


Unrecognized
Period End2020-12-312019-12-312018-12-312017-12-31
Value127.6041.1820.296
Percentage of UnrecognizedTaxBenefits100.0100.0100.0100.0

Deferred Tax Assets Valuation Allowance

us-gaap:DeferredTaxAssetsValuationAllowance

us-gaap:DeferredTaxAssetsValuationAllowance


Deferred
Period End2020-12-312019-12-312018-12-31
Value22412849
Percentage of DeferredTaxAssetsValuationAllowance100.0100.0100.0

bbio:AdjustmentsOfCarryingValueOfNoncontrollingInterestAdditionalPaidInCapital

bbio:AdjustmentsOfCarryingValueOfNoncontrollingInterestAdditionalPaidInCapital


Adjustments
Period End2021-06-302021-03-312020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-30
Value-1.41.73.111-70.51325-3.0-36.22.3
Percentage of AdjustmentsOfCarryingValueOfNoncontrollingInterestAdditionalPaidInCapital100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

bbio:AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCalls

bbio:AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCalls


Adjustments
Period End2021-03-312020-03-31
Value-61295000.0-49280000.0
Percentage of AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCalls100.0100.0

bbio:AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCalls us-gaap:StatementEquityComponents

us-gaap:AdditionalPaidInCapital


Adjustments
Period End2021-03-312020-03-31
Value-61295000.0-49280000.0
Percentage of AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCalls100.0100.0

us-gaap:Parent


Adjustments
Period End2021-03-312020-03-31
Value-61295000.0-49280000.0
Percentage of AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCalls100.0100.0

bbio:AdjustmentsToAdditionalPaidInCapitalRelatedToPremiumPayments us-gaap:DebtInstrument

bbio:AdjustmentsToAdditionalPaidInCapitalRelatedToPremiumPayments

bbio:TwoThousandTwentyOneCappedCallTransactions


Adjustments
Period End2021-03-31
Value61
Percentage of AdjustmentsToAdditionalPaidInCapitalRelatedToPremiumPayments100.0

bbio:CallOptionExpenseIncome

bbio:CallOptionExpenseIncome


Call
Period End2021-06-302021-03-312020-06-302020-03-312019-06-302019-03-31
Value0-5550000.01737000.0-539000.0-226000.01514000.0
Percentage of CallOptionExpenseIncome0.0100.0100.0100.0100.0100.0

bbio:DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock us-gaap:DebtInstrument

bbio:DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock

bbio:TwoPointTwoFivePercentageConvertibleSeniorNotesDueTwoThousandAndTwentyNine


Debt
Period End2021-01-28
Value1000.0
Percentage of DebtInstrumentPrincipalAmountDenominationForConversionIntoCommonStock100.0

bbio:DirectTransactionCostsInRepurchaseOfNoncontrollingInterestIncludedInAccountsPayableAndAccruedProfessionalServices

bbio:DirectTransactionCostsInRepurchaseOfNoncontrollingInterestIncludedInAccountsPayableAndAccruedProfessionalServices


Direct
Period End2021-03-31
Value4766000.0
Percentage of DirectTransactionCostsInRepurchaseOfNoncontrollingInterestIncludedInAccountsPayableAndAccruedProfessionalServices100.0

bbio:DirectTransactionCostsInRepurchaseOfNoncontrollingInterestRecordedInAdditionalPaidInCapitalPreviouslyClassifiedInPrepaidExpensesAndOtherCurrentAssets

bbio:DirectTransactionCostsInRepurchaseOfNoncontrollingInterestRecordedInAdditionalPaidInCapitalPreviouslyClassifiedInPrepaidExpensesAndOtherCurrentAssets


Direct
Period End2021-06-302021-03-31
Value08749000.0
Percentage of DirectTransactionCostsInRepurchaseOfNoncontrollingInterestRecordedInAdditionalPaidInCapitalPreviouslyClassifiedInPrepaidExpensesAndOtherCurrentAssets0.0100.0

bbio:FinanceLeaseStraightLineFinanceLeaseCosts

bbio:FinanceLeaseStraightLineFinanceLeaseCosts


Finance
Period End2021-06-302021-03-31
Value88000.029000.0
Percentage of FinanceLeaseStraightLineFinanceLeaseCosts100.0100.0

bbio:IncreaseDecreaseInAccruedProfessionalService

bbio:IncreaseDecreaseInAccruedProfessionalService


Increase
Period End2021-06-302021-03-312020-06-302020-03-31
Value1859000.0-360000.05465000.0923000.0
Percentage of IncreaseDecreaseInAccruedProfessionalService100.0100.0100.0100.0

bbio:IncreaseDecreaseInAccruedResearchAndDevelopmentLiabilities

bbio:IncreaseDecreaseInAccruedResearchAndDevelopmentLiabilities


Increase
Period End2021-06-302021-03-312020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-31
Value-3.6716.1347.7198.6267.6973.779-1.2051.71-0.351
Percentage of IncreaseDecreaseInAccruedResearchAndDevelopmentLiabilities100.0100.0100.0100.0100.0100.0100.0100.0100.0

bbio:IncreaseDecreaseInOperatingLeaseLiabilities

bbio:IncreaseDecreaseInOperatingLeaseLiabilities


Increase
Period End2021-06-302021-03-312020-06-302020-03-31
Value-1438000.0-1338000.0-862000.0-556000.0
Percentage of IncreaseDecreaseInOperatingLeaseLiabilities100.0100.0100.0100.0

bbio:InterestExpenseAndAmortizationOfDebtDiscount us-gaap:ConsolidatedEntities, us-gaap:LineOfCreditFacility

bbio:InterestExpenseAndAmortizationOfDebtDiscount

bbio:EidosTherapeuticsInc, bbio:SiliconValleyBankAndHerculesLoan


Interest
Period End2021-03-312020-06-302020-03-31
Value600000.0700000.0500000.0
Percentage of InterestExpenseAndAmortizationOfDebtDiscount100.0100.0100.0

bbio:IssuanceRepurchaseOfNoncontrollingInterest

bbio:IssuanceRepurchaseOfNoncontrollingInterest


Issuance
Period End2021-06-302021-03-312020-06-302020-03-312019-09-302019-06-302019-03-312018-09-302018-06-302018-03-31
Value0.0055.083.53726-0.098-27.0241.320.974960.553
Percentage of IssuanceRepurchaseOfNoncontrollingInterest100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

bbio:IssuanceRepurchaseOfNoncontrollingInterest us-gaap:StatementEquityComponents

us-gaap:NoncontrollingInterest


Issuance
Period End2021-06-302021-03-312020-06-302020-03-312019-09-302019-06-302019-03-312018-09-302018-06-302018-03-31
Value0.0055.083.53726-0.098-27.0241.320.974960.553
Percentage of IssuanceRepurchaseOfNoncontrollingInterest100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

bbio:LicenseAgreementPercentageShareOfProfitsAndLosses us-gaap:Ownership, us-gaap:TypeOfArrangement

bbio:LicenseAgreementPercentageShareOfProfitsAndLosses

bbio:QEDTherapeuticsInc, bbio:LicenseAndCollaborationAgreement


License
Period End2021-03-29
Value50.0
Percentage of LicenseAgreementPercentageShareOfProfitsAndLosses100.0

bbio:LicenseAgreementsShareOfCoCommercializationLossAsReductionToSellingGeneralAndAdministrativeExpenses us-gaap:AdjustmentsForNewAccountingPronouncements

bbio:LicenseAgreementsShareOfCoCommercializationLossAsReductionToSellingGeneralAndAdministrativeExpenses

us-gaap:AccountingStandardsUpdate201818


License
Period End2021-06-30
Value4100000.0
Percentage of LicenseAgreementsShareOfCoCommercializationLossAsReductionToSellingGeneralAndAdministrativeExpenses100.0

bbio:NetIncomeLossExcludingRedeemableNoncontrollingInterestsNetIncomeLoss

bbio:NetIncomeLossExcludingRedeemableNoncontrollingInterestsNetIncomeLoss


Net
Period End2021-06-302021-03-312020-06-302020-03-312019-09-302019-06-302019-03-312018-09-302018-06-302018-03-31
Value-100510000.0-170210000.0-134640000.0-103220000.0-60029000.0-73649000.0-68646000.0-39723000.0-32084000.0-38816000.0
Percentage of NetIncomeLossExcludingRedeemableNoncontrollingInterestsNetIncomeLoss100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

bbio:NetIncomeLossExcludingRedeemableNoncontrollingInterestsNetIncomeLoss us-gaap:StatementEquityComponents

us-gaap:NoncontrollingInterest


Net
Period End2021-06-302021-03-312020-06-302020-03-312019-09-302019-06-302019-03-312018-09-302018-06-302018-03-31
Value-4164000.0-7127000.0-13602000.0-11366000.0-49000.0-7685000.0-7461000.0-8322000.0-5533000.0-4660000.0
Percentage of NetIncomeLossExcludingRedeemableNoncontrollingInterestsNetIncomeLoss4.14.210.111.00.110.410.921.017.212.0

us-gaap:Parent


Net
Period End2021-06-302021-03-312020-06-302020-03-312019-09-302019-06-302019-03-312018-09-302018-06-302018-03-31
Value-96348000.0-163080000.0-121030000.0-91850000.0-59980000.0-65964000.0-61185000.0-31401000.0-26551000.0-34156000.0
Percentage of NetIncomeLossExcludingRedeemableNoncontrollingInterestsNetIncomeLoss95.995.889.989.099.989.689.179.082.888.0

us-gaap:RetainedEarnings


Net
Period End2021-06-302021-03-312020-06-302020-03-312019-09-302019-06-302019-03-312018-09-302018-06-302018-03-31
Value-96348000.0-163080000.0-121030000.0-91850000.0-59980000.0-65964000.0-61185000.0-31401000.0-26551000.0-34156000.0
Percentage of NetIncomeLossExcludingRedeemableNoncontrollingInterestsNetIncomeLoss95.995.889.989.099.989.689.179.082.888.0

bbio:NetNonCashPortionOfRepurchaseOfNoncontrollingInterests

bbio:NetNonCashPortionOfRepurchaseOfNoncontrollingInterests


Net
Period End2021-06-302021-03-31
Value0.038
Percentage of NetNonCashPortionOfRepurchaseOfNoncontrollingInterests0.0100.0

bbio:NewAccountingPronouncementEffectOfAdoption us-gaap:PropertyPlantAndEquipmentByType

bbio:NewAccountingPronouncementEffectOfAdoption

us-gaap:ConstructionInProgress


New
Period End2021-06-302021-03-31
Value010000000.0
Percentage of NewAccountingPronouncementEffectOfAdoption0.0100.0

bbio:NoncashOrPartNoncashInvestingTransferFromToNoncontrollingInterest

bbio:NoncashOrPartNoncashInvestingTransferFromToNoncontrollingInterest


Noncash
Period End2021-06-302021-03-312020-06-302020-03-312019-03-31
Value-1.4161.69-3.1111-2.968
Percentage of NoncashOrPartNoncashInvestingTransferFromToNoncontrollingInterest100.0100.0100.0100.0100.0

bbio:NonrefundableUpfrontPaymentReceivable us-gaap:CounterpartyName, us-gaap:TypeOfArrangement

bbio:NonrefundableUpfrontPaymentReceivable

bbio:LianBio, bbio:LicenseAgreement


Nonrefundable
Period End2020-08-31
Value8000000.0
Percentage of NonrefundableUpfrontPaymentReceivable100.0

bbio:NumberOfSharesIssuedInExchangeOfSubsidiaryEquity us-gaap:ConsolidatedEntities, us-gaap:SubsequentEventType

bbio:NumberOfSharesIssuedInExchangeOfSubsidiaryEquity

bbio:EidosTherapeuticsInc, us-gaap:SubsequentEvent


Number
Period End2021-01-26
Value26
Percentage of NumberOfSharesIssuedInExchangeOfSubsidiaryEquity100.0

bbio:PercentageShareOfGlobalDevelopmentCosts us-gaap:CounterpartyName, us-gaap:TypeOfArrangement

bbio:PercentageShareOfGlobalDevelopmentCosts

bbio:HelsinnTherapeutics, bbio:LicenseAndCollaborationAgreement


Percentage
Period End2021-03-29
Value60.0
Percentage of PercentageShareOfGlobalDevelopmentCosts100.0

bbio:PercentageShareOfGlobalDevelopmentCosts us-gaap:Ownership, us-gaap:TypeOfArrangement

bbio:QEDTherapeuticsInc, bbio:LicenseAndCollaborationAgreement


Percentage
Period End2021-03-29
Value40.0
Percentage of PercentageShareOfGlobalDevelopmentCosts66.7

bbio:PerformanceBasedMilestoneAwardsCompensationExpense us-gaap:ConsolidatedEntities

bbio:PerformanceBasedMilestoneAwardsCompensationExpense

bbio:BridgeBioServicesInc


Performance
Period End2021-06-302021-03-31
Value1900000.01300000.0
Percentage of PerformanceBasedMilestoneAwardsCompensationExpense100.0100.0

bbio:PerformanceBasedMilestoneAwardsCompensationExpenseSettledWithEquity us-gaap:AwardType, us-gaap:PlanName

bbio:PerformanceBasedMilestoneAwardsCompensationExpenseSettledWithEquity

us-gaap:RestrictedStock, bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlan


Performance
Period End2021-03-31
Value6700000.0
Percentage of PerformanceBasedMilestoneAwardsCompensationExpenseSettledWithEquity100.0

bbio:PerformanceBasedMilestoneAwardsCompensationExpenseSettledWithEquity us-gaap:AwardType, us-gaap:ShareRepurchaseProgram

us-gaap:RestrictedStock, bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgram


Performance
Period End2021-06-302021-03-31
Value2500000.06700000.0
Percentage of PerformanceBasedMilestoneAwardsCompensationExpenseSettledWithEquity0.0100.0

bbio:PerformanceBasedMilestoneAwardsCompensationRecognized us-gaap:ShareRepurchaseProgram

bbio:PerformanceBasedMilestoneAwardsCompensationRecognized

bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgram


Performance
Period End2021-06-302021-03-312020-06-302019-06-30
Value137.78.00.0
Percentage of PerformanceBasedMilestoneAwardsCompensationRecognized100.0100.0100.00.0

bbio:PerformanceBasedMilestoneAwardsGrantsInPeriodWeightedAverageGrantDateFairValue us-gaap:AwardType, us-gaap:PlanName

bbio:PerformanceBasedMilestoneAwardsGrantsInPeriodWeightedAverageGrantDateFairValue

us-gaap:RestrictedStock, bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlan


Performance
Period End2021-03-31
Value68.91
Percentage of PerformanceBasedMilestoneAwardsGrantsInPeriodWeightedAverageGrantDateFairValue100.0

bbio:PotentialTerminationFee us-gaap:ConsolidatedEntities, us-gaap:TypeOfArrangement

bbio:PotentialTerminationFee

bbio:EidosTherapeuticsInc, bbio:AgreementAndPlanOfMerger


Potential
Period End2020-10-05
Value35
Percentage of PotentialTerminationFee100.0

bbio:PreferredStockOwnershipPercentage dei:LegalEntity

bbio:PreferredStockOwnershipPercentage

bbio:PellePharmInc


Preferred
Period End2021-06-302021-03-31
Value061.9
Percentage of PreferredStockOwnershipPercentage0.0100.0

bbio:ProceedsFromIssuanceOfNotesAfterDeductingDiscountAndOfferingExpenses us-gaap:DebtInstrument

bbio:ProceedsFromIssuanceOfNotesAfterDeductingDiscountAndOfferingExpenses

bbio:TwoPointTwoFivePercentageConvertibleSeniorNotesDueTwoThousandAndTwentyNine


Proceeds
Period End2021-01-28
Value731
Percentage of ProceedsFromIssuanceOfNotesAfterDeductingDiscountAndOfferingExpenses100.0

bbio:ProceedsFromIssuanceOfNotesAfterDeductingDiscountAndOfferingExpenses us-gaap:DebtInstrument, us-gaap:SubsequentEventType

bbio:TwoPointTwoFivePercentageConvertibleSeniorNotesDueTwoThousandAndTwentyNine, us-gaap:SubsequentEvent


Proceeds
Period End2021-01-28
Value731
Percentage of ProceedsFromIssuanceOfNotesAfterDeductingDiscountAndOfferingExpenses100.0

bbio:PurchaseOfCappedCalls

bbio:PurchaseOfCappedCalls


Purchase
Period End2021-06-302021-03-312020-06-302020-03-31
Value0.0610.049
Percentage of PurchaseOfCappedCalls0.0100.00.0100.0

bbio:PurchaseOfCappedCalls us-gaap:DebtInstrument

bbio:TwoPointTwoFivePercentageConvertibleSeniorNotesDueTwoThousandAndTwentyNine


Purchase
Period End2021-01-28
Value61
Percentage of PurchaseOfCappedCalls0.0

bbio:TwoThousandTwentyOneCappedCallTransactions


Purchase
Period End2021-01-25
Value61
Percentage of PurchaseOfCappedCalls0.0

bbio:PurchaseOfCappedCalls us-gaap:DebtInstrument, us-gaap:SubsequentEventType

bbio:TwoPointTwoFivePercentageConvertibleSeniorNotesDueTwoThousandAndTwentyNine, us-gaap:SubsequentEvent


Purchase
Period End2021-01-28
Value61
Percentage of PurchaseOfCappedCalls0.0

bbio:RepurchaseOfNoncontrollingInterestIncludingDirectTransactionCosts

bbio:RepurchaseOfNoncontrollingInterestIncludingDirectTransactionCosts


Repurchase
Period End2021-06-302021-03-31
Value4.51680
Percentage of RepurchaseOfNoncontrollingInterestIncludingDirectTransactionCosts100.0100.0

bbio:StockBasedCompensationExpenseToBeSettledInEitherCashOrEquity

bbio:StockBasedCompensationExpenseToBeSettledInEitherCashOrEquity


Stock
Period End2021-03-312020-06-302019-06-30
Value2200000.0200000.00
Percentage of StockBasedCompensationExpenseToBeSettledInEitherCashOrEquity100.0100.00.0

bbio:StockBasedCompensationExpenseToBeSettledInEquity us-gaap:StatementEquityComponents

bbio:StockBasedCompensationExpenseToBeSettledInEquity

bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgram


Stock
Period End2021-03-312020-06-302019-06-30
Value7700000.08000000.00
Percentage of StockBasedCompensationExpenseToBeSettledInEquity100.0100.00.0

bbio:TemporaryEquityFairValueOfNoncontrollingInterest us-gaap:StatementClassOfStock

bbio:TemporaryEquityFairValueOfNoncontrollingInterest

bbio:RedeemableConvertibleNoncontrollingInterests


Temporary
Period End2021-06-30
Value5074000.0
Percentage of TemporaryEquityFairValueOfNoncontrollingInterest100.0

bbio:TemporaryEquityIssuanceRepurchaseOfNoncontrollingInterestValue us-gaap:StatementClassOfStock

bbio:TemporaryEquityIssuanceRepurchaseOfNoncontrollingInterestValue

bbio:RedeemableConvertibleNoncontrollingInterests


Temporary
Period End2021-06-302020-03-312019-09-302018-06-302018-03-31
Value0.71.1023.1964615
Percentage of TemporaryEquityIssuanceRepurchaseOfNoncontrollingInterestValue100.0100.0100.0100.0100.0

bbio:TemporaryEquityTransferToFromNoncontrollingInterest us-gaap:StatementClassOfStock

bbio:TemporaryEquityTransferToFromNoncontrollingInterest

bbio:RedeemableConvertibleNoncontrollingInterests


Temporary
Period End2021-06-302021-03-312020-06-302020-03-312019-09-302019-06-302019-03-312018-09-302018-06-302018-03-31
Value-3618000.0517000.0431000.0574000.0-166000.0658000.0870000.075000.0-41450000.0-11286000.0
Percentage of TemporaryEquityTransferToFromNoncontrollingInterest100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

bbio:TerminationFee us-gaap:TypeOfArrangement

bbio:TerminationFee

bbio:AgreementAndPlanOfMerger


Termination
Period End2020-10-05
Value100
Percentage of TerminationFee100.0

us-gaap:AccretionExpense

us-gaap:AccretionExpense


Accretion
Period End2021-06-302021-03-312020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-31
Value1.4041.2495.2191.7610.7870.020.3480.3540.242
Percentage of AccretionExpense100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation us-gaap:AwardType

us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation

bbio:SatisfyTaxWithholding


Adjustments
Period End2021-06-302021-03-31
Value2281000.01021000.0
Percentage of AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation100.0100.0

us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation us-gaap:AwardType, us-gaap:StatementEquityComponents

bbio:SatisfyTaxWithholding, us-gaap:AdditionalPaidInCapital


Adjustments
Period End2021-06-302021-03-31
Value2281000.01021000.0
Percentage of AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation100.0100.0

bbio:SatisfyTaxWithholding, us-gaap:Parent


Adjustments
Period End2021-06-302021-03-31
Value2281000.01021000.0
Percentage of AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation100.0100.0

us-gaap:AmortizationOfDebtDiscountPremium

us-gaap:AmortizationOfDebtDiscountPremium


Amortization
Period End2021-06-302020-06-30
Value0.8435.574
Percentage of AmortizationOfDebtDiscountPremium100.0100.0

us-gaap:AmortizationOfDebtDiscountPremium us-gaap:DebtInstrument

bbio:TwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySeven


Amortization
Period End2021-06-302021-03-312020-06-302020-03-31
Value0.3890.3864.4951.079
Percentage of AmortizationOfDebtDiscountPremium46.10.080.60.0

bbio:TwoPointTwoFivePercentageConvertibleSeniorNotesDueTwoThousandAndTwentyNine


Amortization
Period End2021-06-302021-03-31
Value0.4540.311
Percentage of AmortizationOfDebtDiscountPremium53.90.0

us-gaap:AmortizationOfFinancingCostsAndDiscounts us-gaap:LineOfCreditFacility

us-gaap:AmortizationOfFinancingCostsAndDiscounts

bbio:HerculesCapitalInc


Amortization
Period End2021-06-302021-03-312020-06-302020-03-312019-06-302019-03-31
Value500000.0300000.0300000.0400000.0300000.0400000.0
Percentage of AmortizationOfFinancingCostsAndDiscounts100.0100.0100.0100.0100.0100.0

us-gaap:BusinessCombinationConsiderationTransferred1 us-gaap:ConsolidatedEntities

us-gaap:BusinessCombinationConsiderationTransferred1

bbio:EidosTherapeuticsInc


Business
Period End2021-01-26
Value1651
Percentage of BusinessCombinationConsiderationTransferred1100.0

us-gaap:CapitalExpendituresIncurredButNotYetPaid

us-gaap:CapitalExpendituresIncurredButNotYetPaid


Capital
Period End2021-03-31
Value1787000.0
Percentage of CapitalExpendituresIncurredButNotYetPaid100.0

us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 us-gaap:ConsolidatedEntities, us-gaap:DebtInstrument, us-gaap:LineOfCreditFacility, us-gaap:VariableRate

us-gaap:DebtInstrumentBasisSpreadOnVariableRate1

bbio:EidosTherapeuticsInc, bbio:TrancheALoan, bbio:SiliconValleyBankAndHerculesLoan, us-gaap:PrimeRate


Debt
Period End2021-03-312020-03-312019-11-302019-11-13
Value8.50.0853.250.0325
Percentage of DebtInstrumentBasisSpreadOnVariableRate1100.0100.0100.0100.0

us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 us-gaap:LineOfCreditFacility, us-gaap:SubsequentEventType, us-gaap:VariableRate

bbio:HerculesCapitalInc, us-gaap:SubsequentEvent, us-gaap:PrimeRate


Debt
Period End2021-04-13
Value4.4
Percentage of DebtInstrumentBasisSpreadOnVariableRate10.0

us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 us-gaap:LineOfCreditFacility, us-gaap:VariableRate

bbio:HerculesCapitalInc, us-gaap:PrimeRate


Debt
Period End2021-04-302020-04-30
Value4.42.85
Percentage of DebtInstrumentBasisSpreadOnVariableRate10.00.0

us-gaap:DebtInstrumentConvertibleConversionRatio1 us-gaap:DebtInstrument

us-gaap:DebtInstrumentConvertibleConversionRatio1

bbio:TwoPointTwoFivePercentageConvertibleSeniorNotesDueTwoThousandAndTwentyNine


Debt
Period End2021-01-28
Value1.0305e-05
Percentage of DebtInstrumentConvertibleConversionRatio1100.0

us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal us-gaap:DebtInstrument

us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal

bbio:TwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySeven


Debt
Period End2021-06-302021-03-31
Value-8.2243
Percentage of DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal100.0100.0

us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1 us-gaap:DebtInstrument

us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1

bbio:TwoPointTwoFivePercentageConvertibleSeniorNotesDueTwoThousandAndTwentyNine


Debt
Period End2021-01-28
Value30.0
Percentage of DebtInstrumentConvertibleThresholdConsecutiveTradingDays1100.0

us-gaap:DebtInstrumentConvertibleThresholdTradingDays us-gaap:DebtInstrument

us-gaap:DebtInstrumentConvertibleThresholdTradingDays

bbio:TwoPointTwoFivePercentageConvertibleSeniorNotesDueTwoThousandAndTwentyNine


Debt
Period End2021-01-28
Value20.0
Percentage of DebtInstrumentConvertibleThresholdTradingDays100.0

us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements us-gaap:FairValueByLiabilityClass

us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements

bbio:LEOCallOption


Fair
Period End2021-03-31
Value5550000.0
Percentage of FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements100.0

us-gaap:FinanceLeaseInterestPaymentOnLiability

us-gaap:FinanceLeaseInterestPaymentOnLiability


Finance
Period End2021-06-302021-03-31
Value27000.036000.0
Percentage of FinanceLeaseInterestPaymentOnLiability100.0100.0

us-gaap:ImpairmentOfLongLivedAssetsHeldForUse us-gaap:BalanceSheetLocation

us-gaap:ImpairmentOfLongLivedAssetsHeldForUse

us-gaap:PropertyPlantAndEquipment


Impairment
Period End2021-03-31
Value700000.0
Percentage of ImpairmentOfLongLivedAssetsHeldForUse100.0

us-gaap:ImpairmentOfLongLivedAssetsHeldForUse us-gaap:IncomeStatementLocation

us-gaap:GeneralAndAdministrativeExpense


Impairment
Period End2021-03-31
Value3300000.0
Percentage of ImpairmentOfLongLivedAssetsHeldForUse471.4

us-gaap:SellingGeneralAndAdministrativeExpenses


Impairment
Period End2021-03-31
Value3300000.0
Percentage of ImpairmentOfLongLivedAssetsHeldForUse471.4

us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities

us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities


Increase
Period End2021-06-302021-03-312020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-31
Value6139000.0-3540000.05324000.015000.0-1162000.03328000.0-1362000.0723000.01753000.0
Percentage of IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:IncreaseDecreaseInDueFromRelatedParties

us-gaap:IncreaseDecreaseInDueFromRelatedParties


Increase
Period End2021-06-302021-03-312020-03-31
Value8500000.0462000.0-2845000.0
Percentage of IncreaseDecreaseInDueFromRelatedParties100.0100.0100.0

us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities

us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities


Increase
Period End2021-06-302021-03-312020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-31
Value4487000.0-12981000.05619000.0-7670000.05737000.02844000.01121000.0-432000.01027000.0
Percentage of IncreaseDecreaseInEmployeeRelatedLiabilities100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:IncreaseDecreaseInOtherOperatingAssets

us-gaap:IncreaseDecreaseInOtherOperatingAssets


Increase
Period End2021-06-302021-03-312020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-31
Value-0.396.1130.2310.73415-0.4130.2251.8520.972
Percentage of IncreaseDecreaseInOtherOperatingAssets100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets


Increase
Period End2021-06-302021-03-312020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-31
Value0.048-1.4481.212-2.8460.9519.1963.0360.309-5.561
Percentage of IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:InterestExpenseDebtExcludingAmortization

us-gaap:InterestExpenseDebtExcludingAmortization


Interest
Period End2021-06-302020-06-30
Value7.6424.354
Percentage of InterestExpenseDebtExcludingAmortization100.0100.0

us-gaap:InterestExpenseDebtExcludingAmortization us-gaap:DebtInstrument

bbio:TwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySeven


Interest
Period End2021-06-302021-03-312020-06-302020-03-31
Value3.4373.4383.4750.879
Percentage of InterestExpenseDebtExcludingAmortization45.00.079.80.0

bbio:TwoPointTwoFivePercentageConvertibleSeniorNotesDueTwoThousandAndTwentyNine


Interest
Period End2021-06-302021-03-31
Value4.2052.943
Percentage of InterestExpenseDebtExcludingAmortization55.00.0

us-gaap:InvestmentIncomeInterest

us-gaap:InvestmentIncomeInterest


Investment
Period End2021-06-302021-03-312020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-30
Value323000.0394000.0934000.01941000.02410000.02736000.01662000.02107000.01473000.0528000.0
Percentage of InvestmentIncomeInterest100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:LeaseCost

us-gaap:LeaseCost


Lease
Period End2021-06-302021-03-312020-06-302020-03-31
Value2341000.02173000.01137000.0853000.0
Percentage of LeaseCost100.0100.0100.0100.0

us-gaap:MinorityInterestDecreaseFromRedemptions

us-gaap:MinorityInterestDecreaseFromRedemptions


Minority
Period End2021-03-31
Value-91.997
Percentage of MinorityInterestDecreaseFromRedemptions100.0

us-gaap:MinorityInterestDecreaseFromRedemptions us-gaap:ConsolidatedEntities, us-gaap:StatementEquityComponents

bbio:EidosTherapeuticsInc, us-gaap:AdditionalPaidInCapital


Minority
Period End2021-01-26
Value1613
Percentage of MinorityInterestDecreaseFromRedemptions0.0

us-gaap:MinorityInterestDecreaseFromRedemptions us-gaap:StatementEquityComponents

us-gaap:AdditionalPaidInCapital


Minority
Period End2021-03-31
Value-53.856
Percentage of MinorityInterestDecreaseFromRedemptions58.5

us-gaap:CommonStock


Minority
Period End2021-03-31
Value0.026
Percentage of MinorityInterestDecreaseFromRedemptions-0.0

us-gaap:NoncontrollingInterest


Minority
Period End2021-03-31
Value-38.167
Percentage of MinorityInterestDecreaseFromRedemptions41.5

us-gaap:Parent


Minority
Period End2021-03-31
Value-53.83
Percentage of MinorityInterestDecreaseFromRedemptions58.5

us-gaap:MinorityInterestPeriodIncreaseDecrease

us-gaap:MinorityInterestPeriodIncreaseDecrease


Minority
Period End2021-06-302021-03-312020-06-302020-03-312019-09-302019-06-302019-03-312018-09-302018-06-302018-03-31
Value3.618-0.517-0.431-0.5740.166-0.658-0.87-0.0754111
Percentage of MinorityInterestPeriodIncreaseDecrease100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:MinorityInterestPeriodIncreaseDecrease us-gaap:StatementEquityComponents

us-gaap:AdditionalPaidInCapital


Minority
Period End2021-06-302021-03-312020-06-302020-03-312019-09-302019-06-302019-03-312018-09-302018-06-302018-03-31
Value-1.4161.69-3.1111-13.529-25.44-2.968-2.253563.876
Percentage of MinorityInterestPeriodIncreaseDecrease-39.1-326.9721.6-2021.1-8150.03866.3341.13004.0135.534.3

us-gaap:NoncontrollingInterest


Minority
Period End2021-06-302021-03-312020-06-302020-03-312019-09-302019-06-302019-03-312018-09-302018-06-302018-03-31
Value5.034-2.2072.679-12.17513242.0982.178-14.7327.41
Percentage of MinorityInterestPeriodIncreaseDecrease139.1426.9-621.62121.18250.0-3766.3-241.1-2904.0-35.565.7

us-gaap:Parent


Minority
Period End2021-06-302021-03-312020-06-302020-03-312019-09-302019-06-302019-03-312018-09-302018-06-302018-03-31
Value-1.4161.69-3.1111-13.529-25.44-2.968-2.253563.876
Percentage of MinorityInterestPeriodIncreaseDecrease-39.1-326.9721.6-2021.1-8150.03866.3341.13004.0135.534.3

us-gaap:OperatingLeaseCost

us-gaap:OperatingLeaseCost


Operating
Period End2021-06-302021-03-312020-06-302020-03-31
Value1256000.01365000.0995000.0694000.0
Percentage of OperatingLeaseCost100.0100.0100.0100.0

us-gaap:OperatingLeaseImpairmentLoss

us-gaap:OperatingLeaseImpairmentLoss


Operating
Period End2021-03-31
Value2600000.0
Percentage of OperatingLeaseImpairmentLoss100.0

us-gaap:OperatingLeasePayments

us-gaap:OperatingLeasePayments


Operating
Period End2021-06-302021-03-312020-06-302020-03-31
Value1388000.01470000.01700000.0730000.0
Percentage of OperatingLeasePayments100.0100.0100.0100.0

us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense

us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense


Operating
Period End2021-03-312020-03-31
Value1365000.0541000.0
Percentage of OperatingLeaseRightOfUseAssetAmortizationExpense100.0100.0

us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax


Other
Period End2021-06-302021-03-312020-06-302020-03-312019-12-312019-09-30
Value93000.0-249000.0132000.0472000.0102000.0152000.0
Percentage of OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax100.0100.0100.0100.0100.0100.0

us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax us-gaap:StatementEquityComponents

us-gaap:AccumulatedOtherComprehensiveIncome


Other
Period End2021-06-302021-03-312020-06-302020-03-312019-09-30
Value93000.0-249000.0132000.0472000.0152000.0
Percentage of OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax100.0100.0100.0100.0100.0

us-gaap:Parent


Other
Period End2021-06-302021-03-312020-06-302020-03-312019-09-30
Value93000.0-249000.0132000.0472000.0152000.0
Percentage of OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax100.0100.0100.0100.0100.0

us-gaap:OtherNoncashIncomeExpense

us-gaap:OtherNoncashIncomeExpense


Other
Period End2021-06-302021-03-312020-06-302020-03-312019-06-302019-03-31
Value-2110000.0-5096000.0-1446000.0-1034000.0-133000.0-339000.0
Percentage of OtherNoncashIncomeExpense100.0100.0100.0100.0100.0100.0

us-gaap:PaymentsOfDebtExtinguishmentCosts us-gaap:ConsolidatedEntities, us-gaap:DebtInstrument, us-gaap:LineOfCreditFacility, us-gaap:SubsequentEventType

us-gaap:PaymentsOfDebtExtinguishmentCosts

bbio:EidosTherapeuticsInc, bbio:TrancheALoan, bbio:SiliconValleyBankAndHerculesLoan, us-gaap:SubsequentEvent


Payments
Period End2021-04-13
Value17
Percentage of PaymentsOfDebtExtinguishmentCosts100.0

us-gaap:PaymentsOfDebtIssuanceCosts

us-gaap:PaymentsOfDebtIssuanceCosts


Payments
Period End2021-06-302021-03-312020-06-302020-03-31
Value0.0160.66412
Percentage of PaymentsOfDebtIssuanceCosts0.0100.0100.0100.0

us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation

us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation


Payments
Period End2021-06-302021-03-31
Value2281000.01021000.0
Percentage of PaymentsRelatedToTaxWithholdingForShareBasedCompensation100.0100.0

us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries us-gaap:ConsolidatedEntities

us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries

bbio:EidosTherapeuticsInc


Payments
Period End2021-01-26
Value21
Percentage of PaymentsToAcquireAdditionalInterestInSubsidiaries100.0

us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries us-gaap:ConsolidatedEntities, us-gaap:SubsequentEventType

bbio:EidosTherapeuticsInc, us-gaap:SubsequentEvent


Payments
Period End2021-01-26
Value21
Percentage of PaymentsToAcquireAdditionalInterestInSubsidiaries100.0

us-gaap:PaymentsToAcquireMarketableSecurities

us-gaap:PaymentsToAcquireMarketableSecurities


Payments
Period End2021-06-302021-03-31
Value130379
Percentage of PaymentsToAcquireMarketableSecurities100.0100.0

us-gaap:ProceedsFromConvertibleDebt

us-gaap:ProceedsFromConvertibleDebt


Proceeds
Period End2021-06-302021-03-312020-06-302020-03-31
Value0.07470.0550
Percentage of ProceedsFromConvertibleDebt0.0100.00.0100.0

us-gaap:ProceedsFromIssuanceOfDebt us-gaap:LineOfCreditFacility, us-gaap:SubsequentEventType

us-gaap:ProceedsFromIssuanceOfDebt

bbio:HerculesCapitalInc, us-gaap:SubsequentEvent


Proceeds
Period End2021-04-13
Value25
Percentage of ProceedsFromIssuanceOfDebt100.0

us-gaap:ProceedsFromNotesPayable us-gaap:DebtInstrument, us-gaap:SubsequentEventType

us-gaap:ProceedsFromNotesPayable

bbio:TwoPointTwoFivePercentageConvertibleSeniorNotesDueTwoThousandAndTwentyNine, us-gaap:SubsequentEvent


Proceeds
Period End2021-01-28
Value67
Percentage of ProceedsFromNotesPayable100.0

us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities

us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities


Proceeds
Period End2021-06-302021-03-312020-06-302020-03-31
Value139994042
Percentage of ProceedsFromSaleAndMaturityOfMarketableSecurities100.0100.0100.0100.0

us-gaap:ProceedsFromStockOptionsExercised

us-gaap:ProceedsFromStockOptionsExercised


Proceeds
Period End2021-06-302021-03-312020-06-302020-03-312019-06-302019-03-31
Value3.7527.4641.3670.7340.4350.103
Percentage of ProceedsFromStockOptionsExercised100.0100.0100.0100.0100.0100.0

us-gaap:ProceedsFromStockPlans

us-gaap:ProceedsFromStockPlans


Proceeds
Period End2021-06-302021-03-31
Value01652000.0
Percentage of ProceedsFromStockPlans0.0100.0

us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability

us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability


Right
Period End2021-06-302021-03-312020-06-302020-03-31
Value3.9080.1332.4199.395
Percentage of RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability100.0100.0100.0100.0

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue us-gaap:AwardType, us-gaap:PlanName

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue

us-gaap:RestrictedStockUnitsRSU, bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlan


Share
Period End2021-06-302021-03-31
Value16.1836.04
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue100.0100.0

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue us-gaap:AwardType, us-gaap:PlanName

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

us-gaap:RestrictedStockUnitsRSU, bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlan


Share
Period End2021-06-302021-03-312020-06-302020-03-31
Value-1.8768.52-1.9734.49
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue100.0100.0100.0100.0

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue us-gaap:AwardType, us-gaap:PlanName

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue

us-gaap:RestrictedStock, bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlan


Share
Period End2021-06-302021-03-312020-06-302020-03-31
Value-9.612.510.212.22
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue100.0100.0100.0100.0

us-gaap:RestrictedStockUnitsRSU, bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlan


Share
Period End2021-06-302021-03-31
Value3.1440.36
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue-32.7322.6

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate us-gaap:AwardType

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

us-gaap:EmployeeStockOption


Share
Period End2021-03-312019-12-31
Value51.4-0.001
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate100.0100.0

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum us-gaap:SubsidiarySaleOfStock

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum

us-gaap:EmployeeStock


Share
Period End2021-06-302021-03-31
Value00.5197
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum0.0100.0

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum us-gaap:SubsidiarySaleOfStock

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum

us-gaap:EmployeeStock


Share
Period End2021-06-302021-03-31
Value00.4761
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum0.0100.0

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate us-gaap:AwardType

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

us-gaap:EmployeeStockOption


Share
Period End2021-03-312019-12-31
Value0.63-0.0002
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate100.0100.0

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum us-gaap:SubsidiarySaleOfStock

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum

us-gaap:EmployeeStock


Share
Period End2021-06-302021-03-31
Value00.0013
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum0.0100.0

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum us-gaap:SubsidiarySaleOfStock

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum

us-gaap:EmployeeStock


Share
Period End2021-06-302021-03-31
Value00.0006
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum0.0100.0

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue us-gaap:AwardType

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

us-gaap:EmployeeStockOption


Share
Period End2021-06-302021-03-312020-06-302020-03-312019-12-31
Value-1.0133.19-1.9713.011.17
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue100.0100.0100.0100.0100.0

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue us-gaap:SubsidiarySaleOfStock

us-gaap:EmployeeStock


Share
Period End2021-06-302021-03-312020-06-302020-03-31
Value-0.3915.44010.34
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue38.646.5-0.079.5

us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice us-gaap:ConsolidatedEntities, us-gaap:PlanName

us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

bbio:EidosTherapeuticsInc, bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlan


Share
Period End2021-06-302021-03-31
Value1.9914.09
Percentage of ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice100.0100.0

us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice us-gaap:PlanName

bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlan


Share
Period End2021-06-302021-03-312020-06-302020-03-31
Value-0.9120.51017.0
Percentage of ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-45.7145.60.00.0

us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice us-gaap:PlanName, us-gaap:ShareRepurchaseProgram

bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlan, bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgram


Share
Period End2021-06-302021-03-31
Value0.31.31
Percentage of ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice15.19.3

us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice us-gaap:PlanName

us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice

bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlan


Share
Period End2021-06-302021-03-312020-06-302020-03-31
Value-0.7527.248.4417.0
Percentage of ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice100.0100.0100.0100.0

us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice us-gaap:PlanName, us-gaap:ShareRepurchaseProgram

bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlan, bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgram


Share
Period End2021-06-302021-03-31
Value03.37
Percentage of ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice-0.012.4

us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice us-gaap:ConsolidatedEntities, us-gaap:PlanName

us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

bbio:EidosTherapeuticsInc, bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlan


Share
Period End2021-06-302021-03-31
Value016.33
Percentage of ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice0.0100.0

us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice us-gaap:PlanName

bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlan


Share
Period End2021-06-302021-03-312020-06-302020-03-31
Value-2.6868.87-4.8234.66
Percentage of ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice0.0421.70.00.0

us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation us-gaap:AwardType

us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation

us-gaap:EmployeeStock


Stock
Period End2021-03-31
Value1.651
Percentage of StockIssuedDuringPeriodValueShareBasedCompensation100.0

us-gaap:StockCompensationPlan


Stock
Period End2021-06-302021-03-312020-06-302020-03-31
Value3.7516.8420.6910.529
Percentage of StockIssuedDuringPeriodValueShareBasedCompensation0.0414.40.00.0

us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation us-gaap:AwardType, us-gaap:StatementEquityComponents

us-gaap:EmployeeStock, us-gaap:AdditionalPaidInCapital


Stock
Period End2021-03-31
Value1.651
Percentage of StockIssuedDuringPeriodValueShareBasedCompensation100.0

us-gaap:EmployeeStock, us-gaap:Parent


Stock
Period End2021-03-31
Value1.651
Percentage of StockIssuedDuringPeriodValueShareBasedCompensation100.0

us-gaap:StockCompensationPlan, us-gaap:AdditionalPaidInCapital


Stock
Period End2021-06-302021-03-312020-06-302020-03-31
Value3.756.8410.6910.529
Percentage of StockIssuedDuringPeriodValueShareBasedCompensation0.0414.40.00.0

us-gaap:StockCompensationPlan, us-gaap:Parent


Stock
Period End2021-06-302021-03-312020-06-302020-03-31
Value3.7516.8420.6910.529
Percentage of StockIssuedDuringPeriodValueShareBasedCompensation0.0414.40.00.0

us-gaap:TemporaryEquityNetIncome us-gaap:StatementClassOfStock

us-gaap:TemporaryEquityNetIncome

bbio:RedeemableConvertibleNoncontrollingInterests


Temporary
Period End2021-06-302021-03-312020-06-302020-03-312019-09-302019-06-302019-03-312018-09-302018-06-302018-03-31
Value-1562000.0-876000.0-1578000.0-866000.0-635000.0-685000.0-790000.0-2355000.0-3618000.0-3614000.0
Percentage of TemporaryEquityNetIncome100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:TreasuryStockValueAcquiredCostMethod

us-gaap:TreasuryStockValueAcquiredCostMethod


Treasury
Period End2021-06-302021-03-312020-03-31
Value5.3085075
Percentage of TreasuryStockValueAcquiredCostMethod100.0100.0100.0

us-gaap:TreasuryStockValueAcquiredCostMethod us-gaap:StatementEquityComponents

us-gaap:Parent


Treasury
Period End2021-06-302021-03-312020-03-31
Value5.3085075
Percentage of TreasuryStockValueAcquiredCostMethod100.0100.0100.0

us-gaap:TreasuryStock


Treasury
Period End2021-06-302021-03-312020-03-31
Value5.3085075
Percentage of TreasuryStockValueAcquiredCostMethod100.0100.0100.0

us-gaap:VariableInterestEntityOwnershipPercentage dei:LegalEntity, us-gaap:ConsolidatedEntities

us-gaap:VariableInterestEntityOwnershipPercentage

bbio:EidosTherapeuticsInc, us-gaap:VariableInterestEntityPrimaryBeneficiary


Variable
Period End2021-06-302021-03-312020-06-302020-03-31
Value050.000.5
Percentage of VariableInterestEntityOwnershipPercentage0.0100.00.0100.0

us-gaap:VariableLeaseCost

us-gaap:VariableLeaseCost


Variable
Period End2021-06-302021-03-312020-06-302020-03-31
Value969000.0751000.0142000.0159000.0
Percentage of VariableLeaseCost100.0100.0100.0100.0

bbio:AccruedResearchAndDevelopmentLiabilitiesCurrent

bbio:AccruedResearchAndDevelopmentLiabilitiesCurrent


Accrued
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-312019-09-302018-12-31
Value553327372920138.915
Percentage of AccruedResearchAndDevelopmentLiabilitiesCurrent100.0100.0100.0100.0100.0100.0100.0100.0

bbio:BusinessAcquisitionCashPerShare us-gaap:ConsolidatedEntities, us-gaap:TypeOfArrangement

bbio:BusinessAcquisitionCashPerShare

bbio:EidosTherapeuticsInc, bbio:AgreementAndPlanOfMerger


Business
Period End2020-10-05
Value73.26
Percentage of BusinessAcquisitionCashPerShare100.0

bbio:BusinessAcquisitionCommonShare us-gaap:ConsolidatedEntities, us-gaap:TypeOfArrangement

bbio:BusinessAcquisitionCommonShare

bbio:EidosTherapeuticsInc, bbio:AgreementAndPlanOfMerger


Business
Period End2020-10-05
Value1.85
Percentage of BusinessAcquisitionCommonShare100.0

bbio:BusinessAcquisitionEquityInterestsIssuedOrIssuableFairValue us-gaap:ConsolidatedEntities

bbio:BusinessAcquisitionEquityInterestsIssuedOrIssuableFairValue

bbio:EidosTherapeuticsInc


Business
Period End2021-01-26
Value1630
Percentage of BusinessAcquisitionEquityInterestsIssuedOrIssuableFairValue100.0

bbio:BusinessCombinationPotentialCashConsideration us-gaap:ConsolidatedEntities, us-gaap:Range, us-gaap:TypeOfArrangement

bbio:BusinessCombinationPotentialCashConsideration

bbio:EidosTherapeuticsInc, srt:Maximum, bbio:AgreementAndPlanOfMerger


Business
Period End2020-10-05
Value175
Percentage of BusinessCombinationPotentialCashConsideration100.0

bbio:CallOptionLiabilityFairValueDisclosure us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency

bbio:CallOptionLiabilityFairValueDisclosure

us-gaap:FairValueInputsLevel3, us-gaap:FairValueMeasurementsRecurring


Call
Period End2020-12-312020-06-302020-03-312019-12-312019-09-302018-12-31
Value5550000.05276000.03539000.04078000.04021000.03009000.0
Percentage of CallOptionLiabilityFairValueDisclosure100.0100.0100.0100.0100.0100.0

bbio:CallOptionLiabilityFairValueDisclosure us-gaap:FairValueByMeasurementFrequency

us-gaap:FairValueMeasurementsRecurring


Call
Period End2020-12-312020-06-302020-03-312019-12-312019-09-302018-12-31
Value5550000.05276000.03539000.04078000.04021000.03009000.0
Percentage of CallOptionLiabilityFairValueDisclosure100.0100.0100.0100.0100.0100.0

bbio:ConvertibleSeniorNotes

bbio:ConvertibleSeniorNotes


Convertible
Period End2020-12-31
Value383
Percentage of ConvertibleSeniorNotes100.0

bbio:ConvertibleSeniorNotes us-gaap:CumulativeEffectPeriodOfAdoption, us-gaap:AdjustmentsForNewAccountingPronouncements, us-gaap:DebtInstrument

srt:CumulativeEffectPeriodOfAdoptionAdjustment, bbio:AccountingStandardsUpdate202006, bbio:TwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySeven


Convertible
Period End2021-01-01
Value-14.328
Percentage of ConvertibleSeniorNotes0.0

bbio:ConvertibleSeniorNotes us-gaap:DebtInstrument

bbio:TwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySeven


Convertible
Period End2021-06-302021-03-312020-12-31
Value539538383
Percentage of ConvertibleSeniorNotes0.00.0100.0

bbio:TwoPointTwoFivePercentageConvertibleSeniorNotesDueTwoThousandAndTwentyNine


Convertible
Period End2021-06-302021-03-31
Value732731
Percentage of ConvertibleSeniorNotes0.00.0

bbio:ConvertibleSeniorNotes us-gaap:Restatement, us-gaap:AdjustmentsForNewAccountingPronouncements, us-gaap:DebtInstrument

srt:RevisionOfPriorPeriodAccountingStandardsUpdateAdjustment, bbio:AccountingStandardsUpdate202006, bbio:TwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySeven


Convertible
Period End2021-01-01
Value169
Percentage of ConvertibleSeniorNotes0.0

bbio:DebtInstrumentAdditionalIncreaseAvailableInLoanFacilities us-gaap:LineOfCreditFacility

bbio:DebtInstrumentAdditionalIncreaseAvailableInLoanFacilities

bbio:HerculesCapitalInc


Debt
Period End2021-06-302021-04-302021-03-312020-12-312020-04-30
Value0.1850.185125100125
Percentage of DebtInstrumentAdditionalIncreaseAvailableInLoanFacilities100.0100.0100.0100.0100.0

bbio:DebtInstrumentAdditionalIncreaseAvailableInLoanFacilitiesNoLaterThanFourteenMonths us-gaap:LineOfCreditFacility

bbio:DebtInstrumentAdditionalIncreaseAvailableInLoanFacilitiesNoLaterThanFourteenMonths

bbio:HerculesCapitalInc


Debt
Period End2021-04-30
Value0.07
Percentage of DebtInstrumentAdditionalIncreaseAvailableInLoanFacilitiesNoLaterThanFourteenMonths100.0

bbio:DebtInstrumentAdditionalIncreaseAvailableInLoanFacilitiesNoLaterThanFourteenMonths us-gaap:LineOfCreditFacility, us-gaap:SubsequentEventType

bbio:HerculesCapitalInc, us-gaap:SubsequentEvent


Debt
Period End2021-04-13
Value70
Percentage of DebtInstrumentAdditionalIncreaseAvailableInLoanFacilitiesNoLaterThanFourteenMonths0.0

bbio:DebtInstrumentAdditionalIncreaseAvailableInLoanFacilitiesUponAchievementOfCertainPerformanceMilestones us-gaap:LineOfCreditFacility

bbio:DebtInstrumentAdditionalIncreaseAvailableInLoanFacilitiesUponAchievementOfCertainPerformanceMilestones

bbio:HerculesCapitalInc


Debt
Period End2021-04-302020-04-30
Value0.0425
Percentage of DebtInstrumentAdditionalIncreaseAvailableInLoanFacilitiesUponAchievementOfCertainPerformanceMilestones100.0100.0

bbio:DebtInstrumentAdditionalIncreaseAvailableInLoanFacilitiesUponAchievementOfCertainPerformanceMilestones us-gaap:LineOfCreditFacility, us-gaap:SubsequentEventType

bbio:HerculesCapitalInc, us-gaap:SubsequentEvent


Debt
Period End2021-04-13
Value40
Percentage of DebtInstrumentAdditionalIncreaseAvailableInLoanFacilitiesUponAchievementOfCertainPerformanceMilestones0.0

bbio:DebtInstrumentAdditionalIncreaseAvailableInLoanFacilitiesYearThree us-gaap:LineOfCreditFacility

bbio:DebtInstrumentAdditionalIncreaseAvailableInLoanFacilitiesYearThree

bbio:HerculesCapitalInc


Debt
Period End2021-04-302020-04-30
Value0.07550
Percentage of DebtInstrumentAdditionalIncreaseAvailableInLoanFacilitiesYearThree100.0100.0

bbio:DebtInstrumentAdditionalIncreaseAvailableInLoanFacilitiesYearThree us-gaap:LineOfCreditFacility, us-gaap:SubsequentEventType

bbio:HerculesCapitalInc, us-gaap:SubsequentEvent


Debt
Period End2021-04-13
Value75
Percentage of DebtInstrumentAdditionalIncreaseAvailableInLoanFacilitiesYearThree0.0

bbio:DebtInstrumentAdditionalPrincipalBorrowingAmount us-gaap:DebtInstrument, us-gaap:LineOfCreditFacility

bbio:DebtInstrumentAdditionalPrincipalBorrowingAmount

bbio:DebtInstrumentTrancheFour, bbio:HerculesCapitalInc


Debt
Period End2021-04-30
Value25
Percentage of DebtInstrumentAdditionalPrincipalBorrowingAmount100.0

bbio:DebtInstrumentCappedCallTransactionCapPricePerShare us-gaap:DebtInstrument

bbio:DebtInstrumentCappedCallTransactionCapPricePerShare

bbio:TwoThousandTwentyOneCappedCallTransactions


Debt
Period End2021-01-25
Value131.58
Percentage of DebtInstrumentCappedCallTransactionCapPricePerShare100.0

bbio:DebtInstrumentOptionToPurchaseAdditionalNotes us-gaap:DebtInstrument

bbio:DebtInstrumentOptionToPurchaseAdditionalNotes

bbio:TwoPointTwoFivePercentageConvertibleSeniorNotesDueTwoThousandAndTwentyNine


Debt
Period End2021-01-28
Value97
Percentage of DebtInstrumentOptionToPurchaseAdditionalNotes100.0

bbio:DebtInstrumentOptionToPurchaseAdditionalNotes us-gaap:DebtInstrument, us-gaap:SubsequentEventType

bbio:TwoPointTwoFivePercentageConvertibleSeniorNotesDueTwoThousandAndTwentyNine, us-gaap:SubsequentEvent


Debt
Period End2021-01-28
Value97
Percentage of DebtInstrumentOptionToPurchaseAdditionalNotes100.0

bbio:DebtInstrumentOptionToPurchaseAdditionalNotesExercised us-gaap:DebtInstrument

bbio:DebtInstrumentOptionToPurchaseAdditionalNotesExercised

bbio:TwoPointTwoFivePercentageConvertibleSeniorNotesDueTwoThousandAndTwentyNine


Debt
Period End2021-01-28
Value67
Percentage of DebtInstrumentOptionToPurchaseAdditionalNotesExercised100.0

bbio:DebtInstrumentOptionToPurchaseAdditionalNotesExercised us-gaap:DebtInstrument, us-gaap:SubsequentEventType

bbio:TwoPointTwoFivePercentageConvertibleSeniorNotesDueTwoThousandAndTwentyNine, us-gaap:SubsequentEvent


Debt
Period End2021-01-28
Value30
Percentage of DebtInstrumentOptionToPurchaseAdditionalNotesExercised44.4

bbio:DebtInstrumentOptionToPurchaseAdditionalNotesRemainingPortionExercised us-gaap:DebtInstrument

bbio:DebtInstrumentOptionToPurchaseAdditionalNotesRemainingPortionExercised

bbio:TwoPointTwoFivePercentageConvertibleSeniorNotesDueTwoThousandAndTwentyNine


Debt
Period End2021-01-28
Value30
Percentage of DebtInstrumentOptionToPurchaseAdditionalNotesRemainingPortionExercised100.0

bbio:DebtIssuanceCostsAndDebtAccretion us-gaap:DebtInstrument

bbio:DebtIssuanceCostsAndDebtAccretion

bbio:HerculesTermLoan


Debt
Period End2020-12-312019-12-312018-12-31
Value1936000.0679000.0-493000.0
Percentage of DebtIssuanceCostsAndDebtAccretion100.0100.0100.0

bbio:DeferredTaxAssetsAmortizationOfAssets

bbio:DeferredTaxAssetsAmortizationOfAssets


Deferred
Period End2020-12-312019-12-312018-12-31
Value7427000.05196000.04424000.0
Percentage of DeferredTaxAssetsAmortizationOfAssets100.0100.0100.0

bbio:DeferredTaxAssetsLeaseLiabilities

bbio:DeferredTaxAssetsLeaseLiabilities


Deferred
Period End2020-12-31
Value3932000.0
Percentage of DeferredTaxAssetsLeaseLiabilities100.0

bbio:DeferredTaxLiabilitiesRightOfUseAssets

bbio:DeferredTaxLiabilitiesRightOfUseAssets


Deferred
Period End2020-12-31
Value3514000.0
Percentage of DeferredTaxLiabilitiesRightOfUseAssets100.0

bbio:EstimatedTransactionCostsIncurredInMergerTransactions us-gaap:ConsolidatedEntities, us-gaap:SubsequentEventType

bbio:EstimatedTransactionCostsIncurredInMergerTransactions

bbio:EidosTherapeuticsInc, us-gaap:SubsequentEvent


Estimated
Period End2021-01-26
Value78
Percentage of EstimatedTransactionCostsIncurredInMergerTransactions100.0

bbio:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFour

bbio:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFour


Finite
Period End2021-06-30
Value13
Percentage of FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFour100.0

bbio:InvestmentsInEquitySecurities

bbio:InvestmentsInEquitySecurities


Investments
Period End2021-06-30
Value18
Percentage of InvestmentsInEquitySecurities100.0

bbio:InvestmentsInEquitySecurities us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency

us-gaap:FairValueInputsLevel1, us-gaap:FairValueMeasurementsRecurring


Investments
Period End2021-06-30
Value18
Percentage of InvestmentsInEquitySecurities100.0

bbio:InvestmentsInEquitySecurities us-gaap:FairValueByMeasurementFrequency

us-gaap:FairValueMeasurementsRecurring


Investments
Period End2021-06-30
Value18
Percentage of InvestmentsInEquitySecurities100.0

bbio:LEOCallOptionLiabilityCurrent

bbio:LEOCallOptionLiabilityCurrent


L
Period End2020-12-312020-06-302020-03-312019-12-312019-09-302018-12-31
Value5550000.05276000.03539000.04078000.04021000.03009000.0
Percentage of LEOCallOptionLiabilityCurrent100.0100.0100.0100.0100.0100.0

bbio:LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedFuturePayments

bbio:LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedFuturePayments


Lessee
Period End2021-03-31
Value5700000.0
Percentage of LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedFuturePayments100.0

bbio:LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedFuturePayments us-gaap:PropertyPlantAndEquipmentByType

bbio:LaboratoryFacility


Lessee
Period End2020-12-31
Value6000000.0
Percentage of LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedFuturePayments0.0

bbio:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour

bbio:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour


Lessee
Period End2021-06-302021-03-31
Value6419000.02622000.0
Percentage of LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour100.0100.0

bbio:LongTermMarketableSecuritiesFairValueDisclosure us-gaap:FairValueByAssetClass, us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency

bbio:LongTermMarketableSecuritiesFairValueDisclosure

us-gaap:CorporateDebtSecurities, us-gaap:FairValueInputsLevel2, us-gaap:FairValueMeasurementsRecurring


Long
Period End2021-03-312020-03-312019-12-312019-09-30
Value217.7071530
Percentage of LongTermMarketableSecuritiesFairValueDisclosure100.0100.0100.0100.0

us-gaap:USTreasurySecurities, us-gaap:FairValueInputsLevel2, us-gaap:FairValueMeasurementsRecurring


Long
Period End2021-06-302021-03-312019-12-31
Value606015
Percentage of LongTermMarketableSecuritiesFairValueDisclosure0.0284.796.7

bbio:LongTermMarketableSecuritiesFairValueDisclosure us-gaap:FairValueByAssetClass, us-gaap:FairValueByMeasurementFrequency

us-gaap:CorporateDebtSecurities, us-gaap:FairValueMeasurementsRecurring


Long
Period End2021-03-312020-03-312019-12-312019-09-30
Value217.7071530
Percentage of LongTermMarketableSecuritiesFairValueDisclosure100.0100.0100.0100.0

us-gaap:USTreasurySecurities, us-gaap:FairValueMeasurementsRecurring


Long
Period End2021-06-302021-03-312019-12-31
Value606015
Percentage of LongTermMarketableSecuritiesFairValueDisclosure0.0284.796.7

bbio:LongTermMarketableSecuritiesFairValueDisclosure us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency

us-gaap:FairValueInputsLevel2, us-gaap:FairValueMeasurementsRecurring


Long
Period End2021-03-312020-03-312019-12-312019-09-30
Value82233175
Percentage of LongTermMarketableSecuritiesFairValueDisclosure384.7301.2196.7249.6

bbio:LongTermMarketableSecuritiesFairValueDisclosure us-gaap:FairValueByMeasurementFrequency

us-gaap:FairValueMeasurementsRecurring


Long
Period End2021-03-312020-03-312019-12-312019-09-30
Value82233175
Percentage of LongTermMarketableSecuritiesFairValueDisclosure384.7301.2196.7249.6

bbio:MaximumPotentialPerformanceBasedMilestoneAwardsToBeSettledInShares us-gaap:ShareRepurchaseProgram

bbio:MaximumPotentialPerformanceBasedMilestoneAwardsToBeSettledInShares

bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgram


Maximum
Period End2020-11-182020-04-22
Value11183
Percentage of MaximumPotentialPerformanceBasedMilestoneAwardsToBeSettledInShares100.0100.0

bbio:PayableRelatedToManufacturingSuite

bbio:PayableRelatedToManufacturingSuite


Payable
Period End2021-06-302021-03-312020-12-31
Value2000000.04000000.04000000.0
Percentage of PayableRelatedToManufacturingSuite100.0100.0100.0

bbio:PercentageOfCashCommissionOnGrossProceedsOfSalesOfCommonStock us-gaap:Range, us-gaap:SubsequentEventType, us-gaap:SubsidiarySaleOfStock

bbio:PercentageOfCashCommissionOnGrossProceedsOfSalesOfCommonStock

srt:Maximum, us-gaap:SubsequentEvent, bbio:AtTheMarketSalesAgreement


Percentage
Period End2020-07-07
Value0.03
Percentage of PercentageOfCashCommissionOnGrossProceedsOfSalesOfCommonStock100.0

bbio:PerformanceBasedMilestoneAwards us-gaap:ShareRepurchaseProgram

bbio:PerformanceBasedMilestoneAwards

bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgram


Performance
Period End2020-12-312020-04-22
Value1117
Percentage of PerformanceBasedMilestoneAwards100.0100.0

bbio:PotentialMilestoneAccruedAmountSettlementInCash

bbio:PotentialMilestoneAccruedAmountSettlementInCash


Potential
Period End2021-06-302021-03-312020-12-31
Value1176000.0398000.0367000.0
Percentage of PotentialMilestoneAccruedAmountSettlementInCash100.0100.0100.0

bbio:PotentialMilestoneAccruedAmountSettlementInCashOrStockAtSoleDiscretion

bbio:PotentialMilestoneAccruedAmountSettlementInCashOrStockAtSoleDiscretion


Potential
Period End2021-06-302021-03-312020-12-31
Value3419000.02834000.0634000.0
Percentage of PotentialMilestoneAccruedAmountSettlementInCashOrStockAtSoleDiscretion100.0100.0100.0

bbio:PotentialMilestoneAccruedAmountSettlementInStock

bbio:PotentialMilestoneAccruedAmountSettlementInStock


Potential
Period End2021-06-302021-03-312020-12-31
Value13179.571
Percentage of PotentialMilestoneAccruedAmountSettlementInStock100.0100.0100.0

bbio:PotentialMilestoneAccruedSettlementAmount

bbio:PotentialMilestoneAccruedSettlementAmount


Potential
Period End2021-06-302021-03-312020-12-31
Value182010
Percentage of PotentialMilestoneAccruedSettlementAmount100.0100.0100.0

bbio:PotentialMilestoneAmount

bbio:PotentialMilestoneAmount


Potential
Period End2021-03-31
Value266
Percentage of PotentialMilestoneAmount100.0

bbio:PotentialMilestoneAmount us-gaap:Range

srt:Maximum


Potential
Period End2020-12-31
Value267
Percentage of PotentialMilestoneAmount0.0

bbio:PotentialMilestoneFixedMonetaryAmountSettlementInCash

bbio:PotentialMilestoneFixedMonetaryAmountSettlementInCash


Potential
Period End2021-06-302021-03-312020-12-31
Value111315
Percentage of PotentialMilestoneFixedMonetaryAmountSettlementInCash100.0100.0100.0

bbio:PotentialMilestoneFixedMonetaryAmountSettlementInCashOrStockAtSoleDiscretion

bbio:PotentialMilestoneFixedMonetaryAmountSettlementInCashOrStockAtSoleDiscretion


Potential
Period End2021-06-302021-03-312020-12-31
Value969284
Percentage of PotentialMilestoneFixedMonetaryAmountSettlementInCashOrStockAtSoleDiscretion100.0100.0100.0

bbio:PotentialMilestoneFixedMonetaryAmountSettlementInStock

bbio:PotentialMilestoneFixedMonetaryAmountSettlementInStock


Potential
Period End2021-06-302021-03-312020-12-31
Value136160168
Percentage of PotentialMilestoneFixedMonetaryAmountSettlementInStock100.0100.0100.0

bbio:PotentialMilestoneFixedMonetarySettlementAmount

bbio:PotentialMilestoneFixedMonetarySettlementAmount


Potential
Period End2021-06-302021-03-312020-12-31
Value243266267
Percentage of PotentialMilestoneFixedMonetarySettlementAmount100.0100.0100.0

bbio:PotentialMilestonePayments us-gaap:Ownership, us-gaap:Range, us-gaap:TypeOfArrangement

bbio:PotentialMilestonePayments

bbio:QEDTherapeuticsInc, srt:Maximum, bbio:LicenseAndCollaborationAgreement


Potential
Period End2021-03-29
Value2450
Percentage of PotentialMilestonePayments100.0

bbio:ReceivableCurrentFromLicensingAndCollaborationAgreements

bbio:ReceivableCurrentFromLicensingAndCollaborationAgreements


Receivable
Period End2021-06-30
Value35
Percentage of ReceivableCurrentFromLicensingAndCollaborationAgreements100.0

bbio:ReceivableCurrentFromLicensingAndCollaborationAgreements us-gaap:AdjustmentsForNewAccountingPronouncements

us-gaap:AccountingStandardsUpdate201818


Receivable
Period End2021-06-30
Value9.2
Percentage of ReceivableCurrentFromLicensingAndCollaborationAgreements26.0

bbio:ReceivableCurrentFromLicensingAndCollaborationAgreements us-gaap:ProductOrService, us-gaap:TypeOfArrangement

us-gaap:License, bbio:LicenseAndCollaborationAgreement


Receivable
Period End2021-06-30
Value26
Percentage of ReceivableCurrentFromLicensingAndCollaborationAgreements73.5

bbio:RegulatoryMilestonePaymentReceivableSubjectToAchievementOfRegulatorMilestones us-gaap:ConsolidatedEntities, us-gaap:TypeOfArrangement

bbio:RegulatoryMilestonePaymentReceivableSubjectToAchievementOfRegulatorMilestones

bbio:EidosTherapeuticsInc, bbio:AlexionLicenseAgreements


Regulatory
Period End2020-12-31
Value30
Percentage of RegulatoryMilestonePaymentReceivableSubjectToAchievementOfRegulatorMilestones100.0

bbio:RegulatoryMilestonePayments us-gaap:ContingentConsiderationByType

bbio:RegulatoryMilestonePayments

bbio:PaymentFollowingFDAApprovalOfTruseltiq


Regulatory
Period End2021-05-31
Value20
Percentage of RegulatoryMilestonePayments100.0

bbio:RepurchaseOfNoncontrollingInterestsTransactionCosts

bbio:RepurchaseOfNoncontrollingInterestsTransactionCosts


Repurchase
Period End2021-03-31
Value70
Percentage of RepurchaseOfNoncontrollingInterestsTransactionCosts100.0

bbio:ShortTermMarketableSecuritiesFairValueDisclosure us-gaap:FairValueByAssetClass, us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency

bbio:ShortTermMarketableSecuritiesFairValueDisclosure

bbio:SupranationalDebtSecurities, us-gaap:FairValueInputsLevel2, us-gaap:FairValueMeasurementsRecurring


Short
Period End2021-06-302021-03-31
Value7575
Percentage of ShortTermMarketableSecuritiesFairValueDisclosure100.0100.0

us-gaap:CommercialPaper, us-gaap:FairValueInputsLevel2, us-gaap:FairValueMeasurementsRecurring


Short
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-312019-09-30
Value26321314459236565
Percentage of ShortTermMarketableSecuritiesFairValueDisclosure349.3283.70.00.00.00.00.0

us-gaap:CorporateDebtSecurities, us-gaap:FairValueInputsLevel2, us-gaap:FairValueMeasurementsRecurring


Short
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-312019-09-30
Value12011345104797156
Percentage of ShortTermMarketableSecuritiesFairValueDisclosure160.6150.30.00.00.00.00.0

us-gaap:USTreasuryBillSecurities, us-gaap:FairValueInputsLevel2, us-gaap:FairValueMeasurementsRecurring


Short
Period End2020-12-31
Value14
Percentage of ShortTermMarketableSecuritiesFairValueDisclosure0.0

us-gaap:USTreasurySecurities, us-gaap:FairValueInputsLevel2, us-gaap:FairValueMeasurementsRecurring


Short
Period End2021-03-312020-12-312020-06-302020-03-312019-12-31
Value45451354545
Percentage of ShortTermMarketableSecuritiesFairValueDisclosure59.90.00.00.00.0

bbio:ShortTermMarketableSecuritiesFairValueDisclosure us-gaap:FairValueByAssetClass, us-gaap:FairValueByMeasurementFrequency

bbio:SupranationalDebtSecurities, us-gaap:FairValueMeasurementsRecurring


Short
Period End2021-06-302021-03-31
Value7575
Percentage of ShortTermMarketableSecuritiesFairValueDisclosure100.0100.0

us-gaap:CommercialPaper, us-gaap:FairValueMeasurementsRecurring


Short
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-312019-09-30
Value26321314459236565
Percentage of ShortTermMarketableSecuritiesFairValueDisclosure349.3283.70.00.00.00.00.0

us-gaap:CorporateDebtSecurities, us-gaap:FairValueMeasurementsRecurring


Short
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-312019-09-30
Value12011345104797156
Percentage of ShortTermMarketableSecuritiesFairValueDisclosure160.6150.30.00.00.00.00.0

us-gaap:USTreasuryBillSecurities, us-gaap:FairValueMeasurementsRecurring


Short
Period End2020-12-31
Value14
Percentage of ShortTermMarketableSecuritiesFairValueDisclosure0.0

us-gaap:USTreasurySecurities, us-gaap:FairValueMeasurementsRecurring


Short
Period End2021-03-312020-12-312020-06-302020-03-312019-12-31
Value45451354545
Percentage of ShortTermMarketableSecuritiesFairValueDisclosure59.90.00.00.00.0

bbio:ShortTermMarketableSecuritiesFairValueDisclosure us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency

us-gaap:FairValueInputsLevel2, us-gaap:FairValueMeasurementsRecurring


Short
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-312019-09-30
Value459447251300148182122
Percentage of ShortTermMarketableSecuritiesFairValueDisclosure610.0593.90.00.00.00.00.0

bbio:ShortTermMarketableSecuritiesFairValueDisclosure us-gaap:FairValueByMeasurementFrequency

us-gaap:FairValueMeasurementsRecurring


Short
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-312019-09-30
Value459447251300148182122
Percentage of ShortTermMarketableSecuritiesFairValueDisclosure610.0593.90.00.00.00.00.0

bbio:StockIssuableInTransactionValueNewIssues us-gaap:Range, us-gaap:StatementEquityComponents, us-gaap:SubsidiarySaleOfStock

bbio:StockIssuableInTransactionValueNewIssues

srt:Maximum, us-gaap:CommonStock, bbio:AtTheMarketOffering


Stock
Period End2020-07-07
Value350
Percentage of StockIssuableInTransactionValueNewIssues100.0

bbio:TermLoanMandatoryPrepaymentPercentageOnNetCashProceedsReceived us-gaap:Collateral, us-gaap:LineOfCreditFacility

bbio:TermLoanMandatoryPrepaymentPercentageOnNetCashProceedsReceived

us-gaap:CollateralPledged, bbio:HerculesCapitalInc


Term
Period End2020-12-31
Value75.0
Percentage of TermLoanMandatoryPrepaymentPercentageOnNetCashProceedsReceived100.0

bbio:UpfrontRegulatoryAndLaunchMilestonePaymentsYetToBeReceived us-gaap:Ownership, us-gaap:TypeOfArrangement

bbio:UpfrontRegulatoryAndLaunchMilestonePaymentsYetToBeReceived

bbio:QEDTherapeuticsInc, bbio:LicenseAndCollaborationAgreement


Upfront
Period End2021-03-29
Value100
Percentage of UpfrontRegulatoryAndLaunchMilestonePaymentsYetToBeReceived100.0

bbio:WarrantsFairValueDisclosure us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency

bbio:WarrantsFairValueDisclosure

us-gaap:FairValueInputsLevel3, us-gaap:FairValueMeasurementsRecurring


Warrants
Period End2021-06-302021-03-312020-12-31
Value2878000.03338000.03338000.0
Percentage of WarrantsFairValueDisclosure100.0100.0100.0

bbio:WarrantsFairValueDisclosure us-gaap:FairValueByMeasurementFrequency

us-gaap:FairValueMeasurementsRecurring


Warrants
Period End2021-06-302021-03-312020-12-31
Value2878000.03338000.03338000.0
Percentage of WarrantsFairValueDisclosure100.0100.0100.0

us-gaap:AccruedProfessionalFeesCurrent

us-gaap:AccruedProfessionalFeesCurrent


Accrued
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-312019-09-302018-12-31
Value6378000.04518000.05579000.08609000.03145000.02222000.01570000.0772000.0
Percentage of AccruedProfessionalFeesCurrent100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:AssetsFairValueDisclosure us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency

us-gaap:AssetsFairValueDisclosure

us-gaap:FairValueInputsLevel1, us-gaap:FairValueMeasurementsRecurring


Assets
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-312019-09-30
Value274333266436670307356
Percentage of AssetsFairValueDisclosure100.0100.0100.0100.0100.0100.0100.0

us-gaap:FairValueInputsLevel2, us-gaap:FairValueMeasurementsRecurring


Assets
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-312019-09-30
Value519530251307171213197
Percentage of AssetsFairValueDisclosure189.4159.194.270.425.569.355.5

us-gaap:FairValueInputsLevel3, us-gaap:FairValueMeasurementsRecurring


Assets
Period End2021-06-302021-03-312020-12-31
Value2.8783.3383.338
Percentage of AssetsFairValueDisclosure1.01.01.3

us-gaap:AssetsFairValueDisclosure us-gaap:FairValueByMeasurementFrequency

us-gaap:FairValueMeasurementsRecurring


Assets
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-312019-09-30
Value797866520743842521554
Percentage of AssetsFairValueDisclosure290.4260.1195.5170.4125.5169.3155.5

us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax

us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax


Available
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-312019-09-30
Value60000.067000.0196000.0860000.0792000.0254000.0175000.0
Percentage of AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax100.0100.0100.0100.0100.0100.0100.0

us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax us-gaap:FairValueByAssetClass, us-gaap:InvestmentType

us-gaap:CommercialPaper, us-gaap:ShortTermInvestments


Available
Period End2021-06-30
Value22000.0
Percentage of AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax36.7

us-gaap:CorporateDebtSecurities, us-gaap:ShortTermInvestments


Available
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-312019-09-30
Value23000.014000.093000.0369000.05000.083000.062000.0
Percentage of AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax38.320.947.442.90.632.735.4

us-gaap:USTreasuryBillSecurities, us-gaap:ShortTermInvestments


Available
Period End2020-12-31
Value3000.0
Percentage of AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax1.5

us-gaap:USTreasurySecurities, bbio:LongTermMarketableSecurities


Available
Period End2021-06-302021-03-312020-03-312019-12-31
Value15000.015000.0299000.059000.0
Percentage of AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax25.022.437.823.2

us-gaap:USTreasurySecurities, us-gaap:ShortTermInvestments


Available
Period End2021-03-312020-12-312020-06-302020-03-312019-12-31
Value38000.0100000.0491000.0470000.056000.0
Percentage of AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax56.751.057.159.322.0

us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax us-gaap:InvestmentType

bbio:LongTermMarketableSecurities


Available
Period End2021-03-312020-03-312019-12-312019-09-30
Value15000.0317000.0115000.0113000.0
Percentage of AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax22.440.045.364.6

us-gaap:ShortTermInvestments


Available
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-312019-09-30
Value45000.052000.0196000.0860000.0475000.0139000.062000.0
Percentage of AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax75.077.6100.0100.060.054.735.4

us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax

us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax


Available
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-09-30
Value24000.0124000.04000.02000.066000.023000.0
Percentage of AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax100.0100.0100.0100.0100.0100.0

us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax us-gaap:FairValueByAssetClass, us-gaap:InvestmentType

bbio:SupranationalDebtSecurities, us-gaap:ShortTermInvestments


Available
Period End2021-06-302021-03-31
Value8000.017000.0
Percentage of AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax33.313.7

us-gaap:CommercialPaper, us-gaap:ShortTermInvestments


Available
Period End2021-06-30
Value4000.0
Percentage of AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax16.7

us-gaap:CorporateDebtSecurities, bbio:LongTermMarketableSecurities


Available
Period End2021-03-312019-09-30
Value47000.011000.0
Percentage of AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax37.947.8

us-gaap:CorporateDebtSecurities, us-gaap:ShortTermInvestments


Available
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-09-30
Value12000.060000.03000.01000.066000.07000.0
Percentage of AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax50.048.475.050.0100.030.4

us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax us-gaap:InvestmentType

bbio:LongTermMarketableSecurities


Available
Period End2021-03-312019-09-30
Value47000.016000.0
Percentage of AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax37.969.6

us-gaap:ShortTermInvestments


Available
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-09-30
Value24000.077000.04000.02000.066000.07000.0
Percentage of AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax100.062.1100.0100.0100.030.4

us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis

us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis


Available
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-312019-09-30
Value775863517742841520554
Percentage of AvailableForSaleDebtSecuritiesAmortizedCostBasis100.0100.0100.0100.0100.0100.0100.0

us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis us-gaap:FairValueByAssetClass, us-gaap:InvestmentType

bbio:SupranationalDebtSecurities, us-gaap:ShortTermInvestments


Available
Period End2021-06-302021-03-31
Value7575
Percentage of AvailableForSaleDebtSecuritiesAmortizedCostBasis9.78.7

us-gaap:CommercialPaper, us-gaap:ShortTermInvestments


Available
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-312019-09-30
Value26221314459236565
Percentage of AvailableForSaleDebtSecuritiesAmortizedCostBasis33.924.828.08.12.812.611.8

us-gaap:CorporateDebtSecurities, bbio:LongTermMarketableSecurities


Available
Period End2021-03-312020-03-312019-12-312019-09-30
Value217.6891545
Percentage of AvailableForSaleDebtSecuritiesAmortizedCostBasis2.50.93.08.2

us-gaap:CorporateDebtSecurities, us-gaap:ShortTermInvestments


Available
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-312019-09-30
Value12011345103797156
Percentage of AvailableForSaleDebtSecuritiesAmortizedCostBasis15.613.18.814.09.413.710.2

us-gaap:USTreasuryBillSecurities, us-gaap:ShortTermInvestments


Available
Period End2020-12-31
Value14
Percentage of AvailableForSaleDebtSecuritiesAmortizedCostBasis2.9

us-gaap:USTreasurySecurities, bbio:LongTermMarketableSecurities


Available
Period End2021-06-302021-03-312020-03-312019-12-31
Value60601515
Percentage of AvailableForSaleDebtSecuritiesAmortizedCostBasis7.87.01.82.9

us-gaap:USTreasurySecurities, us-gaap:ShortTermInvestments


Available
Period End2021-03-312020-12-312020-06-302020-03-312019-12-31
Value45451354545
Percentage of AvailableForSaleDebtSecuritiesAmortizedCostBasis5.28.818.25.48.7

us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis us-gaap:InvestmentType

bbio:LongTermMarketableSecurities


Available
Period End2021-03-312020-03-312019-12-312019-09-30
Value82223175
Percentage of AvailableForSaleDebtSecuritiesAmortizedCostBasis9.52.76.013.7

us-gaap:ShortTermInvestments


Available
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-312019-09-30
Value459447250299147182122
Percentage of AvailableForSaleDebtSecuritiesAmortizedCostBasis59.251.948.540.317.635.022.0

us-gaap:AvailableForSaleSecuritiesDebtSecurities

us-gaap:AvailableForSaleSecuritiesDebtSecurities


Available
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-312019-09-30
Value775863517743842521554
Percentage of AvailableForSaleSecuritiesDebtSecurities100.0100.0100.0100.0100.0100.0100.0

us-gaap:AvailableForSaleSecuritiesDebtSecurities us-gaap:FairValueByAssetClass, us-gaap:InvestmentType

bbio:SupranationalDebtSecurities, us-gaap:ShortTermInvestments


Available
Period End2021-06-302021-03-31
Value7575
Percentage of AvailableForSaleSecuritiesDebtSecurities9.78.7

us-gaap:CommercialPaper, us-gaap:ShortTermInvestments


Available
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-312019-09-30
Value26321314459236565
Percentage of AvailableForSaleSecuritiesDebtSecurities33.924.828.08.02.812.611.8

us-gaap:CorporateDebtSecurities, bbio:LongTermMarketableSecurities


Available
Period End2021-03-312020-03-312019-12-312019-09-30
Value217.7071545
Percentage of AvailableForSaleSecuritiesDebtSecurities2.50.93.08.2

us-gaap:CorporateDebtSecurities, us-gaap:ShortTermInvestments


Available
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-312019-09-30
Value12011345104797156
Percentage of AvailableForSaleSecuritiesDebtSecurities15.613.18.814.09.413.710.2

us-gaap:USTreasuryBillSecurities, us-gaap:ShortTermInvestments


Available
Period End2020-12-31
Value14
Percentage of AvailableForSaleSecuritiesDebtSecurities2.9

us-gaap:USTreasurySecurities, bbio:LongTermMarketableSecurities


Available
Period End2021-06-302021-03-312020-03-312019-12-31
Value60601515
Percentage of AvailableForSaleSecuritiesDebtSecurities7.87.01.82.9

us-gaap:USTreasurySecurities, us-gaap:ShortTermInvestments


Available
Period End2021-03-312020-12-312020-06-302020-03-312019-12-31
Value45451354545
Percentage of AvailableForSaleSecuritiesDebtSecurities5.28.818.35.48.7

us-gaap:AvailableForSaleSecuritiesDebtSecurities us-gaap:InvestmentType

bbio:LongTermMarketableSecurities


Available
Period End2021-03-312020-03-312019-12-312019-09-30
Value82233175
Percentage of AvailableForSaleSecuritiesDebtSecurities9.52.86.013.7

us-gaap:ShortTermInvestments


Available
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-312019-09-30
Value459447251300148182122
Percentage of AvailableForSaleSecuritiesDebtSecurities59.251.948.540.417.635.022.0

us-gaap:CashAndCashEquivalentsFairValueDisclosure us-gaap:FairValueByAssetClass, us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency

us-gaap:CashAndCashEquivalentsFairValueDisclosure

us-gaap:MoneyMarketFunds, us-gaap:FairValueInputsLevel1, us-gaap:FairValueMeasurementsRecurring


Cash
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-312019-09-302018-12-31
Value255333266436670248256395
Percentage of CashAndCashEquivalentsFairValueDisclosure100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:CashAndCashEquivalentsFairValueDisclosure us-gaap:FairValueByAssetClass, us-gaap:FairValueByMeasurementFrequency

us-gaap:MoneyMarketFunds, us-gaap:FairValueMeasurementsRecurring


Cash
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-312019-09-302018-12-31
Value255333266436670248256395
Percentage of CashAndCashEquivalentsFairValueDisclosure100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:CashAndCashEquivalentsFairValueDisclosure us-gaap:InvestmentType

us-gaap:MoneyMarketFunds


Cash
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-312019-09-30
Value255333266436670248256
Percentage of CashAndCashEquivalentsFairValueDisclosure100.0100.0100.0100.0100.0100.0100.0

us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations

us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations


Cash
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302017-12-312016-12-31
Value3814733585417573644142943734362129220
Percentage of CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:CashEquivalentsAtCarryingValue us-gaap:InvestmentType

us-gaap:CashEquivalentsAtCarryingValue

us-gaap:MoneyMarketFunds


Cash
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-312019-09-30
Value255333266436670248256
Percentage of CashEquivalentsAtCarryingValue100.0100.0100.0100.0100.0100.0100.0

us-gaap:ContractualObligation us-gaap:ConsolidatedEntities, us-gaap:DebtInstrument, us-gaap:FinancialInstrument

us-gaap:ContractualObligation

bbio:EidosTherapeuticsInc, bbio:DebtInstrumentTrancheA, bbio:InterestAdjustOnSiliconValleyBankAndHerculesTermLoan


Contractual
Period End2020-12-31
Value-3.87
Percentage of ContractualObligation100.0

bbio:EidosTherapeuticsInc, bbio:DebtInstrumentTrancheA, bbio:PrincipalValueAndInterestOnTermLoanOfSiliconValleyBankAndHerculesTermLoan


Contractual
Period End2020-12-31
Value21
Percentage of ContractualObligation-552.2

bbio:EidosTherapeuticsInc, bbio:DebtInstrumentTrancheA, bbio:PrincipalValueOfSiliconValleyBankAndHerculesTermLoan


Contractual
Period End2020-12-31
Value17
Percentage of ContractualObligation-452.2

us-gaap:ContractualObligation us-gaap:FinancialInstrument

bbio:FinalEndOfTermPaymentsOfHerculesTermLoanAdjust


Contractual
Period End2020-12-31
Value-4.523
Percentage of ContractualObligation116.9

bbio:InterestAdjustOnHerculesTermLoan


Contractual
Period End2020-12-31
Value-14.483
Percentage of ContractualObligation374.2

bbio:InterestAdjustOnTwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySeven


Contractual
Period End2020-12-31
Value-89.375
Percentage of ContractualObligation2309.4

bbio:PrincipalValueAndInterestOnTwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySeven


Contractual
Period End2021-06-302021-03-312020-12-31
Value632632639
Percentage of ContractualObligation0.00.0-16521.3

bbio:PrincipalValueInterestOnTermLoansAndFinalEndOfTermPaymentsOfHerculesTermLoan


Contractual
Period End2020-12-31
Value94
Percentage of ContractualObligation-2429.1

bbio:PrincipalValueOfHerculesTermLoan


Contractual
Period End2020-12-31
Value75
Percentage of ContractualObligation-1938.0

us-gaap:ContractualObligationDueAfterFifthYear us-gaap:FinancialInstrument

us-gaap:ContractualObligationDueAfterFifthYear

bbio:PrincipalValueAndInterestOnTwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySeven


Contractual
Period End2020-12-31
Value570
Percentage of ContractualObligationDueAfterFifthYear100.0

us-gaap:ContractualObligationDueInFifthYear us-gaap:FinancialInstrument

us-gaap:ContractualObligationDueInFifthYear

bbio:PrincipalValueAndInterestOnTwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySeven


Contractual
Period End2020-12-31
Value13
Percentage of ContractualObligationDueInFifthYear100.0

us-gaap:ContractualObligationDueInNextTwelveMonths us-gaap:ConsolidatedEntities, us-gaap:DebtInstrument, us-gaap:FinancialInstrument

us-gaap:ContractualObligationDueInNextTwelveMonths

bbio:EidosTherapeuticsInc, bbio:DebtInstrumentTrancheA, bbio:PrincipalValueAndInterestOnTermLoanOfSiliconValleyBankAndHerculesTermLoan


Contractual
Period End2020-12-31
Value2.961
Percentage of ContractualObligationDueInNextTwelveMonths100.0

us-gaap:ContractualObligationDueInNextTwelveMonths us-gaap:FinancialInstrument

bbio:PrincipalValueInterestOnTermLoansAndFinalEndOfTermPaymentsOfHerculesTermLoan


Contractual
Period End2020-12-31
Value6.644
Percentage of ContractualObligationDueInNextTwelveMonths224.4

us-gaap:ContractualObligationDueInSecondYear us-gaap:ConsolidatedEntities, us-gaap:DebtInstrument, us-gaap:FinancialInstrument

us-gaap:ContractualObligationDueInSecondYear

bbio:EidosTherapeuticsInc, bbio:DebtInstrumentTrancheA, bbio:PrincipalValueAndInterestOnTermLoanOfSiliconValleyBankAndHerculesTermLoan


Contractual
Period End2020-12-31
Value9.787
Percentage of ContractualObligationDueInSecondYear100.0

us-gaap:ContractualObligationDueInSecondYear us-gaap:FinancialInstrument

bbio:PrincipalValueInterestOnTermLoansAndFinalEndOfTermPaymentsOfHerculesTermLoan


Contractual
Period End2020-12-31
Value40
Percentage of ContractualObligationDueInSecondYear410.9

us-gaap:ContractualObligationDueInThirdYear us-gaap:ConsolidatedEntities, us-gaap:DebtInstrument, us-gaap:FinancialInstrument

us-gaap:ContractualObligationDueInThirdYear

bbio:EidosTherapeuticsInc, bbio:DebtInstrumentTrancheA, bbio:PrincipalValueAndInterestOnTermLoanOfSiliconValleyBankAndHerculesTermLoan


Contractual
Period End2020-12-31
Value8.622
Percentage of ContractualObligationDueInThirdYear100.0

us-gaap:ContractualObligationDueInThirdYear us-gaap:FinancialInstrument

bbio:PrincipalValueInterestOnTermLoansAndFinalEndOfTermPaymentsOfHerculesTermLoan


Contractual
Period End2020-12-31
Value47
Percentage of ContractualObligationDueInThirdYear546.8

us-gaap:DebtInstrumentCarryingAmount us-gaap:ConsolidatedEntities, us-gaap:DebtInstrument, us-gaap:LineOfCreditFacility

us-gaap:DebtInstrumentCarryingAmount

bbio:EidosTherapeuticsInc, bbio:TrancheALoan, bbio:SiliconValleyBankAndHerculesLoan


Debt
Period End2020-12-312020-03-312019-12-31
Value161616
Percentage of DebtInstrumentCarryingAmount100.0100.0100.0

us-gaap:DebtInstrumentCarryingAmount us-gaap:ConsolidatedEntities, us-gaap:LineOfCreditFacility

bbio:EidosTherapeuticsInc, bbio:SiliconValleyBankAndHerculesLoan


Debt
Period End2021-03-312020-06-30
Value1716
Percentage of DebtInstrumentCarryingAmount0.00.0

us-gaap:DebtInstrumentCarryingAmount us-gaap:DebtInstrument

bbio:HerculesTermLoan


Debt
Period End2020-12-312019-12-312018-12-31
Value757555
Percentage of DebtInstrumentCarryingAmount443.8465.80.0

us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent us-gaap:DebtInstrument

us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent

bbio:TwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySeven


Debt
Period End2020-12-31
Value169
Percentage of DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent100.0

us-gaap:DebtInstrumentConvertibleConversionPrice1 us-gaap:DebtInstrument

us-gaap:DebtInstrumentConvertibleConversionPrice1

bbio:TwoPointTwoFivePercentageConvertibleSeniorNotesDueTwoThousandAndTwentyNine


Debt
Period End2021-01-28
Value97.04
Percentage of DebtInstrumentConvertibleConversionPrice1100.0

bbio:TwoThousandTwentyOneCappedCallTransactions


Debt
Period End2021-01-25
Value97.04
Percentage of DebtInstrumentConvertibleConversionPrice10.0

us-gaap:DebtInstrumentFaceAmount us-gaap:DebtInstrument

us-gaap:DebtInstrumentFaceAmount

bbio:DebtInstrumentTrancheFour


Debt
Period End2021-01-31
Value25
Percentage of DebtInstrumentFaceAmount100.0

bbio:TwoPointTwoFivePercentageConvertibleSeniorNotesDueTwoThousandAndTwentyNine


Debt
Period End2021-06-302021-03-312021-01-28
Value747747717
Percentage of DebtInstrumentFaceAmount0.00.00.0

us-gaap:DebtInstrumentFaceAmount us-gaap:DebtInstrument, us-gaap:SubsequentEventType

bbio:TwoPointTwoFivePercentageConvertibleSeniorNotesDueTwoThousandAndTwentyNine, us-gaap:SubsequentEvent


Debt
Period End2021-01-28
Value717
Percentage of DebtInstrumentFaceAmount0.0

us-gaap:DebtInstrumentInterestRateEffectivePercentage us-gaap:DebtInstrument

us-gaap:DebtInstrumentInterestRateEffectivePercentage

bbio:TwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySeven


Debt
Period End2021-06-302021-03-312020-12-312020-06-302020-03-31
Value2.82.88.88.88.8
Percentage of DebtInstrumentInterestRateEffectivePercentage100.0100.0100.0100.0100.0

us-gaap:DebtInstrumentUnamortizedDiscount us-gaap:ConsolidatedEntities, us-gaap:DebtInstrument, us-gaap:LineOfCreditFacility

us-gaap:DebtInstrumentUnamortizedDiscount

bbio:EidosTherapeuticsInc, bbio:TrancheALoan, bbio:SiliconValleyBankAndHerculesLoan


Debt
Period End2020-12-312019-12-31
Value1.62.4
Percentage of DebtInstrumentUnamortizedDiscount100.0100.0

us-gaap:DebtInstrumentUnamortizedDiscount us-gaap:ConsolidatedEntities, us-gaap:LineOfCreditFacility

bbio:EidosTherapeuticsInc, bbio:SiliconValleyBankAndHerculesLoan


Debt
Period End2021-03-31
Value1.4
Percentage of DebtInstrumentUnamortizedDiscount0.0

us-gaap:DebtInstrumentUnamortizedDiscount us-gaap:DebtInstrument

bbio:TwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySeven


Debt
Period End2021-06-302021-03-312020-12-31
Value1010158
Percentage of DebtInstrumentUnamortizedDiscount0.00.09900.2

bbio:TwoPointTwoFivePercentageConvertibleSeniorNotesDueTwoThousandAndTwentyNine


Debt
Period End2021-06-302021-03-31
Value1515
Percentage of DebtInstrumentUnamortizedDiscount0.00.0

us-gaap:DebtInstrumentUnamortizedDiscountNoncurrent us-gaap:DebtInstrument

us-gaap:DebtInstrumentUnamortizedDiscountNoncurrent

bbio:TwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySeven


Debt
Period End2020-12-31
Value158
Percentage of DebtInstrumentUnamortizedDiscountNoncurrent100.0

us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount us-gaap:ConsolidatedEntities, us-gaap:Range, us-gaap:DebtInstrument, us-gaap:LineOfCreditFacility

us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount

bbio:EidosTherapeuticsInc, srt:Maximum, bbio:TrancheBLoan, bbio:SiliconValleyBankAndHerculesLoan


Debt
Period End2020-10-31
Value22
Percentage of DebtInstrumentUnusedBorrowingCapacityAmount100.0

us-gaap:DeferredCosts us-gaap:ConsolidatedEntities, us-gaap:BalanceSheetLocation

us-gaap:DeferredCosts

bbio:EidosTherapeuticsInc, us-gaap:OtherCurrentAssets


Deferred
Period End2020-12-31
Value8700000.0
Percentage of DeferredCosts100.0

us-gaap:DeferredFinanceCostsNet us-gaap:DebtInstrument

us-gaap:DeferredFinanceCostsNet

bbio:TwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySeven


Deferred
Period End2021-06-302021-03-312020-12-312020-03-09
Value0.5420.5658.1613
Percentage of DeferredFinanceCostsNet100.0100.0100.0100.0

bbio:TwoPointTwoFivePercentageConvertibleSeniorNotesDueTwoThousandAndTwentyNine


Deferred
Period End2021-01-28
Value16
Percentage of DeferredFinanceCostsNet0.0

us-gaap:DeferredIncomeTaxLiabilities

us-gaap:DeferredIncomeTaxLiabilities


Deferred
Period End2020-12-312019-12-312018-12-31
Value360.290.018
Percentage of DeferredIncomeTaxLiabilities100.0100.0100.0

us-gaap:DeferredTaxAssetsEquityMethodInvestments

us-gaap:DeferredTaxAssetsEquityMethodInvestments


Deferred
Period End2020-12-312019-12-31
Value7608000.07297000.0
Percentage of DeferredTaxAssetsEquityMethodInvestments100.0100.0

us-gaap:DeferredTaxAssetsGross

us-gaap:DeferredTaxAssetsGross


Deferred
Period End2020-12-312019-12-312018-12-31
Value26012949
Percentage of DeferredTaxAssetsGross100.0100.0100.0

us-gaap:DeferredTaxAssetsOperatingLossCarryforwards

us-gaap:DeferredTaxAssetsOperatingLossCarryforwards


Deferred
Period End2020-12-312019-12-312018-12-31
Value1919440
Percentage of DeferredTaxAssetsOperatingLossCarryforwards100.0100.0100.0

us-gaap:DeferredTaxAssetsOther

us-gaap:DeferredTaxAssetsOther


Deferred
Period End2020-12-312019-12-312018-12-31
Value613000.0210000.023000.0
Percentage of DeferredTaxAssetsOther100.0100.0100.0

us-gaap:DeferredTaxAssetsTaxCreditCarryforwards

us-gaap:DeferredTaxAssetsTaxCreditCarryforwards


Deferred
Period End2020-12-312019-12-312018-12-31
Value37183.728
Percentage of DeferredTaxAssetsTaxCreditCarryforwards100.0100.0100.0

us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost

us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost


Deferred
Period End2020-12-312019-12-312018-12-31
Value5471000.01820000.0268000.0
Percentage of DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost100.0100.0100.0

us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals

us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals


Deferred
Period End2020-12-312019-12-312018-12-31
Value5707000.01917000.0434000.0
Percentage of DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals100.0100.0100.0

us-gaap:DeferredTaxLiabilitiesFinancingArrangements

us-gaap:DeferredTaxLiabilitiesFinancingArrangements


Deferred
Period End2020-12-31
Value32
Percentage of DeferredTaxLiabilitiesFinancingArrangements100.0

us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment

us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment


Deferred
Period End2020-12-312019-12-312018-12-31
Value221000.0290000.018000.0
Percentage of DeferredTaxLiabilitiesPropertyPlantAndEquipment100.0100.0100.0

us-gaap:DerivativeFairValueOfDerivativeLiability us-gaap:ConsolidatedEntities, us-gaap:DebtInstrument, us-gaap:LineOfCreditFacility

us-gaap:DerivativeFairValueOfDerivativeLiability

bbio:EidosTherapeuticsInc, bbio:TrancheALoan, bbio:SiliconValleyBankAndHerculesLoan


Derivative
Period End2020-12-312019-12-31
Value1300000.01200000.0
Percentage of DerivativeFairValueOfDerivativeLiability100.0100.0

us-gaap:DueFromRelatedPartiesCurrent

us-gaap:DueFromRelatedPartiesCurrent


Due
Period End2021-06-302021-03-312019-12-31
Value8962000.0462000.02845000.0
Percentage of DueFromRelatedPartiesCurrent100.0100.0100.0

us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency

us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability

us-gaap:FairValueInputsLevel3, us-gaap:FairValueMeasurementsRecurring


Embedded
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-31
Value1366000.01410000.01340000.01123000.01103000.01165000.0
Percentage of EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability100.0100.0100.0100.0100.0100.0

us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability us-gaap:FairValueByMeasurementFrequency

us-gaap:FairValueMeasurementsRecurring


Embedded
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-31
Value1366000.01410000.01340000.01123000.01103000.01165000.0
Percentage of EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability100.0100.0100.0100.0100.0100.0

us-gaap:EmployeeRelatedLiabilitiesCurrent

us-gaap:EmployeeRelatedLiabilitiesCurrent


Employee
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-312019-09-302018-12-31
Value212029135.647137.584.047
Percentage of EmployeeRelatedLiabilitiesCurrent100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized us-gaap:PlanName

us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized

bbio:TwoThousandSixteenEquityIncentivePlanAndTwoThousandEighteenStockOptionAndIncentivePlan


Employee
Period End2020-12-31
Value24
Percentage of EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized100.0

us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions us-gaap:AwardType, us-gaap:PlanName

us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions

us-gaap:RestrictedStock, bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlan


Employee
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-31
Value131416202126
Percentage of EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions100.0100.0100.0100.0100.0100.0

us-gaap:RestrictedStockUnitsRSU, bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlan


Employee
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-31
Value798232321011
Percentage of EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions599.2557.8198.8162.749.543.8

us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions us-gaap:AwardType, us-gaap:PlanName

us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions

us-gaap:EmployeeStockOption, bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlan


Employee
Period End2021-06-302021-03-312020-12-31
Value767343
Percentage of EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions100.0100.0100.0

us-gaap:EquityMethodInvestmentOwnershipPercentage dei:LegalEntity, us-gaap:StatementEquityComponents

us-gaap:EquityMethodInvestmentOwnershipPercentage

bbio:BiotechCompany, us-gaap:CommonStock


Equity
Period End2020-12-312019-12-31
Value6.00.1
Percentage of EquityMethodInvestmentOwnershipPercentage100.0100.0

us-gaap:EquityMethodInvestments dei:LegalEntity

us-gaap:EquityMethodInvestments

bbio:PellePharmInc


Equity
Period End2021-03-312020-12-312020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-31
Value00000000200000.0
Percentage of EquityMethodInvestments0.00.00.00.00.00.00.00.0100.0

us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue us-gaap:FairValueByLiabilityClass

us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue

bbio:LEOCallOption


Fair
Period End2020-12-312020-06-302020-03-312019-12-312019-09-302018-12-31
Value5550000.05276000.03539000.04078000.04021000.03009000.0
Percentage of FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue100.0100.0100.0100.0100.0100.0

us-gaap:FinanceLeaseLiability

us-gaap:FinanceLeaseLiability


Finance
Period End2021-06-302021-03-312020-12-31
Value1670000.01694000.01701000.0
Percentage of FinanceLeaseLiability100.0100.0100.0

us-gaap:FinanceLeaseLiabilityCurrent

us-gaap:FinanceLeaseLiabilityCurrent


Finance
Period End2021-06-302021-03-312020-12-31
Value258000.0200000.0128000.0
Percentage of FinanceLeaseLiabilityCurrent100.0100.0100.0

us-gaap:FinanceLeaseLiabilityNoncurrent

us-gaap:FinanceLeaseLiabilityNoncurrent


Finance
Period End2021-06-302021-03-312020-12-31
Value1412000.01494000.01573000.0
Percentage of FinanceLeaseLiabilityNoncurrent100.0100.0100.0

us-gaap:FinanceLeaseLiabilityPaymentsDue

us-gaap:FinanceLeaseLiabilityPaymentsDue


Finance
Period End2021-06-302021-03-312020-12-31
Value1945000.01996000.02031000.0
Percentage of FinanceLeaseLiabilityPaymentsDue100.0100.0100.0

us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive

us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive


Finance
Period End2020-12-31
Value37000.0
Percentage of FinanceLeaseLiabilityPaymentsDueAfterYearFive100.0

us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths

us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths


Finance
Period End2021-06-302021-03-312020-12-31
Value420000.0420000.0238000.0
Percentage of FinanceLeaseLiabilityPaymentsDueNextTwelveMonths100.0100.0100.0

us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive

us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive


Finance
Period End2020-12-31
Value459000.0
Percentage of FinanceLeaseLiabilityPaymentsDueYearFive100.0

us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour

us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour


Finance
Period End2021-06-302021-03-312020-12-31
Value459000.0459000.0445000.0
Percentage of FinanceLeaseLiabilityPaymentsDueYearFour100.0100.0100.0

us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree

us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree


Finance
Period End2021-06-302021-03-312020-12-31
Value445000.0445000.0432000.0
Percentage of FinanceLeaseLiabilityPaymentsDueYearThree100.0100.0100.0

us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo

us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo


Finance
Period End2021-06-302021-03-312020-12-31
Value432000.0432000.0420000.0
Percentage of FinanceLeaseLiabilityPaymentsDueYearTwo100.0100.0100.0

us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear

us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear


Finance
Period End2021-06-302021-03-31
Value151000.0202000.0
Percentage of FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear100.0100.0

us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount

us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount


Finance
Period End2021-06-302021-03-312020-12-31
Value275000.0302000.0330000.0
Percentage of FinanceLeaseLiabilityUndiscountedExcessAmount100.0100.0100.0

us-gaap:FinancialLiabilitiesFairValueDisclosure us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency

us-gaap:FinancialLiabilitiesFairValueDisclosure

us-gaap:FairValueInputsLevel3, us-gaap:FairValueMeasurementsRecurring


Financial
Period End2020-12-312020-06-302020-03-312019-12-31
Value6890000.06399000.04642000.05243000.0
Percentage of FinancialLiabilitiesFairValueDisclosure100.0100.0100.0100.0

us-gaap:FinancialLiabilitiesFairValueDisclosure us-gaap:FairValueByMeasurementFrequency

us-gaap:FairValueMeasurementsRecurring


Financial
Period End2020-12-312020-06-302020-03-312019-12-31
Value6890000.06399000.04642000.05243000.0
Percentage of FinancialLiabilitiesFairValueDisclosure100.0100.0100.0100.0

us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths

us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths


Finite
Period End2021-06-30
Value1500000.0
Percentage of FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths100.0

us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear

us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear


Finite
Period End2021-06-30
Value900000.0
Percentage of FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear100.0

us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour

us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour


Finite
Period End2021-06-30
Value1500000.0
Percentage of FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour100.0

us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree

us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree


Finite
Period End2021-06-30
Value1500000.0
Percentage of FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree100.0

us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo

us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo


Finite
Period End2021-06-30
Value1500000.0
Percentage of FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo100.0

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths


Lessee
Period End2021-06-302021-03-312020-12-31
Value5360000.04344000.04825000.0
Percentage of LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths100.0100.0100.0

us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear

us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear


Lessee
Period End2021-06-302021-03-31
Value2783000.03536000.0
Percentage of LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear100.0100.0

us-gaap:MarketableSecuritiesNoncurrent

us-gaap:MarketableSecuritiesNoncurrent


Marketable
Period End2021-06-302021-03-312020-03-312019-12-31
Value60822331
Percentage of MarketableSecuritiesNoncurrent100.0100.0100.0100.0

us-gaap:NotesPayableFairValueDisclosure us-gaap:DebtInstrument

us-gaap:NotesPayableFairValueDisclosure

bbio:TwoPointFiveZeroPercentageConvertibleSeniorNotesDueTwoThousandAndTwentySeven


Notes
Period End2021-06-302021-03-312020-12-31
Value880874997
Percentage of NotesPayableFairValueDisclosure100.0100.0100.0

bbio:TwoPointTwoFivePercentageConvertibleSeniorNotesDueTwoThousandAndTwentyNine


Notes
Period End2021-06-302021-03-31
Value717714
Percentage of NotesPayableFairValueDisclosure81.681.7

us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent

us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent


Operating
Period End2021-06-302021-03-312020-12-312020-06-302020-03-31
Value5.796.276.245.876.22
Percentage of OperatingLeaseWeightedAverageDiscountRatePercent100.0100.0100.0100.0100.0

us-gaap:OperatingLossCarryforwards us-gaap:IncomeTaxAuthority

us-gaap:OperatingLossCarryforwards

us-gaap:DomesticCountry


Operating
Period End2020-12-312019-12-31
Value852393
Percentage of OperatingLossCarryforwards100.0100.0

us-gaap:OperatingLossCarryforwards us-gaap:StatementGeographical, us-gaap:IncomeTaxAuthority

country:CA, us-gaap:StateAndLocalJurisdiction


Operating
Period End2020-12-312019-12-31
Value177160
Percentage of OperatingLossCarryforwards20.940.7

us-gaap:RestrictedCash

us-gaap:RestrictedCash


Restricted
Period End2020-12-312020-06-302019-12-312019-09-302019-06-302018-12-312018-09-302017-12-31
Value2600000.0424000.0424000.0424000.0424000.0159000.0359000.0381000.0
Percentage of RestrictedCash100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:RestrictedCash us-gaap:BalanceSheetLocation

us-gaap:OtherAssets


Restricted
Period End2020-12-312019-12-312018-12-31
Value2458000.0400000.0200000.0
Percentage of RestrictedCash94.594.3125.8

us-gaap:PrepaidExpensesAndOtherCurrentAssets


Restricted
Period End2020-12-31
Value139000.0
Percentage of RestrictedCash5.3

us-gaap:RestrictedCashCurrent

us-gaap:RestrictedCashCurrent


Restricted
Period End2021-06-302021-03-31
Value176000.0139000.0
Percentage of RestrictedCashCurrent100.0100.0

us-gaap:RestrictedCashNoncurrent

us-gaap:RestrictedCashNoncurrent


Restricted
Period End2021-06-302021-03-312020-06-302020-03-31
Value2532000.02459000.0424000.0424000.0
Percentage of RestrictedCashNoncurrent100.0100.0100.0100.0

us-gaap:RevenueRemainingPerformanceObligation us-gaap:ProductOrService, us-gaap:TypeOfArrangement

us-gaap:RevenueRemainingPerformanceObligation

us-gaap:License, bbio:LicenseAndCollaborationAgreement


Revenue
Period End2021-06-30
Value1600000.0
Percentage of RevenueRemainingPerformanceObligation100.0

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue us-gaap:AwardType

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue

bbio:MarketBasedRestrictedStockUnits


Share
Period End2020-12-312020-06-302020-03-312019-12-31
Value34.8111.9211.9228.98
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue100.0100.0100.0100.0

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue us-gaap:AwardType, us-gaap:PlanName

us-gaap:RestrictedStock, bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlan


Share
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-31
Value5.034.874.473.913.793.63
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue0.00.012.832.831.812.5

us-gaap:RestrictedStockUnitsRSU, bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlan


Share
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-31
Value50.6550.2134.2132.2731.8931.98
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue0.00.098.3270.7267.5110.4

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice us-gaap:ConsolidatedEntities

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

bbio:EidosTherapeuticsInc


Share
Period End2020-12-312020-06-302020-03-312019-12-312019-09-30
Value18.7316.711.9511.1614.02
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice100.0100.0100.0100.0100.0

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice us-gaap:ConsolidatedEntities, us-gaap:PlanName

bbio:EidosTherapeuticsInc, bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlan


Share
Period End2021-06-302021-03-31
Value11.7510.03
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice0.00.0

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice us-gaap:PlanName

bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlan


Share
Period End2021-06-302021-03-312020-06-302020-03-312019-12-31
Value23.4421.7617.9818.2417.89
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice0.00.0107.7152.6160.3

bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlans


Share
Period End2020-12-31
Value21.22
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice113.3

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice us-gaap:PlanName, us-gaap:ShareRepurchaseProgram

bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlan, bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgram


Share
Period End2021-06-302021-03-312020-06-30
Value1.992.011.34
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice0.00.08.0

bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlans, bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgram


Share
Period End2020-12-31
Value1.75
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice9.3

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue us-gaap:ConsolidatedEntities

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

bbio:EidosTherapeuticsInc


Share
Period End2020-12-312020-06-302020-03-312019-12-312019-09-302019-06-302018-12-31
Value15638405431286.928
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue100.0100.0100.0100.0100.0100.0100.0

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue us-gaap:ConsolidatedEntities, us-gaap:PlanName

bbio:EidosTherapeuticsInc, bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlan


Share
Period End2021-06-302021-03-31
Value105114
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue0.00.0

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue us-gaap:PlanName

bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlan


Share
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-31
Value239249320664570
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue0.00.0204.9171.7111.1130.1

bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlans


Share
Period End2020-12-312019-12-31
Value32070
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue204.9130.1

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue us-gaap:PlanName, us-gaap:ShareRepurchaseProgram

bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlan, bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgram


Share
Period End2021-06-302021-03-312020-12-312020-06-30
Value34385831
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue0.00.037.781.1

bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlans, bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgram


Share
Period End2020-12-31
Value58
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue37.7

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue us-gaap:ConsolidatedEntities

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue

bbio:EidosTherapeuticsInc


Share
Period End2020-12-31
Value156
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue100.0

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice us-gaap:ConsolidatedEntities

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice

bbio:EidosTherapeuticsInc


Share
Period End2020-12-31
Value29.71
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice100.0

us-gaap:SharePrice us-gaap:DebtInstrument, us-gaap:ShareRepurchaseProgram

us-gaap:SharePrice

bbio:TwoThousandTwentyOneCappedCallTransactions, bbio:ShareRepurchaseTransactions


Share
Period End2021-01-25
Value65.79
Percentage of SharePrice100.0

us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 us-gaap:ConsolidatedEntities

us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1

bbio:EidosTherapeuticsInc


Sharebased
Period End2020-12-312020-06-302020-03-312019-12-312019-09-30
Value4114101131
Percentage of SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1100.0100.0100.0100.0100.0

us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 us-gaap:ConsolidatedEntities, us-gaap:PlanName

bbio:EidosTherapeuticsInc, bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlan


Sharebased
Period End2021-06-302021-03-31
Value5448
Percentage of SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue10.00.0

us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 us-gaap:PlanName

bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlan


Sharebased
Period End2021-06-302021-03-312020-06-302020-03-312019-12-31
Value9778148.1188.83
Percentage of SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue10.00.094.976.979.2

bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlans


Sharebased
Period End2020-12-31
Value86
Percentage of SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1206.5

us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 us-gaap:PlanName, us-gaap:ShareRepurchaseProgram

bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlan, bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgram


Sharebased
Period End2021-06-302021-03-312020-06-30
Value283022
Percentage of SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue10.00.0149.2

bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlans, bbio:TwoThousandTwentyStockAndEquityAwardExchangeProgram


Sharebased
Period End2020-12-31
Value46
Percentage of SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1110.4

us-gaap:StockRepurchaseProgramAuthorizedAmount1 us-gaap:Range, us-gaap:ShareRepurchaseProgram, us-gaap:StatementEquityComponents

us-gaap:StockRepurchaseProgramAuthorizedAmount1

srt:Maximum, bbio:TwoThousandTwentyOneShareRepurchaseProgram, us-gaap:CommonStock


Stock
Period End2021-05-31
Value150
Percentage of StockRepurchaseProgramAuthorizedAmount1100.0

us-gaap:TaxCreditCarryforwardAmount us-gaap:IncomeTaxAuthority, us-gaap:TaxCreditCarryforward

us-gaap:TaxCreditCarryforwardAmount

us-gaap:DomesticCountry, bbio:ResearchAndDevelopmentAndOrphanDrugCreditCarryforwards


Tax
Period End2020-12-31
Value41
Percentage of TaxCreditCarryforwardAmount100.0

us-gaap:StateAndLocalJurisdiction, us-gaap:Research


Tax
Period End2020-12-312019-12-31
Value6.32.6
Percentage of TaxCreditCarryforwardAmount15.40.0

us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests

us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests


Temporary
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-312019-09-302019-03-312018-12-31
Value1.8651.2711.631.9063.0532.2432.570.2020.122
Percentage of TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests us-gaap:StatementClassOfStock

bbio:RedeemableConvertibleNoncontrollingInterests


Temporary
Period End2021-06-302021-03-312020-12-312020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312016-12-31
Value1.8651.2711.631.9063.0532.2432.570.1750.2020.1220.9123.1921.550.8331.52
Percentage of TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests100.0100.0100.0100.0100.0100.0100.00.0100.0100.00.00.00.00.00.0

us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests us-gaap:StatementEquityComponents

us-gaap:CommonStock


Temporary
Period End2021-03-31
Value0.152
Percentage of TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests12.0

Line plots across dimensions of each concept


TTM Greenblatt ROC
_
(None,)
T T M  Greenblatt  R O C_
us-gaap:AllocatedShareBasedCompensationExpense
us-gaap:ConsolidatedEntities, us-gaap:IncomeStatementLocation
(None, 'us-gaap:GeneralAndAdministrativeExpense')
Allocated Share Based Compensation Expenseus-gaap: Consolidated Entities, us-gaap: Income Statement Location
us-gaap:AllocatedShareBasedCompensationExpense
us-gaap:IncomeStatementLocation
(None,)
Allocated Share Based Compensation Expenseus-gaap: Income Statement Location
us-gaap:AllocatedShareBasedCompensationExpense
us-gaap:ConsolidatedEntities
(None,)
Allocated Share Based Compensation Expenseus-gaap: Consolidated Entities
us-gaap:AllocatedShareBasedCompensationExpense
us-gaap:AwardType, us-gaap:PlanName
(None, 'bbio:TwoThousandNineteenStockOptionAndIncentivePlanAndInducementEquityPlan')
Allocated Share Based Compensation Expenseus-gaap: Award Type, us-gaap: Plan Name
us-gaap:InterestExpenseDebt
us-gaap:DebtInstrument
(None,)
Interest Expense Debtus-gaap: Debt Instrument
us-gaap:LongTermDebtNoncurrent
us-gaap:DebtInstrument
(None,)
Long Term Debt Noncurrentus-gaap: Debt Instrument
us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
us-gaap:StatementEquityComponents
(None,)
Stockholders Equity Including Portion Attributable To Noncontrolling Interestus-gaap: Statement Equity Components
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
us-gaap:StatementEquityComponents
(None,)
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Valueus-gaap: Statement Equity Components